Compositions and methods for the treatment of disorders related to ataxin-2
AAV particles delivering modulatory polynucleotides target Ataxin-2 expression in the brain to treat SCA2, addressing the lack of effective treatments for the disease by reducing aberrant protein levels and halting symptom progression.
Patent Information
- Application Number
- PCT/US2024/027327
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-12
- Filing Date
- 2024-05-01
- Publication Date
- 2024-11-07
AI Technical Summary
Current treatments for spinocerebellar ataxia type 2 (SCA2) do not target the underlying cause of the disease, and there is a need for effective methods to reduce or eliminate the aberrant expression of Ataxin-2 protein, which is associated with the progression of SCA2 and other disorders like ALS and Parkinson’s disease.
Adeno-associated virus (AAV) particles are used to deliver modulatory polynucleotides that reduce or eliminate the expression of Ataxin-2 mRNA and protein, specifically targeting the brainstem and cerebellum, using AAV9 capsid variants with peptide inserts in loop IV to achieve high expression and reduced immunogenicity and toxicity.
The AAV-based compositions effectively reduce Ataxin-2 protein levels in CNS cells, slowing or halting the progression of SCA2 symptoms and potentially treating associated disorders by delivering modulatory polynucleotides to the brain with high specificity and reduced side effects.
Smart Images

Figure IMGF000389_0001 
Figure IMGF000146_0001 
Figure IMGF000147_0001
Abstract
Description
COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERSRELATED TO ATAXIN-2RELATED APPLICATIONS
[0081] This application claims the benefit of and priority to US Provisional Application Serial No. 63 / 463,841, filed May 3, 2.023, US Provisional Application Serial No. 63 / 593,857, filed October 27, 2023, and US Provisional Application Serial No. 63 / 564,435, filed March 12, 2024, the contents of each of which are incorporated herein by reference in their entirety .SEQUENCE LISTING
[0002] The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing file, entitled “14640 0083-00304 SL.xnil”, was created on March 21, 2024, and. is 5,499,942 bytes in size. The information in electronic format of the Sequence Listing is incorporated herein by reference in its entirety.FIELD
[0003] Described herein are compositions and methods relating to adeno-associated virus (AAV) viral particles for the delivery- of polynucleotides, e.g., modulatory polynucleotides for reducing or eliminating expression of ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2. protein, and their use in the treatment of spinocerebellar ataxia type 2 (SCA2) and other disorders associated with aberrant ATXN2 protein expression or activity or mutated ATXN2 protein. In some embodiments, compositions described herein may be used to treat a subject in need thereof, such as a human subject diagnosed with SCA2 or another condition resulting from mutant ATXN2 protein or aberrant ATXN2 protein expression or activity.BACKGROUND
[0004] Ataxin-2 is a protein encoded by the ATXN2 gene (Ensembl Gene ID No. EN SG00000204842), which is also known as ATX2 and TNR.C 13. It is located on chromosome 12 of the human genome.
[0005] The function of Ataxin-2 is not known, but it is found in the cytoplasm, and is thought to interact with the endoplasmic reticulum.
[0006] Mutations to ATXN2. cause disease in human subjects. ATXN2 mutations are known to cause spinocerebellar ataxia type 2 (SCA2). SCA2 is an autosomal dominantcerebellar ataxia. ATXN2 mutations also play a role in other ATXN2-related disorders, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and frontotemporal lobar degeneration (FTLD).
[0007] SCA2 is typically caused by CAG trinucleotide repeat expansions in the ATXN2 gene on I2q24.1. Patients with SCA2 have ATXN2 alleles with 32 or more trinucleotide repeats, resulting in ATXN2 protein with polyQ expansions. PolyQ expansions in ATXN2 (e.g., intermediate length polyQ expansions) have been associated with other diseases, like ALS, as well.
[0008] The age of onset of SCA2 is thought to correlate with the number of CAG trinucleotide repeats. Onset is typically later than age 60 in subjects with 32-34 CAG repeats (SEQ ID NO: 6432). Onset is Apically between ages 20 and. 60 in subjects with 35-40 CAG repeats (SEQ ID NO: 6433). Onset is typically before age 20 for patients with 45 or more CAG repeats (SEQ ID NO: 6434).
[0009] Mutated ATXN2 is thought to produce an Ataxin-2. protein with an abnormally long stretch of glutamine residues. The cellular impact of mutant Ataxin-2 protein is not confirmed. Without wishing to be bound by any particular theory, mutant Ataxin-2 may accumulate in cells and cause cell death.
[0010] SCA2 is characterized by progressive cerebellar ataxia, including nystagmus, and slow saccadic eye movements. It may also present with ophthalmoparesis and / or parkinsonism. Later stages of SCA2 mainly involve the brainstem and cerebellum.[Oil] There are no specific treatments for SCA2. Trials have considered riluzole, which inhibits glutamic acid release, for treating SCA2. However, there are no treatments targeting the cause of SCA2. Thus, there remains a long -felt need to develop pharmaceutical compositions and methods for the treatment of SCA2. In particular, a need exists for treatments of SCA2 targeting the brainstem and cerebellum.
[0012] There remains a need for effective methods of treatment using AAV capsid variants that are capable of delivering a modulatory polynucleotide for reducing or eliminating expression of human ATXN2 mRNA (thereby reducing or eliminating ATXN2 protein), to a target cell or tissue, e.g., a CNS cell or tissue.SUMMARY
[0013] The present disclosure addresses these challenges by providing AAV -based compositions comprising AAV capsid variants and methods for treating SCA2 -relateddisorder in subjects. Disclosed herein are compositions and methods directed to AAV-based gene delivery of modulatory polynucleotides for reducing or eliminating expression of ATXN2 to treat SCA2. In some embodiments, the compositions and methods reduce or eliminate expression of ATXN2 mRNA, and thereby reduce or eliminate ATXN2 protein, to treat SCA2. The compositions and methods are useful to reduce the effects of mutant ATXN2 or aberrant ATXN2 protein expression or activity, and to slow, halt or reverse muscular and other symptoms of SCA2. In some embodiments, aberrant ATXN2 expression refers to expression of ATXN2 comprising 32 or more CAG trinucleotide repeats (SEQ ID NO: 6435) (and thus polyQ expansions). Unless otherwise specified, ATXN2, ATX2, and TNRC13 are synonymous terms and are used interchangeably to refer to ATXN2. ATXN2 refers to the transcript encoding the ATXN2 (Ataxin 2) protein, and ATXN2 protein refers to the protein encoded by the ATXN2 gene and mRNA. SCA2 is used to refer to spinocerebellar ataxia type 2.
[0014] In some embodiments, the present disclosure provides an A AV particle comprising an AAV capsid and a nucleotide sequence encoding a modulatory polynucleotide tor reducing or eliminating expression of ATXN2. In some embodiments, the modulatory polynucleotide reduces or eliminates mRNA encoding ATXN2. In some embodiments, the modulatory polynucleotide reduces or eliminates ATXN2 protein (e.g., a human ATXN2 protein). In some embodiments, the AAV capsid is an AAV capsid variant. In some embodiments, the AAV capsid variant is an AAV9 capsid variant.
[0015] In some embodiments, the AAV capsid variant is an AAV9 capsid variant comprising a peptide insert in the loop IV region. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SPH in loop IV. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SPH in loop IV wherein the amino acid sequence (SPH) is present immediately subsequent to position 455 as numbered according to SEQ ID NO: 138.
[0016] In some embodiments, the AAV particles described herein surprisingly provide high expression of the modulatory polynucleotide in the brain (e.g., the cortex, striatum, and brainstem), high modulatory polynucleotide activity in the brain, reduced immunogenicity, and / or reduced toxicity to other tissues of the body. In some embodiments, the AAV particles described herein surprisingly provide reduced modulatory polynucleotide expression in the liver while retaining high modulatory polynucleotide activity in other areas of the brain (e.g., the brain stem), e.g., relative to AAV9. In some embodiments, the AAV particles describedherein can be administered to a. subject having a ATXN2-related disorder such as SCA2, ALS, PD, or FTLD.
[0017] In some embodiments, administration of an A AV particle to a. subject results m greater reduction in the expression and / or activity of ATXN2 in CNS cells or tissues of the subject as compared to administration of an AAV9 particle comprising a wildtype AAV9 capsid and the modulatory polynucleotide sequence.
[0018] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) particle comprising: a) an AAV capsid variant comprising an amino acid sequence having the following formula [N1 ]-[N2]-[N3], wherein (i) optionally [N1] comprises X1, X2, and X3, wherein at least one of XL X2, or X3 is G; (ii) [N2] comprises the amino acid sequence of SPH; and (iii) [N3] comprises X4, X5, and X6, wherein at least one of X4, X5, or X6 is a basic amino acid: and b) a viral genome comprising a nucleic acid sequence encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2). In some embodiments, the modulatory polynucleotide comprises an RNAi agent targeting ATXN2 mRNA. In some embodiments, the amino acid sequence [N1]-[N2]-[N3] is in hypervariable loop IV of the AAV capsid variant. In some embodiments, the .AAV capsid variant is an AAV9 capsid variant. In some embodiments, [N1] comprises XL X2, and X3, wherein at least one of X1, X2 or X3 is G.
[0019] In some embodiments, [N1]-[N2]-[N3] is presen t immediately subsequent to a position corresponding to the amino acid position 452 of SEQ ID MO: 982 and the AAV capsid variant comprises an amino acid sequence at least 90% identical, e.g., at least 91%, at least 92%, at least 93%, at least 94%), at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical, to the amino acid sequence of positions 203-742 of SEQ ID NO: 982. In some embodiments, [N1]-[N2]-[N3] is present immediately subsequent to a position corresponding to the amino acid position 452 of SEQ ID NO: 982 and the AAV capsid variant comprises an amino acid sequence at least 90% identical, e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical, to the amino acid sequence of SEQ ID NO: 982.
[0020] In some embodiments, [N1] comprises GHD. In some embodiments, [N1] comprises the amino acid G at a position corresponding to position 453, the amino acid H at position 454, and the amino acid D at position 455 of SEQ ID NO: 138 or SEQ ID NO: 982. In some embodiments [N3] comprises KSG.
[0021] In some embodiments, the AAV capsid variant comprises: (i) a VP 1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having atleast 90% identity to SEQ ID NO; 982; (ii) a. VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity to positions 138-742 SEQ ID NO: 982; or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity to positions 203-742 of SEQ ID NO: 982.
[0822] In some embodiments, the AAV capsid variant comprises: (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having at least 95% identity to SEQ ID NO; 982; (ii) a. VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least 95% identity to positions 138-742 SEQ ID NO: 982; or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid sequence having at least 95% identity to positions 203-742 of SEQ ID NO: 982.
[0023] In some embodiments, the AAV capsid variant comprises: (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having at least 99% identity to SEQ ID NO; 982; (ii) a. VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least 99% identity to positions 138-742 SEQ ID NO: 982; or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid sequence having at least 99% identity to positions 203-742 of SEQ ID NO: 982.
[0024] In some embodiments, the AAV capsid variant comprises: (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982; or (iii) a. VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO; 982.
[0025] In some embodiments, [N2]-[N3] comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941).
[0026] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) particle comprising (a) a viral genome comprising a nucleic acid sequence encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2), and (b) an AAV9 capsid variant comprising the amino acid sequence of SPHSKA (SEQ ID NO: 941). In some embodiments, the amino acid sequence of SPHSKA (SEQ ID NO: 941) is in hypervariable loop IV of the AAV capsid variant. In some embodiments, the amino acid sequence of SPHSKA (SEQ ID NO: 941) is present immediately subsequent to an amino acid position corresponding to position 455 of SEQ ID NO: 36 or SEQ ID NO: 4.
[0027] In some embodiments, the AAV 9 capsid variant comprises one, two, or all of: an E at an amino acid position corresponding to position 451, an R at an amino acid position corresponding to position 452, and / or a V at an amino acid position corresponding to position 453 of SEQ ID NO: 36. In some embodiments, the AAV9 capsid variant comprises the amino acid sequence of KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589).
[0028] In some embodiments, the AAV9 capsid variant comprises: (i) a VP1 protein composing an amino acid sequence having at least 90% identity to SEQ ID NO: 36; (ii) a VP2 protein comprising an amino acid sequence having at least 90% identity to positions 138-742 SEQ ID NO: 36; and / or (iii) a VP3 protein comprising an amino acid sequence having at least 90% identity to positions 203-742 of SEQ ID NO: 36.
[0029] In some embodiments, the AA.V9 capsid variant comprises: (i) a VP1 protein comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 36; (ii) a VP2 protein comprising an amino acid sequence having at least 95% identity to positions 138-742 SEQ ID NO: 36; and / or (iii) a VP3 protein comprising an amino acid sequence having at least 95% identity to positions 203-742 of SEQ ID NO: 36.
[0030] In some embodiments, the AAV9 capsid variant comprises: (i) a VP1 protein comprising an amino acid sequence having at least 99% identity to SEQ ID NO: 36; (ii) a VP2 protein comprising an amino acid sequence having at least 99% identity to positions 138-742 of SEQ ID NO: 36; and / or (iii) a VP3 protein comprising an amino acid sequence having at least 99% identity to positions 203-742 of SEQ ID NO: 36.
[0031] In some embodiments, the AAV9 capsid variant comprises: (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 36; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 36; and / or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 36.
[0032] In some embodiments, the AAV9 capsid variant comprises: (i) the amino acid sequence SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to an amino acid position corresponding to position 455 of SEQ ID NO 36; (ii) an E at an amino acid position corresponding to position 451 , an R at an amino acid position corresponding to position 452, and a. V at an amino acid position corresponding to position 453 of SEQ ID NO: 36; and (iii) no other modifications relative to wild type AAV 9.
[0033] In some embodiments, the AAV9 capsid variant comprises one, two, or all of: an N at an amino acid position corresponding to position 452, an E at an amino acid position corresponding to position 451, and / or a V at an amino acid position corresponding to position453 of SEQ ID NO: 4. In some embodiments, the AAV9 capsid variant comprises the amino acid sequence of KTENVSGSPHSKAQNQQT (SEQ ID NO: 3272).
[0034] In some embodiments, the AA.V9 capsid variant comprises: (i) a VP1 protein comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 4; (ii) a VP2 protein comprising an amino acid sequence having at least 90% identity to positions 138-742 of SEQ ID NO: 4; and / or (iii) a VP3 protein comprising an amino acid sequence having at least 90% identity to positions 203-742 of SEQ ID NO: 4.
[0035] In some embodiments, the AAV9 capsid variant comprises: (i) a VP1 protein comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 4; (ii) a VP2 protein comprising an amino acid sequence having at least 95% identity to positions 138-742 SEQ ID NO: 4; and / or (iii) a VP3 protein comprising an amino acid sequence having at least 95% identity to positions 203-742 of SEQ ID NO: 4.
[0036] In some embodiments, the AAV9 capsid variant comprises: (i) a VP1 protein comprising an amino acid sequence having at least 99% identity to SEQ ID NO: 4; (ii) a VP2 protein comprising an amino acid sequence having at least 99% identity to positions 138-742 of SEQ ID NO: 4; and / or (iii) a VP3 protein comprising an amino acid sequence having at least 99% identity to positions 203-742 of SEQ ID NO: 4.
[0037] In some embodiments, the AAV9 capsid variant comprises: (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 4; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 4; and / or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 4,
[0038] In some embodiments, the AAV9 capsid variant comprises: (i) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to an amino acid position corresponding to position 455 of SEQ ID NO 4; (ii) an E at an amino acid position corresponding to position 451 and a. V at an amino acid position corresponding to position 453 of SEQ ID NO: 4; and (iii) no other modifications relative to wild type AAV9.
[0039] In some embodiments, the modulatory polynucleotide comprises: (a) a 5’ flanking region comprising any one of SEQ ID NOs: 6413-6416 or a nucleotide sequence at least 95% identical thereto; (b) a loop region comprising any one of SEQ ID NOs: 6417-6421 or a nucleotide sequence at least 95% identical thereto; and (c) a 3’ flanking region comprising any one of SEQ ID NOs: 6422.-6427 or a nucleotide sequence at least 95% identical thereto.
[0040] In some embodiments, (a.) the 5' flanking region comprises SEQ ID NO: 6414 or SEQ ID NO: 6415, or a nucleotide sequence at least 95% identical thereto; (b) the loopregion comprises SEQ ID NO: 6417, SEQ ID NO: 6418, or SEQ ID NO: 6421 , or a nucleotide sequence at least 95% identical thereto; and (c) the 3' flanking region comprises SEQ ID NO: 6423, SEQ ID NO: 6424, or SEQ ID NO: 6425, or a nucleotide sequence at least 95% identical thereto.
[0041] In some embodiments, the 5’ flanking region comprises SEQ ID NO; 6414 or a nucleotide sequence at least 95% identical thereto, the loop region comprises SEQ ID NO: 6417 or a nucleotide sequence at least 95% identical thereto, and the 3’ flanking region comprises SEQ ID NO; 6423 or a. nucleotide sequence at least 95% identical thereto. In some embodiments, the 5’ flanking region comprises SEQ ID NO: 6415 or a nucleotide sequence at least 95% identical thereto, the loop region comprises SEQ ID NO: 6421 or a nucleotide sequence at least 95% identical thereto, and the 3’ flanking region comprises SEQ ID NO: 6425 or a nucleotide sequence at least 95% identical thereto. In some embodiments, the 5’ flanlang region comprises SEQ ID NO: 6414 or a nucleotide sequence at least 95% identical thereto, the loop region comprises SEQ ID NO: 6417 or a nucleotide sequence at least 95% identical thereto, and the 3" flanking region comprises SEQ ID NO: 6424 or a nucleotide sequence at least 95% identical thereto. In some embodiments, the 5’ flanking region comprises SEQ ID NO: 6414 or a nucleotide sequence at least 95% identical thereto, the loop region comprises SEQ ID NO: 6418 or a nucleotide sequence at least 95% identical thereto, and the 3’ flanking region comprises SEQ ID NO: 6423 or a nucleotide sequence at least 95% identical thereto.
[0042] In some embodiments, the modulatory polynucleotide comprises siRNA .
[0043] In some embodiments, the modulatory polynucleotide comprises shRNA.
[0044] In some embodiments, the modulatory polynucleotide further comprises a passenger strand and a guide strand, wherein the guide strand binds to and reduces or eliminates expression of one or more ATXN2 mRNA transcripts. In some embodiments, the modulatory polynucleotide comprises from 5'to 3‘: the 5' flanking region, the passenger strand, the loop region, tire guide strand, and the 3' flanking region. In some embodiments, the modulatory polynucleotide comprises from 5' to 3': the 5' flanking region, the guide strand, the loop region, the passenger strand; and the 3' flanking region.
[0045] In some embodiments, the passenger strand is 15-30 nucleotides in length. In some embodiments, the guide strand is 15-30 nucleotides in length. In some embodiments, the guide strand is 21-25 nucleotides in length. In some embodiments, the passenger strand is 21- 25 nucleotides in length. In some embodiments, the passenger strand is at least 70%, at least 80%, at least 90%, at least 95% or is 100% complementary to the guide strand.
[0046] In some embodiments, the one or more ATXN2 mRNA transcripts comprises SEQ ID NO: 6428, SEQ ID NO: 6429, SEQ ID NO: 6430, and / or SEQ ID NO: 6431, or a trinucleotide repeat expansion thereof.
[0047] In some embodiments, the viral genome comprises a promoter operably linked to the nucleic acid sequence encoding the modulatory polynucleotide.
[0048] In some embodiments, the viral genome further comprises an inverted terminal repeat (ITR) sequence. In some embodiments, the viral genome comprises an ITR sequence positioned 5’ relative to the nucleic acid sequence encoding the modulatory polynucleotide. In some embodiments, the viral genome comprises an ITR sequence positioned 3' relative to the nucleic acid sequence encoding the modulatory polynucleotide . In some embodiments, viral genome comprises an ITR sequence positioned 5’ relative to the nucleic acid sequence encoding the modulatory polynucleotide, and an ITR sequence positioned 3’ relative to the nucleic, acid sequence encoding the modulatory polynucleotide.
[0049] In some embodiments, the present disclosure provides a cell comprising an AAV particle described herein. In some embodiments, the cell is a mammalian cell (e.g., an HEK293 cell), an insect cell (e.g., an Sf9 cell), or a bacterial ceil.
[0050] In some embodiments, the present disclosure provides a method of making an AAV particle described herein, the method comprising (i) providing a cell comprising the viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of ATXN2 mRNA; and (ii) incubating the cell under conditions suitable to encapsulate the viral genome in the AAV capsid variant; thereby making the AAV particle.
[0051] In some embodiments, the AAV capsid variant comprises (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least. 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to SEQ ID NO: 982; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least. 90% identity (e.g,, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 138-742 SEQ ID NO: 982; and / or (in) a VP3 protein comprising tire amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91 %, at least 92%), at least 93%, at least 94%, at least 95%, at least 96%, at least 97%), at least 98%), or at least 99%) identity) to positions 203-742 of SEQ ID NO: 982.
[0052] In some embodiments, the AAV capsid variant comprises (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 36 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to SEQ ID NO: 36; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 36 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 138-742 SEQ ID NO: 36; and / or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 36 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91 %, at least 92%), at least 93%, at least 94%, at least 95%, at least 96%, at least 97%), at least 98%), or at least 99%) identity) to positions 203-742 of SEQ ID NO: 36.
[0853] In some embodiments, the AAV capsid variant comprises (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%), at least 95%, at least 96%, at least 97%>, at least 98%, or at least 99% identity) to SEQ ID NO: 4; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 4 or an amino acid, sequence having at. least 90% identity (e.g., at least. 90%, at. least 91%), at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%o, or at least 99%o identity) to positions 138-742 SEQ ID NO: 4; or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 4 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%>, at least 97%, at least 98%, or at least 99% identity) to positions 203-742 of SEQ ID NO: 4.
[0054] In some embodiments, the method, further comprises, prior to step (i), introducing a first nucleic acid molecule comprising the viral genome into the cell. In some embodiments, the cell comprises a second nucleic acid molecule encoding the AAV capsid variant. In some embodiments, the method further comprises, prior to step (i), introducing the second nucleic acid molecule into the cell. In some embodiments, the cell comprises a mammalian cell, e.g., an HEK293 cell, an insect cell, e.g., an Sf9 cell, or a bacterial cell.
[0055] In some embodiments, the present disclosure provides a pharmaceutical composition comprising an AAV particle described herein, and a pharmaceutically acceptable excipient.
[0056] In some embodiments, the present disclosure provides a method of delivering a modulatory polynucleotide for reducing or eliminating expression of ATXN2 to a subject, comprising administering to the subject an effective amount of a pharmaceutical composition or AAV particle described herein, thereby delivering the modulatory polynucleotide. In some embodiments, the method reduces or eliminates ATXN2 protein in the subject. In some embodiments, the subject has, has been diagnosed with having, or is at risk of having an ATXN2-related disorder. In some embodiments, the ATXN2-related disorder is spinocerebellar ataxia type 2 (SCA2).
[0057] In some embodiments, the present disclosure provides a method of treating an ATXN2-related disorder in a subject, comprising administering to tire subject an effective amount of a pharmaceutical composition or AAV particle described herein, thereby treating the ATXN2-related disorder. In some embodiments, the subject has, has been diagnosed, or is at risk of having the ATXN2 -related disorder.
[0058] In some embodiments, the subject has one or more mutations in the ATXN2 gene. In some embodiments, the one or more mutations in the ATXN2 gene comprises a trinucleotide repeat expansion. In some embodiments, the trinucleotide repeat expansion in the ATXX2 gene comprises 32 or more CAG repeats.
[0059] In some embodiments, treating results in prevention of progression of the ATXN2- related disorder in the subject. In some embodiments, the treating results in amelioration of at least one symptom of the ATXN 2 -related disorder and / or a change in at least one biomarker of the AT.XN2 -related disorder in the subject. In some embodiments, the at least one symptom comprises progressive cerebellar ataxia, nystagmus, slow saccadic eye movements, ophthahnoparesis, parkinsonism, or a combination thereof. In some embodiments, the ATXN2-related disorder is spinocerebellar ataxia type 2 (SCA2).
[0060] In some embodiments, the present disclosure provides a method of treating spinocerebellar ataxia type 2 (SCA2) in a. subject, comprising administering to the subject an effective amount of the pharmaceutical composition described herein or the AAV particle described herein, thereby treating SCA2. In some embodiments, the subject has, has been diagnosed with having, or is at risk of having SCA2.
[0061] In some embodiments, the subject is a human.
[0062] In some embodiments, the AAV particle or the pharmaceutical composition is delivered to a cell or tissue of the CNS. In some embodiments, the cell or tissue of the CNS is a cell or tissue of the amygdala, brainstem, caudate, central grey, cerebellum (e.g., Purkinje cell layer and deep cerebellar nuclei), cortex (e.g., frontal cortex, motor cortex, perirhinalcortex, sensory cortex, temporal cortex), external cuneate nucleus, geniculate nucleus, globus pallidus, gracile nucleus, hippocampus, inferior colliculus, inferior olivary complex, nucleus ambiguous, oculomotor nucleus, putamen, substantia nigra, thalamus, ventral palladium, vestibular nucleus, and / or spinal cord (e.g., cervical spinal cord region, lumbar spinal cord region, or thoracic spinal cord region). In some embodiments, the AAV particle or the pharmaceutical composition is delivered via intravenous administration.
[0063] In some embodiments, the method of delivering or treating further comprises evaluating, e.g., measuring, the level of modulatory polynucleotide expression, and / or the level of ATXN2 expression, e.g., ATXN2 gene, ATXN2 mRNA, and / or ATXN2 protein expression, in the subject, e.g., in a cell, tissue, or fluid, of the subject. In some embodiments, the level of ATXN2 protein is measured by an ELISA, a Western blot, or an immunohistochemistry assay. In some embodiments, the evaluating of the subject’s level of modulatory polynucleotide expression and / or level of ATXN2 expression is performed prior to and / or subsequent to administration of the pharmaceutical composition or AAV particle, optionally wherein the subject’s level of modulatory polynucleotide expression and / or the subject’s level of ATXN2 expression prior to administration is compared to the subject’s level of modulatory polynucleotide expression and / or the subject’s level of ATXN2 expression subsequent to administration. In some embodiments, the subject’s level of ATXN2 protein expression subsequent to administration is decreased relative to the subject’s level of ATXN2 protein expression prior to administration.
[0064] In some embodiments, the method of delivering or treating further comprises evaluating, e.g., measuring, the level of modulatory polynucleotide activity and / or ATXN2 activity in the subject, e.g., in a cell or tissue of the subject. In some embodiments, the administration results in: (i) a decrease in ATXN2 protein expression in a cell, tissue (e.g., amygdala, brainstem, caudate, central grey, cerebellum (e.g., Purkinje cell layer and deep cerebellar nuclei), cortex (e.g., frontal cortex, motor cortex, perirhinal cortex, sensory cortex, temporal cortex), external cuneate nucleus, geniculate nucleus, globus pallidus, gracile nucleus, hippocampus, inferior colliculus, inferior olivary complex, nucleus ambiguous, oculomotor nucleus, putamen, substantia nigra, thalamus, ventral palladium, vestibular nucleus, spinal cord (e.g., cervical spinal cord region, lumbar spinal cord region, or thoracic spinal cord region)), and / or fluid (e.g., CSF and / or serum) of the subject relative to baseline and / or relative to ATXN2 protein expression in a. cell, tissue, or fluid, of an individual with an ATXN2-relat.ed disorder who has not been administered the pharmaceutical composition or AAV particle; (ii) an increase in the number and / or level of viral genomes (VG) per cell in aCNS tissue (e.g., amygdala, brainstem, caudate, central grey, cerebellum (e.g., Purkinje cell layer and deep cerebellar nuclei), cortex (e.g., frontal cortex, motor cortex, perirhinal cortex, sensory cortex, temporal cortex), external cuneate nucleus, geniculate nucleus, globus pallidus, gracile nucleus, hippocampus, inferior colliculus, inferior olivary complex, nucleus ambiguous, oculomotor nucleus, putamen, substantia nigra, thalamus, ventral palladium, vestibular nucleus, and / or spinal cord (e.g., cervical spinal cord region, lumbar spinal cord region, or thoracic spinal cord region) of the subject relative to the number and / or level of VG per cell in a peripheral tissue of the subject; and / or (iii) a decrease in ATXN2 mRNA expression in a cell or tissue (e.g., a cell or tissue of the CNS, e.g., the amygdala, brainstem, caudate, central grey, cerebellum (e.g., Purkinje cell layer and deep cerebellar nuclei), cortex (e.g., frontal cortex, motor cortex, perirhinal cortex, sensory cortex, temporal cortex), external cuneate nucleus, geniculate nucleus, globus pallidus, gracile nucleus, hippocampus, inferior colliculus, inferior olivary complex, nucleus ambiguous, oculomotor nucleus, putamen, substantia nigra, thalamus, ventral palladium, vestibular nucleus, and / or spinal cord (e.g., cervical spinal cord region, lumbar spinal cord region, or thoracic spinal cord region) of the subject relative to baseline and / or relative to ATXN2 mRNA expression in a cell or tissue of an individual with an ATXN2-related disorder who has not been administered the pharmaceutical composition or AAV particle.
[0065] In some embodiments, the method of delivering or treating further comprises administering to the subject at least one additional therapeutic agent and / or therapy. In some embodiments, the at least one additional therapeutic agent and / or therapy comprises an agent and / or therapy for treating the ATXN2-related disorder. In some embodiments, the at least one additional therapeutic agent and / or therapy comprises one or more of: growth and trophic factors, cytokines, hormones, neurotransmitters, enzymes, anti-apoptotic factors, angiogenic factors, modulatory polynucleotides, and any protein known to be mutated in pathological disorders such as ATXN2-related disorders.
[0866] In some embodiments, the ATXN2-related disorder is SCA2, amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), or frontotemporal lobar degeneration (FTLD). In some embodiments, the ATXN2-related disorder is SCA2.
[0067] In some embodiments, the method of delivering or treating further comprises administering an immunosuppressant to the subject. In some embodiments, the immunosuppressant comprises a corticosteroid (e.g., prednisone, prednisolone, methylprednisolone, and / or dexamethasone), rapamycin, mycophenolate mofetil, tacrolimus, rituximab, and / or eculizumab hydroxychloroquine.
[0068] In some embodiments, the present, disclosure provides a method of treating a subject having or diagnosed with having ALS, PD, or FTLD, comprising administering to the subject an effective amount of a pharmaceutical composition or A AV particle described herein. In some embodiments, the method further comprises administering to the subject at least one additional therapeutic agent and / or therapy. In some embodiments, the at least one additional therapeutic agent and / or therapy comprises one or more of: growth and trophic factors, cytokines, hormones, neurotransmitters, enzymes, anti-apoptotic factors, angiogenic factors, modulatory polynucleotides, and any protein known to be mutated in pathological disorders such as ATXN2-related disorders. In some embodiments, the method further comprises administering an immunosuppressant to the subject. In some embodiments, the immunosuppressant, comprises a corticosteroid (e.g., prednisone, prednisolone, methylprednisolone, and / or dexamethasone), rapamycin, rnycophenolatemofetil, tacrolimus, rituximab, and / or ecuiizumab hydroxychloroquine.
[0069] In some embodiments, the present, disclosure provides a pharmaceutical composition or AAV particle described herein for use in a method of treating a disorder described herein. In some embodiments, the ATXN2-related disorder is SCA2. In some embodiments, the subject has, has been diagnosed 'with having, or is at risk of having the ATXN2-relat.ed disorder, optionally wherein the ATXN2-relat.ed disorder is SCA2.
[0070] In some embodiments, the present disclosure provides a pharmaceutical composition or AAV particle described herein for use in treating an ATXN2 -related disorder in a subject. In some embodiments, the ATXN2-related disorder is SCA2. In some embodiments, the subject, has, has been diagnosed with having, or is at risk of having the ATXN2-related disorder, optionally wherein the ATXN2 -related disorder is SCA2.
[0071] In some embodiments, the present disclosure pro vides a use of a pharmaceutical composition or A AV particle described herein in the manufacture of a medicament for the treatment of an ATXN2-related disorder in a subject. In some embodiments, the ATXN2- related disorder is SCA2. In some embodiments, the subject has, has been diagnosed with having, or is at risk of having the ATXN2-related disorder, optionally wherein the ATXN2- related disorder is SCA2.
[0072] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended, to be encompassed by the following enumerated embodiments.Enumerated Embodiments1, An adeno-associated virus (AAV) particle comprising an AAV capsid, variant (e.g., an AAV9 capsid variant) and a viral genome comprising a. nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein (e.g., human ATXN2 protein), wherein the AAV capsid variant comprises an amino acid sequence having the following formula: [N1]-[N2]- [N3], wherein:(i) optionally [N1] comprises X1, X2, and X3, wherein at least one of X1, X2, or X3 is G;(ii) [N2] comprises the amino acid sequence of SPH; and(iii) [N3] comprises X4, X5, and X6, wherein at least one of X4, X5, or X6 is a basic amino acid, e.g., a K or R.2. The AAV particle of embodiment 1, wherein X4, X5, or both of [N3] is a K.3. The AAV particle of embodiment 1 or 2, wherein X4, X5, or X6 of [N3] is an R.4. The AAV particle of any one of embodiments 1-3, wherein:(a) X 4 of [N3] is: K, S, A, V, T, G, F, W, V, N, or R;(b) X5 of [N3] is: S, K, T, F, I, L, Y, H, M, or R; and / or(c) X6 of [N3] is: G, A, R, M, I, N, T, Y, D, P, V, L, E, W, N, Q, K, or S; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(c).5. The AAV particle of any one of embodiments 1-4, wherein [N3] comprises SK, KA, KS, AR, RM, VK, AS, SR, VK, KR, KK, KN, VR, RS, RK, KT, TS, KF, FG, KI, IG, KL, LG, TT, TY, KY, YG, KD), KP, TR, RG, VR, GA, SL, SS, FL,, WK, SA, RA, LR, KW, RR, GK, TK, NK, AK, KV, KG, KH, KM, TG, SE, SV, SW, SN, HG, SQ, LW, MG, MA, or SG.6. The AAV particle of any one of embodiments 1-5, wherein [N3] is or comprises SKA, KSG, ARM, VKS, ASR, VKI, KKN, VRM, RKA, KTS, KFG, KIG, KLG, KTT, KTY,KYG, SKD, SKP, TRG, VRG, KRG, GAR, KSA, KSR, SKL, SRA, SKR, SLR, SRG, SSR,FLR, SKW, SKS, WK A, VRR, SKV, SKT, SKG, GKA, TKA. NKA, SKL, SKN, AKA,KTG, KSL, KSE, KSV, KSW, KSN, KHG, KSQ, KSK, KLW, WKG, KMG, KMA, or RSG.7. The AAV particle of any one of embodiments 1-6, wherein [N2]-[N3] comprises SPHSK (SEQ ID NO: 4701), SPHKS (SEQ ID NO: 4704), SPHAR (SEQ ID NO: 4705), SPHVK (SEQ ID NO: 4706), SPHAS (SEQ ID NO: 4707), SPHKK (SEQ ID NO: 4708), SPHVR (SEQ ID NO: 4709), SPHRK (SEQ ID NO: 4710), SPHKT (SEQ ID NO: 4711), SPHKF (SEQ ID NO: 4712), SPHKI (SEQ ID NO: 4713), SPHKL (SEQ ID NO: 4714), SPHKY (SEQ ID NO: 4715), SPHTR (SEQ ID NO: 4716), SPHKR (SEQ ID NO: 4717), SPHGA (SEQ ID NO: 4718), SPHSR (SEQ ID NO: 4719), SPHSL (SEQ ID NO: 4720), SPHSS (SEQ ID NO: 4721), SPHFL (SEQ ID NO: 4722), SPIIWK (SEQ ID NO: 4723), SPHGK (SEQ ID NO: 4724), SPHTK (SEQ ID NO: 4725), SPUNK (SEQ ID NO: 4726), SPHAK (SEQ ID NO: 4727), SPHKH (SEQ ID NO: 4728), SPHKM (SEQ ID NO: 4729), or SPHRS (SEQ ID NO: 4730),8. The AAV particle of any one of embodiments 1-7, wherein [N2] [N3] is or comprises:(i) SPHSKA (SEQ ID NO: 941), SPHKSG (SEQ ID NO: 946), SPHARM (SEQ ID NO: 947), SPHVKS (SEQ ID NO: 948), SPHASR (SEQ ID NO: 949), SPHVKI (SEQ ID NO: 950), SPHKKN (SEQ ID NO: 954), SPHVRM (SEQ ID NO: 955), SPHRKA (SEQ ID NO: 956), SPHKFG (SEQ ID NO: 957), SPHKIG (SEQ ID NO: 958), SPHKLG (SEQ ID NO: 959), SPHKTS (SEQ ID NO: 963), SPHKTT (SEQ ID NO: 964), SPHKTY (SEQ ID NO: 965), SPHKYG (SEQ ID NO: 966), SPHSKD (SEQ ID NO: 967), SPHSKP (SEQ ID NO: 968), SPHTRG (SEQ ID NO: 972), SPHVRG (SEQ ID NO: 973), SPHKRG (SEQ ID NO: 974), SPHGAR (SEQ ID NO: 975), SPHKSA (SEQ ID NO: 977), SPHKSR (SEQ ID NO: 951), SPHSKL (SEQ ID NO: 960), SPHSR A (SEQ ID NO: 969), SPHSKR (SEQ ID NO: 978), SPHSLR (SEQ ID NO: 952), SPHSRG (SEQ ID NO: 961), SPHSSR (SEQ ID NO: 970), SPHFLR (SEQ ID NO: 979), SPHSKW (SEQ ID NO: 953), SPHSKS (SEQ ID NO: 962), SPHWKA (SEQ ID NO: 971), SPHVRR (SEQ ID NO: 980), SPHSKT (SEQ ID NO: 4731), SPHSKG (SEQ ID NO: 4732), SPHGKA (SEQ ID NO: 4733), SPHNKA (SEQ ID NO: 4734), SPHSKN (SEQ ID NO: 4735), SPHAKA (SEQ ID NO: 4736), SPHSKV (SEQ ID NO: 4737), SPHKTG (SEQ ID NO: 4738), SPHTKA (SEQ ID NO: 4739), SPHKSL (SEQ ID NO: 4740), SPHKSE (SEQ ID NO: 4741), SPHKSV (SEQ ID NO: 4742), SPHKSW (SEQ ID NO: 4743), SPHKSN (SEQ ID NO: 4744), SPHKHG (SEQ ID NO: 4745), SPHKSQ (SEQ ID NO: 4746), SPHKSK (SEQ ID NO: 4747), SPHKLW (SEQ IDNO: 4748), SPHWKG (SEQ ID NO: 4749), SPHKMG (SEQ ID NO: 4750), SPHKMA (SEQ ID NO: 4751), or SPHRSG (SEQ ID NO: 976);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).9, The AAV particle of any one of embodiments 1-8, wherein the AAV capsid variant comprises an amino acid other than G at position 453 (e.g., V, R, D, E, M, T, I, S, A, N, L, K, H, P, W, or C), an amino acid other than S at position 454 (e.g., V, L, N, D, H, R, P, G, T, I, A, E, Y, M, or Q), and / or an amino acid other than G at position 455 (e.g., C, L, D, E, Y, H, V, A, N, P, or S), numbered according to any one of SEQ ID NOs: 36-59, 138, 981, or 982.10. The AAV particle of any one of embodiments 1-8, wherein the AAV capsid variant comprises the amino acid G at position 453, the amino acid S at position 454, and the amino acid G at position 455, numbered according to SEQ ID NO: 138 or 981 .11. The AAV particle of any one of embodiments 1-9, wherein the AAV capsid variant comprises the amino acid G at position 453, the amino acid H at position 454, and the amino acid D at position 455, numbered according to SEQ ID NO: 138 or 982.12. The AAV particle of any one of embodiments 1-11, wherein [N1] comprises X1, X2, and X3, wherein at least one of X L X2, or X3 is G.13. The AAV particle of any one of embodiments 1-12, wherein:(a) X1 of [N1] is: G, V, R, D, E, M, T, I, S, A, N, I.,, K, H, P, W, or C;(b) X2 of [N1] is: S, V, L, N, D, H, R, P, G, T, I, A, E, Y, M, or Q; and / or(c) X3 of [N1] is: G, C, L, D, E, Y, H, V, A, N, P, or S; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g,, a. conservative substitution, of any of the aforesaid amino acids in (a)-(c).14. The AAV particle of any one of embodiments 1-13, wherein [N1] comprises GS, SG,GH, HD, GQ, QD, VS, CS, GR, RG, QS, SH, MS, RN, TS, IS, GP, ES, SS, GN, AS, NS, LS, GG, KS, GT, PS, RS, GI, WS, DS, ID, GL, DA, DG, ME, EN, KN, KE, Al, NG, PG, TG, SV, IG, LG, AG, EG, SA, YD, HE, HG, RD, ND, PD, MG, QV, DD, HN, HP, GY, GM, GD, or HS.15. The AAV particle of any one of embodiments 1-14, wherein [N1] is or comprises GSG, GHD, GQD, VSG, CSG, GRG, CSH, GQS, GSH, RVG, GSC, GLL, GDD, GHE, GNY, MSG, RNG, TSG, ISG, GPG, ESG, SSG, GNG, ASG, NSG, LSG, GGG, KSG, HSG, GTG, PSG, GSV, RSG, GIG, WSG, DSG, IDG, GLG, DAG, DGG, MEG, ENG, GSA, KNG, KEG, AIG, GYD, GHG, GRD, GND, GPD, GMG, GQV, GHN, GHP, or GHS.16. The AAV particle of any one of embodiments 1-15, wherein [N1]-[N2] comprises:(i) SGSPH (SEQ ID NO: 4752), HDSPH (SEQ ID NO: 4703), QDSPH (SEQ ID NO: 4753), RGSPH (SEQ ID NO: 4754), SHSPH (SEQ ID NO: 4755), QSSPH (SEQ ID NO: 4756), DDSPH (SEQ ID NO: 4757), HESPH (SEQ ID NO: 4758), NYSPH (SEQ ID NO: 4759), VGSPH (SEQ ID NO: 4760), SCSPH (SEQ ID NO: 4761), LLSPH (SEQ ID NO: 4762), NGSPH (SEQ ID NO: 4763), PGSPH (SEQ ID NO: 4764), GGSPH (SEQ ID NO: 4765), TGSPH (SEQ ID NO: 4766), SVSPH (SEQ ID NO: 4767), IGSPH (SEQ ID NO: 4768). DGSPH (SEQ ID NO: 4769), LGSPH (SEQ ID NO: 4770), AGSPH (SEQ ID NO: 4771), EGSPH (SEQ ID NO: 4772), SASPH (SEQ ID NO: 4773), YDSPH (SEQ ID NO: 4774), HGSPH (SEQ ID NO: 4775), RDSPH (SEQ ID NO: 4776), NDSPH (SEQ ID NO: 4777), PDSPH (SEQ ID NO: 4778), MGSPH (SEQ ID NO: 4779), QVSPH (SEQ ID NO: 4780), HNSPH (SEQ ID NO: 4781), HPSPH (SEQ ID NO: 4782). or HSSPH (SEQ ID NO: 4783);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, or 4 amino acids, e.g., consecutive amino acids, thereof:(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).17. The AAV particle of any one of embodiments 1-16, wherein [N1]-[N2] is or comprises:(i) GSGSPH (SEQ ID NO: 4695), GHDSPII (SEQ ID NO: 4784), GQDSPH (SEQ ID NO: 4785), VSGSPH (SEQ ID NO: 4786), CSGSPH (SEQ ID NO: 4787), GRGSPH (SEQ ID NO: 4788), CSHSPH (SEQ ID NO: 4789), GQSSPH (SEQ ID NO: 4790), GSHSPH (SEQ ID NO: 4791), GDDSPII (SEQ ID NO: 4792), GIIESPII (SEQ ID NO: 4793), GNYSPH (SEQ ID NO: 4794), RVGSPH (SEQ ID NO: 4795), GSCSPH (SEQ ID NO: 4796). GLLSPH (SEQ ID NO: 4797), MSGSPH (SEQ ID NO: 4798), RNGSPH (SEQ ID NO: 4799), TSGSPH (SEQ ID NO: 4800), ISGSPH (SEQ ID NO: 4801), GPGSPH (SEQ ID NO: 4802), ESGSPH (SEQ ID NO: 4803), SSGSPH (SEQ ID NO: 4804), GNGSPII (SEQ ID NO: 4805), ASGSPH (SEQ ID NO: 4806), NSGSPH (SEQ ID NO: 4807), LSGSPH (SEQ ID NO: 4808), GGGSPH (SEQ ID NO: 4809), KSGSPH (SEQ ID NO: 4810), HSGSPH (SEQ ID NO: 4811), GTGSPH (SEQ ID NO: 4812), PSGSPH (SEQ ID NO: 4813), GSVSPH (SEQ ID NO: 4814), RSGSPH (SEQ ID NO: 4815), GIGSPH (SEQ ID NO: 4816). WSGSPH (SEQ ID NO: 4817), DSGSPH (SEQ ID NO: 4818), IDGSPH (SEQ ID NO: 4819), GLGSPH (SEQ ID NO: 4820), DAGSPH (SEQ ID NO: 4821), DGGSPH (SEQ ID NO: 4822), MEGSPH (SEQ ID NO: 4823), ENGSPH (SEQ ID NO: 4824), GSASPH (SEQ ID NO: 4825), KNGSPH (SEQ ID NO: 4826), KEGSPH (SEQ ID NO: 4827), AIGSPH (SEQ ID NO: 4828), GYDSPH (SEQ ID NO: 4829), GHGSPH (SEQ ID NO: 4830), GRDSPH (SEQ ID NO: 4831), GNDSPH (SEQ ID NO: 4832), GPDSPH (SEQ ID NO: 4833), GMGSPH (SEQ ID NO: 4834), GQVSPH (SEQ ID NO: 4835), GHNSPH (SEQ ID NO: 4836), GHPSPH (SEQ ID NO: 4837), or GHSSPH (SEQ ID NO: 4838):(ii) an amino acid sequence comprising any portion of an amino acid, sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different: amino acids, relative to any one of the amino acid sequences in (i).18. The AAV particle of any one of embodiments 1-17, wherein [N1]-[N2]-[N3] comprises:(i) SGSPHSK (SEQ ID NO: 4839), HDSPHKS (SEQ ID NO: 4840), SGSPHAR (SEQ ID NO: 4841), SGSPHVK (SEQ ID NO: 4842), QDSPHKS (SEQ ID NO: 4843), SGSPHKK (SEQ ID NO: 4844), SGSPHVR (SEQ ID NO: 4845), SGSPHAS (SEQ ID NO: 4846), SGSPHRK (SEQ ID NO: 4847), SGSPHKT (SEQ ID NO: 4848), SHSPHKS (SEQ ID NO: 4849), QSSPHRS (SEQ ID NO: 4850), RGSPHAS (SEQ ID NO: 4851 ), RGSPHSK (SEQ ID NO: 4852), SGSPHKF (SEQ ID NO: 4853), SGSPHKI (SEQ ID NO: 4854),SGSPHKL (SEQ ID NO: 4855), SGSPHKY (SEQ ID NO: 4856), SGSPHTR (SEQ ID NO: 4857), SHSPHKR (SEQ ID NO: 4858), SGSPHGA (SEQ ID NO: 4859), HDSPHKR (SEQ ID NO: 4860), DDSPHKS (SEQ ID NO: 4861), HESPHKS (SEQ ID NO: 4862), NYSPHKI (SEQ ID NO: 4863), SGSPHSR (SEQ ID NO; 4864), SGSPHSL (SEQ ID NO; 4865), SGSPHSS (SEQ ID NO: 4866), VGSPHSK (SEQ ID NO; 4867), SCSPHRK (SEQ ID NO: 4868). SGSPHFL (SEQ ID NO; 4869), LLSPHWK (SEQ ID NO: 4870), NGSPHSK (SEQ ID NO: 4871), PGSPHSK (SEQ ID NO: 4872), GGSPHSK (SEQ ID NO: 4873), TGSPHSK (SEQ ID NO: 4874), SVSPHGK (SEQ ID NO: 4875), SGSPHTK (SEQ ID NO: 4876), IGSPHSK (SEQ ID NO: 4877), DGSPHSK (SEQ ID NO: 4878), SGSPHNK (SEQ ID NO: 4879), LGSPHSK (SEQ ID NO: 4880), AGSPHSK (SEQ ID NO: 4881), EGSPHSK (SEQ ID NO: 4882), SASPHSK (SEQ ID NO: 4883), SGSPHAK (SEQ ID NO: 4884), HDSPHKI (SEQ ID NO: 4885), YDSPHKS (SEQ ID NO: 4886), HDSPHKT (SEQ ID NO: 4887), RGSPHKR (SEQ ID NO: 4888), HGSPHSK (SEQ ID NO: 4889), RDSPHKS (SEQ ID NO: 4890), NDSPHKS (SEQ ID NO: 4891), QDSPHKI (SEQ ID NO: 4892), PDSPHKI (SEQ ID NO: 4893), PDSPHKS (SEQ ID NO: 4894), MGSPHSK (SEQ ID NO: 4895), HDSPHKH (SEQ ID NO: 4896), QVSPHKS (SEQ ID NO: 4897), HNSPHKS (SEQ ID NO: 4898), NGSPHKR (SEQ ID NO: 4899), HDSPHKY (SEQ ID NO: 4900). NDSPHKI (SEQ ID NO: 4901), HDSPHKI. (SEQ ID NO: 4902), HPSPHWK (SEQ ID NO: 4903), HDSPHKM (SEQ ID NO: 4904), or HSSPHRS (SEQ ID NO: 4905);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, or 6 amino acids, e.g,, consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).19. The AAV particle of any one of embodiments 1-18, wherein [N1]-[N2]-[N3] is or comprises:(i) GSGSPHSKA (SEQ ID NO; 4697), GHDSPHKSG (SEQ ID NO; 4698), GSGSPHARM (SEQ ID NO: 4906), GSGSPHVKS (SEQ ID NO: 4907), GQDSPHKSG (SEQ ID NO: 4908), GSGSPHASR (SEQ ID NO; 4909), GSGSPHVKI (SEQ ID NO: 4910), GSGSPHKKN (SEQ ID NO: 491 1), GSGSPHVRM (SEQ ID NO: 4912), VSGSPHSKA (SEQ ID NO: 4913), CSGSPHSKA (SEQ ID NO: 4914), GSGSPHRKA (SEQ ID NO: 4915), CSGSPHKTS (SEQ ID NO: 4916), CSHSPHKSG (SEQ ID NO: 4917),GQSSPHRSG (SEQ ID NO: 4918), GRGSPHASR (SEQ ID NO: 4919), GRGSPHSKA (SEQ ID NO: 4920), GSGSPHKFG (SEQ ID NO: 4921), GSGSPHKIG (SEQ ID NO: 4922), GSGSPHKLG (SEQ ID NO: 4923), GSGSPHKTS (SEQ ID NO: 4924), GSGSPHKTT (SEQ ID NO: 4925), GSGSPHKTY (SEQ ID NO: 4926), GSGSPHKYG (SEQ ID NO: 4927), GSGSPHSKD (SEQ ID NO: 4928), GSGSPHSKP (SEQ ID NO: 4929), GSGSPHTRG (SEQ ID NO: 4930), GSGSPHVRG (SEQ ID NO: 4931), GSHSPHKRG (SEQ ID NO: 4932), GSHSPHKSG (SEQ ID NO: 4933), VSGSPHASR (SEQ ID NO: 4934), VSGSPHGAR (SEQ ID NO: 4935), VSGSPHKFG (SEQ ID NO: 4936), GHDSPHKRG (SEQ ID NO: 4937), GDDSPHKSG (SEQ ID NO: 4938), GHESPHKSA (SEQ ID NO: 4939), GHDSPHKSA (SEQ ID NO: 4940), GNYSPHKIG (SEQ ID NO: 4941), GHDSPHKSR (SEQ ID NO: 4942), GSGSPHSKL (SEQ ID NO: 4943), GSGSPHSRA (SEQ ID NO: 4944), GSGSPHSKR (SEQ ID NO: 4945), GSGSPHSLR (SEQ ID NO: 4946), GSGSPHSRG (SEQ ID NO: 4947), GSGSPHSSR (SEQ ID NO: 4948), RVGSPHSKA (SEQ ID NO: 4949), GSCSPHRKA (SEQ ID NO: 4950), GSGSPHFLR (SEQ ID NO: 4951), GSGSPHSKW (SEQ ID NO: 4952), GSGSPHSKS (SEQ ID NO: 4953), GLLSPIIWKA (SEQ ID NO: 4954), GSGSPHVRR (SEQ ID NO: 4955), GSGSPHSKV (SEQ ID NO: 4956), MSGSPHSKA (SEQ ID NO: 4957), RNGSPHSKA (SEQ ID NO: 4958), TSGSPHSK A (SEQ ID NO: 4959), ISGSPHSKA (SEQ ID NO: 4960), GPGSPHSKA (SEQ ID NO: 4961), GSGSPHSKT (SEQ ID NO: 4962), ESGSPHSKA (SEQ ID NO: 4963), SSGSPHSKA (SEQ ID NO: 4964), GNGSPHSKA (SEQ ID NO: 4965), ASGSPHSKA (SEQ ID NO: 4966), NSGSPHSKA (SEQ ID NO: 4967), ESGSPHSKA (SEQ ID NO: 4968), GGGSPHSKA (SEQ ID NO: 4969), KSGSPHSKA (SEQ ID NO: 4970), GGGSPHSKS (SEQ ID NO: 4971), GSGSPHSKG (SEQ ID NO: 4972), HSGSPHSKA (SEQ ID NO: 4973), GTGSPHSKA (SEQ ID NO: 4974), PSGSPHSKA (SEQ ID NO: 4975), GSVSPHGKA (SEQ ID NO: 4976), RSGSPHSKA (SEQ ID NO: 4977), GSGSPHTKA (SEQ ID NO: 4978), GIGSPHSKA (SEQ ID NO: 4979), WSGSPHSKA (SEQ ID NO: 4980), DSGSPHSKA (SEQ ID NO: 4981), IDGSPHSKA (SEQ ID NO: 4982), GSGSPHNKA (SEQ ID NO: 4983), GLGSPHSKS (SEQ ID NO: 4984), DAGSPHSKA (SEQ ID NO: 4985), DGGSPHSKA (SEQ ID NO: 4986), MEGSPHSKA (SEQ ID NO: 4987), ENGSPHSKA (SEQ ID NO: 4988), GSASPHSKA (SEQ ID NO: 4989), GNGSPHSKS (SEQ ID NO: 4990), KNGSPHSKA (SEQ ID NO: 4991), KEGSPHSKA (SEQ ID NO: 4992), AIGSPHSKA (SEQ ID NO: 4993), GSGSPHSKN (SEQ ID NO: 4994), GSGSPHAKA (SEQ ID NO: 4995), GHDSPHKIG (SEQ ID NO: 4996), GYDSPHKSG (SEQ ID NO: 4997), GHESPHKSG (SEQ ID NO: 4998), GHDSPHKTG (SEQ ID NO: 4999), GRGSPHKRG(SEQ ID NO: 5000), GQDSPHKSG (SEQ ID NO: 4908), GHDSPHKSL (SEQ ID NO: 5001), GHGSPHSKA (SEQ ID NO: 5002), GHDSPHKSE (SEQ ID NO: 5003), VSGSPHSKA (SEQ ID NO: 4913), GRDSPHKSG (SEQ ID NO: 5004), GNDSPHKSV (SEQ ID NO: 5005), GQDSPHKIG (SEQ ID NO: 5006), GITDSPHKSV (SEQ ID NO: 5007), GPDSPHKIG (SEQ ID NO: 5008), GPDSPHKSG (SEQ ID NO: 5009), GHDSPHKSW (SEQ ID NO: 5010), GHDSPHKSN (SEQ ID NO: 5011), GMGSPHSKT (SEQ ID NO: 50.12), GHDSPHKHG (SEQ ID NO: 5013), GQVSPHKSG (SEQ ID NO: 5014), GDDSPHKSV (SEQ ID NO: 5015), GHNSPHKSG (SEQ ID NO: 5016), GNGSPHKRG (SEQ ID NO: 5017), GHDSPHKYG (SEQ ID NO: 5018), GHDSPHKSQ (SEQ ID NO: 5019), GNDSPHKIG (SEQ ID NO: 5020), GHDSPHKSK (SEQ ID NO: 5021), GHDSPHKLW (SEQ ID NO: 5022), GHPSPHWKG (SEQ ID NO: 5023), GHDSPHKMG (SEQ ID NO: 5024), GHDSPHKMA (SEQ ID NO: 5025), or GHSSPHRSG (SEQ ID NO: 5026):(ii) an amino acid sequence comprising any portion of an amino acid, sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, or 8 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).20. The AAV particle of any one of embodiments 1-19, wherein [N3] comprises SK, KA, KS, or SG.21. The AAV particle of any one of embodiments 1-20, wherein [N3| is or comprises SK A.KSG, or KYG.22. The AAV particle of any one of embodiments 1-21, wherein [N2]-[N3] comprisesSPHSK (SEQ ID NO: 4701), SPHKS (SEQ ID NO: 4704), or SPHKY (SEQ ID NO: 4715).23. The AAV particle of any one of embodiments 1-22, wherein [N2]-[N3] is or comprises SPHSK A (SEQ ID NO: 941).24. The AAV particle of any one of embodiments 1-22, wherein [N2]-[N3] is or comprises SPHKSG (SEQ ID NO: 946).25. The AAV particle of any one of embodiments 1-22, wherein [N2]-[N3] is or comprises SPHKYG (SEQ ID NO: 966).26. The AAV particle of any one of embodiments 1-25, wherein [N1] comprises GS, SG, GH, or HD.27. The AAV particle of any one of embodiments 1-26, wherein [N1] is or comprises GSG.28. The AAV particle of any one of embodiments 1-26, wherein [N1] is or comprises GHD.29. The AAV particle of any one of embodiments 1-23 or 26-27, wherein [N1]-[N2]-[N3] comprises SGSPHSK (SEQ ID NO: 4839).30. The AAV particle of any one of embodiments 1-22, 24, 26, or 28, wherein [N1]-[N2]- [N3] comprises HDSPHKS (SEQ ID NO: 4840).31. The AAV particle of any one of embodiments 1-22 or 2.5-27, wherein [N1]-[N2]-[N3] comprises SGSPHKYG (SEQ ID NO: 5027).32. The AAV particle of any one of embodiments 1-8, 10, 12-2.3, 26-27, or 2.9, wherein [N1]- [N2]-[N3] is or comprises GSGSPHSKA (SEQ ID NO: 4697).33. The AAV particle of any one of embodiments 1-9, 11-22, 24, 26, 28, or 30, wherein [N1]- [N2]-[N3] is or comprises GHDSPHKSG (SEQ ID NO: 4698).34. The AAV particle of any one of embodiments 1-8, 10, 12-22, 25-27, or 31, wherein [N1] [N2]-[N3] is or comprises GSGSPHKYG (SEQ ID NO: 4927).35. The AAV particle of any one of embodiments 1-34, wherein [N1 ]-[N2]-[N3] replaces positions 453-455, numbered according to SEQ ID NO: 138.36. The AAV particle of any one of embodiments 1-35, wherein the AAV capsid variant comprises an amino acid other than Q at position 456 (e.g., W, K, R. G, L, V, S, P, H, K, I,M, A, E, or F), an amino acid other than N at position 457 (e.g., Y, C, K, T, II, R, D, V, S, P, G, W, E, F, A, I, M, Q, or L), an amino acid other than Q at position 458 (e.g., G, K, H, R, T, L, D, A, P, I, F, V, M, W, Y, S, E, N, or Y), and / or an amino acid, other than Q at position 459 (e.g., H, L, R, W, K, A, P, E, M, I, S, G, N, Y, C, V, T, D, or V), numbered according to SEQ ID NO: 138.37. The AAV particle of any one of embodiments 1-36, wherein the AAV capsid variant comprises an amino acid other than Q at position 462 (e.g., W, K, R, G, L, V, S, P, H, K, I, M, A, E, or F), an amino acid other than N at position 463 (e.g., Y, C, K, T, H, R, D, V, S, P, G, W, E, F, A, I, M, Q, or L), an amino acid other than Q at position 464 (e.g., G, K, H, R, T, L, D, A, P, I, F, V, M, W, Y, S, E, N, or Y), and / or an amino acid other than Q at position 465 (e.g., H, L, R, W, K, A, P, E, M, I, S, G, N, Y, C, V, T, D, or V), numbered according to SEQ ID NO: 981, 982, 36, 37, 39, 40. 42-46, 48, 49, 50, 52, 53. 56, or 57.38. The AAV particle of any one of embodiments 1-37, wherein the AAV capsid variant comprises:(a) the amino acid Q at position 456, the amino acid N at position 457, the amino acid Q at position 458, and / or the amino acid Q at position 459, numbered according to SEQ ID NO: 138; or(b) the amino acid Q at position 462, the amino acid N at position 463, the amino acid Q at position 464, and / or the amino acid Q at position 465, numbered according to SEQ ID NO: 981 , 982, 36, 37, 39, 40, 42-46, 48, 49, 50, 52, 53, 56, or 57.39. 'The AAV particle of any one of embodiments 1-38, wherein the AAV capsid variant further comprises [N4] , wherein [N4] comprises X7 X8 X9 X10, and wherein:(a) X7 is: Q, W, K, R, G, L, V, S, P, II, K, I, M, A, E, or F;(b) X8 is: N, Y, C, K, T, H, R, D, V, S, P, G, W, E, F, A, I, M, Q, or L;(c) .X9 is: Q, G, K, H, R, T, L, D, A, P, I, F, V, M, W, Y, S, E, N, or Y; and(d) X10 is: Q, II, L, R, W, K, A, P, E, M, I, S, G, N, Y, C, V, T, D, or V; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(d).40. The AAV particle of embodiment 39, wherein:(a) X7 of [N4] is Q or R;(b) X8 of [N4] is N or R;(c) X9 of [N4] is Q or R; and(d) X10 of [N4] is Q, L, or R.41. The AAV particle of embodiment 39 or 40, wherein [N4] is or comprises:(i) QNQQ (SEQ ID NO: 5028), WNQQ (SEQ ID NO: 5029). QYYV (SEQ ID NO: 5030), RRQQ (SEQ ID NO: 5031), GCGQ (SEQ ID NO: 5032), LRQQ (SEQ ID NO: 5033), RNQQ (SEQ ID NO: 5034), VNQQ (SEQ ID NO: 5035), FREQ (SEQ ID NO: 5036), FNQQ (SEQ ID NO: 5037), LLQQ (SEQ ID NO: 5038), SNQQ (SEQ ID NO: 5039), RLQQ (SEQ ID NO: 5040), LNQQ (SEQ ID NO: 5041), QRKL (SEQ ID NO: 5042), LRRQ (SEQ ID NO: 5043), QRLR (SEQ ID NO: 5044), QRRL (SEQ ID NO: 5045), RRLQ (SEQ ID NO: 5046), RL.RQ (SEQ ID NO: 5047), SKRQ (SEQ ID NO: 5048), QLYR (SEQ ID NO: 5049), QLTV (SEQ ID NO: 5050), QNKQ (SEQ ID NO: 5051), KNQQ (SEQ ID NO: 5052), QKQQ (SEQ ID NO: 5053), QTQQ (SEQ ID NO: 5054), QNHQ (SEQ ID NO: 5055), QIIQQ (SEQ ID NO: 5056), QNQII (SEQ ID NO: 5057), QIIRQ (SEQ ID NO: 5058), LTQQ (SEQ ID NO: 5059), QNQW (SEQ ID NO: 5060), QNTH (SEQ ID NO: 5061), RRRQ (SEQ ID NO: 5062), QYQQ (SEQ ID NO: 5063), QNDQ (SEQ ID NO: 5064), QNRH (SEQ ID NO: 5065), RDQQ (SEQ ID NO: 5066), PNLQ (SEQ ID NO: 5067), HVRQ (SEQ ID NO: 5068), PNQH (SEQ ID NO: 5069), HNQQ (SEQ ID NO: 5070), QSQQ (SEQ ID NO: 5071), QPAK (SEQ ID NO: 5072), QNLA (SEQ ID NO: 5073), QNQL (SEQ ID NO: 5074), QGQQ (SEQ ID NO: 5075), LNRQ (SEQ ID NO: 5076), QNPP (SEQ ID NO: 5077), QNLQ (SEQ ID NO: 5078), QDQE (SEQ ID NO: 5079), QDQQ (SEQ ID NO: 5080), HWQQ (SEQ ID NO: 5081), PNQQ (SEQ ID NO: 5082), PEQQ (SEQ ID NO: 5083), QRTM (SEQ ID NO: 5084), LHQH (SEQ ID NO: 5085), QHRI (SEQ ID NO: 5086), QYIH (SEQ ID NO: 5087), QKFE (SEQ ID NO: 5088), QFPS (SEQ ID NO: 5089), QNPL (SEQ ID NO: 5090), QAIK (SEQ ID NO: 5091), QNRQ (SEQ ID NO: 5092), QYQII (SEQ ID NO: 5093), QNPQ (SEQ ID NO: 5094), QHQL (SEQ ID NO: 5095), QSPP (SEQ ID NO: 5096), QAKL (SEQ ID NO: 5097), KSQQ (SEQ ID NO: 5098), QDRP (SEQ ID NO: 5099), QNLG (SEQ ID NO: 5100), QAFH (SEQ ID NO: 5101), QNAQ (SEQ ID NO: 5102), FINQL (SEQ ID NO: 5103), QKLN (SEQ ID NO: 5104), QNVQ (SEQ ID NO: 5105), QAQQ (SEQ ID NO: 5106), QIPP (SEQ ID NO: 5107), QPPA (SEQ ID NO: 5108). QERP (SEQ ID NO: 5109), QDLQ (SEQ ID NO: 5110), QAMH (SEQ ID NO: 5111), QHPS (SEQ ID NO: 5112), PGLQ (SEQ ID NO: 5113), QGIR (SEQ ID NO: 5114), QAPA (SEQ ID NO: 5115), QIPP (SEQ ID NO: 5116), QTQL (SEQ ID NO: 5117), QAPS (SEQ ID NO: 5118),QNTY (SEQ ID NO: 5119), QDKQ (SEQ ID NO: 5120), QNIIL (SEQ ID NO: 5121), QIGM (SEQ ID NO: 5122), LNKQ (SEQ ID NO: 5123), PNQL (SEQ ID NO: 5124), QLQQ (SEQ ID NO: 5125), QRMS (SEQ ID NO: 5126), QGIL (SEQ ID NO: 5127), QDRQ (SEQ ID NO: 5128), RDWQ (SEQ ID NO: 5129), QERS (SEQ ID NO: 5130), QNYQ (SEQ ID NO: 5131), QRTC (SEQ ID NO: 5132), QIGH (SEQ ID NO: 5133), QGAI (SEQ ID NO: 5134), QVPP (SEQ ID NO: 5135), QVQQ (SEQ ID NO: 5136), LMRQ (SEQ ID NO: 5137), QYSV (SEQ ID NO: 5138), QAIT (SEQ ID NO: 5139), QKTL (SEQ ID NO: 5140), QLHH (SEQ ID NO: 5141), QNII (SEQ ID NO: 5142), QGHH (SEQ ID NO: 5143), QSKV (SEQ ID NO: 5144), QLPS (SEQ ID NO: 5145), 1GKQ (SEQ ID NO: 5146), QAIH (SEQ ID NO: 5147), QHGL (SEQ ID NO: 5148), QFMC (SEQ ID NO: 5149), QNQM (SEQ ID NO: 5150), QHLQ (SEQ ID NO: 5151), QPAR (SEQ ID NO: 5152), QSLQ (SEQ ID NO: 5153), QSQL (SEQ ID NO: 5154), HSQQ (SEQ ID NO: 5155), QMPS (SEQ ID NO: 5156), QGSL (SEQ ID NO: 5157), QVPA (SEQ ID NO: 5158), HYQQ (SEQ ID NO: 5159), QVPS (SEQ ID NO: 5160), RGEQ (SEQ ID NO: 5161), PGQQ (SEQ ID NO: 5162), LEQQ (SEQ ID NO: 5163), QNQS (SEQ ID NO: 5164), QKVI (SEQ ID NO: 5165), QNND (SEQ ID NO: 5166), QSVH (SEQ ID NO: 5167), QPLG (SEQ ID NO: 5168), HNQE (SEQ ID NO: 5169), QIQQ (SEQ ID NO: 5170), QVRN (SEQ ID NO: 5171), PSNQ (SEQ ID NO: 5172), QVGH (SEQ ID NO: 5173), QRDI (SEQ ID NO: 5174), QMPN (SEQ ID NO: 5175), RGEQ (SEQ ID NO: 5176), PSLQ (SEQ ID NO: 5177), QRDQ (SEQ ID NO: 5178), QAKG (SEQ ID NO: 5179), QSAH (SEQ ID NO: 5180), QSTM (SEQ ID NO: 5181), QREM (SEQ ID NO: 5182), QYRA (SEQ ID NO: 5183), QRQQ (SEQ ID NO: 5184), QWQQ (SEQ ID NO: 5185), QRMN (SEQ ID NO: 5186), GDSQ (SEQ ID NO: 5187), QKIS (SEQ ID NO: 5188), PSMQ (SEQ ID NO: 5189), SPRQ (SEQ ID NO: 5190), MEQQ (SEQ ID NO: 5191), QYQN (SEQ ID NO: 5192), QIRQ (SEQ ID NO: 5193), QSVQ (SEQ ID NO: 5194), RSQQ (SEQ ID NO: 5195), QNKL (SEQ ID NO: 5196), QIQH (SEQ ID NO: 5197), PRQQ (SEQ ID NO: 5198), HTQQ (SEQ ID NO: 5199), QRQH (SEQ ID NO: 5200), RNQE (SEQ ID NO: 5201), QSKQ (SEQ ID NO: 5202), QNQP (SEQ ID NO: 5203), QSPQ (SEQ ID NO: 5204), QTRQ (SEQ ID NO: 5205). QNLH (SEQ ID NO: 5206), QNQE (SEQ ID NO: 5207), LNQP (SEQ ID NO: 5208), QNQD (SEQ ID NO: 5209), QNLL (SEQ ID NO: 5210), QLVI (SEQ ID NO: 5211), RTQE (SEQ ID NO: 5212), QTHQ (SEQ ID NO: 5213), QDQH (SEQ ID NO: 5214), QSQH (SEQ ID NO: 5215), VRQQ (SEQ ID NO: 5216). AWQQ (SEQ ID NO: 5217), QSVP (SEQ ID NO: 5218), QNIQ (SEQ ID NO: 5219), LDQQ (SEQ ID NO: 5220), PDQQ (SEQ ID NO: 5221), ESQQ (SEQ ID NO: 5222), QRQL (SEQ ID NO: 5223), QIIV (SEQ ID NO: 5224), QKQS (SEQ ID NO: 5225), QSHQ (SEQ ID NO: 5226), QFVV (SEQ ID NO: 5227), QSQP (SEQ ID NO: 5228),QNEQ (SEQ ID NO: 5229), INQQ (SEQ ID NO: 5230), RNRQ (SEQ ID NO: 5231 ), RDQK (SEQ ID NO: 5232), QWKR (SEQ ID NO: 5233), ENRQ (SEQ ID NO: 5234), QTQP (SEQ ID NO: 5235), QKQL (SEQ ID NO: 5236), RNQL (SEQ ID NO: 5237), ISIQ (SEQ ID NO: 5238), QTVC (SEQ ID NO: 5239), QQIM (SEQ ID NO: 5240), LNIIQ (SEQ ID NO: 5241), QNQA (SEQ ID NO: 5242), QMIH (SEQ ID NO: 5243), RNHQ (SEQ ID NO: 5244), or QKMN (SEQ ID NO: 5245):(ii) an amino acid sequence comprising any portion of an amino acid, sequence in (i), e.g., any 2, or 3 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).42. The AAV particle of any one of embodiments 39-41, wherein [N1]-[N2]-[N3]-[N4] is or comprises:(i) the amino acid sequence of any of SEQ ID NOs: 1800-2241;(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g,, any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).43. The AAV particle of any one of embodiments 39-42, wherein [N1]-[N2]-[N3]-[N4] is or comprises GSGSPHSKAQNQQ (SEQ ID NO: 1801).44. The AAV particle of any one of embodiments 39-42, wherein [N1]-[N2]-[N3]-[N4] is or composes GHDSPHKSGQNQQ (SEQ ID NO: 1800).45. The AAV particle of any one of embodiments 39-42, wherein [N1]-[N2]-[N3]-[N4| is or comprises GSGSPHKYGQNQQT (SEQ ID NO: 910).46. The AAV particle of any one of embodiments 1-45. wherein the AAV capsid variant comprises an amino acid other than T at position 450 (e.g., S, Y, M, A, C, I, R, L, D, F, V, Q,N, H, E, or G), an amino acid other than I at position 451 (e.g., M, P, E, N, D, S, A, T, G, Q, F, V, L, C, H, R, W, or L), and / or an amino acid other than N at position 452 (e.g., M, E, G, Y, W, T, I, Q, F, V, A, L, I, P, K, R, H, S, D, or S), numbered according to any one of SEQ ID NOs: 36-59, 138, 981, or 982.47. The AAV particle of any one of embodiments 1-46, wherein the AAV capsid variant compnses the amino acid T at position 450, the amino acid I at position 451 , and / or the amino acid N at position 452, numbered according to any one of SEQ ID NOs: 138, 981, or 982.48. The AAV particle of any one of embodiments 1-47, wherein the AAV capsid variant further comprises [N0], wherein [N0] comprises XAXBand XC, and wherein:(a) XAis: T, S, Y, M, A, C, I. R. L. D. F. V. Q. N, H. E, or G;(b) XBis: I, M, P, E, N, D, S, A, T, G, Q, F, V, I.,, C, H, R, W, or L; and(c) XCis: N, M, E, G, Y, W, T, I, Q, F, V, A, L, I, P, K, R, H, S, D, or S; and optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(c).49. The AAV particle of embodiment 48, wherein [N0] is or comprises TIN, SMN, TIM, YLS, GLS, MPE, MEG, MEY, AEW, CEW, ANN, IPE. ADM, IEY, ADY, IET, MEW, CEY, RIN, MEI, LEY, ADW, lEI, DIM, FEQ, MEF, CDQ, L PE, IEN, MES, AEI, VEY, UN, TSN, IEV, MEM, AEV, MDA, VEW, AEQ, LEW, MEL, MET, MEA, IES, MEV, CEI, ATN, MDG, QEV, ADQ, NMN, IEM, ISN, TGN, QQQ, HDW, LEG, TII, TFP, TEK, EIN, TVN, TEN, SIN, TER, TSY, ELH, AIN. SVN, TDN, TFH, TVH, TEN. TSS, TID, TCN, NIN, TEH, AEM, AIK, TDK, TFK, SDQ, TEI, NTN, TET, SIK, TEL., TEA, TAN, TTY, TFS, TES, TEN, TED, TNN, EVH, TIS, TVR, TDR, TIK, NHI, TIP, ESD, TDL, TVP, TVI, AEH, NCL, TVK, NAD, TIT, NCV, TIR, NAL. VLN. HQ. TEE, TRE, QGE, SEK, NVN, GGE, EFV, SDK, TEQ, EVQ, TEY, NOW, TDV, SDI, NSI, NSL, EVV, TEP, SEL, TWQ, TEV, AVN, GVL, TEN, TEG, TRD, NAT, AEN, AET, ETA, NNL, or any dipeptide thereof.50. The MV particle of embodiment 48 or 49, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or compnses:(i) the amino acid sequence of any one of SEQ ID NOs: 2242-2886;(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i): or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).51. The AAV particle of any one of embodiments 48-50, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises TINGSGSPHSKAQNQQ (SEQ ID NO: 2242).52. The AAV particle of any one of embodiments 48-50, wherein |N0]-[N1 ]-[N2]-[N3]-[N4] is or comprises TINGHDSPHKSGQNQQ (SEQ ID NO: 2243).53. The AAV particle of any one of embodiments 48-52, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises TINGSGSPHKYGQNQQT (SEQ ID NO: 5246).54. The AAV particle of any one of embodiments 1-53, wherein [N1]-[N2]-[N3] is present in loop IV.55. The AAV particle of any one of embodiments 48-54, wherein [N0] and [N4] are present in loop IV.56. The AAV particle of any one of embodiments 48-55, wherein [N0] is present immediately subsequent to position 449, numbered according to SEQ ID NO: 138.57. The AAV particle of any one of embodiments 48-56, wherein [N0] is present immediately subsequent to position 449, numbered according to any one of SEQ ID NOs: 36- 59, 981, 01' 982.58. lire AAV particle of any one of embodiments 48-57, wherein [N0] replaces positions450, 451, and 452. (e.g., T450, I451, and N452), numbered according to SEQ ID NO: 138.59. The AAV particle of any one of embodiments 48-58, wherein [N0] replaces positions 450-452 (e.g., T450, 1451, and N452), numbered according to any one of SEQ ID NOs: 36- 59, 981 , or 982.60. The AAV particle of any one of embodiments 48-59, wherein [N0] corresponds to positions 450-452 of any one of SEQ ID NOs: 36-59, 138, 981 or 982.61 . The AAV particle of any one of embodiments 48-60, wherein [N0] is present immediately subsequent to position 449 and wherein [N0] replaces positions 450-452 (e.g., T450, 1451, and N452), numbered according to SEQ ID NO: 138.62. The AAV particle of any one of embodiments 48-61, wherein [N0] is present immediately subsequent to position 449 and wherein [N0] replaces positions 450-452 (e.g., T450, 1451, and N452), numbered according to any one of SEQ ID NOs: 36-59, 981, or 982.63. The AAV particle of any one of embodiments 1-62, wherein [N1] is present immediately subsequent to position 452, numbered according to the amino acid sequence of SEQ ID NO: 138.64. The AAV particle of any one of embodiments 1-63, wherein [N1] is present immediately subsequent to position 452, numbered according to SEQ ID NO: 981 or 982.65. The AAV particle of any one of embodiments 1-61, wherein [N1] replaces positions 453455 (e.g., G453, S454, and G455), numbered according to SEQ ID NO; 138.66. The AAV particle of any one of embodiments 1-64, wherein [N1] replaces positions 453 (e.g., G453), numbered according to SEQ ID NO: 138.67. The AAV particle of any one of embodiments 1-65, wherein [N1] replaces positions 453- 455 (e.g., G453, S454, and G455), numbered according to SEQ ID NO: 981.68. The AAV particle of any one of embodiments 1-65 or 67, wherein [N1] replaces positions 453-455, numbered according to SEQ ID NO: 982.69. The AAV particle of any one of embodiments 1-65, 67, or 68, wherein [N1] is present immediately subsequent to position 452 and wherein [N1] replaces positions 453-455 (e.g., G453, S454, and G455), numbered according to SEQ ID NO: 138.70. The AAV particle of any one of embodiments 1-64 or 66, wherein [N1] is present immediately subsequent to position 452 and wherein [N1] replaces positions 453 (e.g., G453), numbered according to SEQ ID NO: 138.71. The AAV particle of any one of embodiments 1-64, 66 or 70, wherein [N1] is present immediately subsequent to position 452 and wherein [N1] replaces positions 453-455, numbered according to SEQ ID NO; 4, 36, 981, or 982.72. The AAV particle of any one of embodiments 1-71, wherein [N1] corresponds to positions 453-455, numbered according to any one of SEQ ID NOs: 4, 36-59, 981, or 982.73. The AAV particle of any one of embodiments 1-72, wherein the AAV capsid variant comprises an amino acid other than S at position 454 and / or an amino acid other than G at position 455, numbered according to SEQ ID NO: 138, 981 , or 982.74. The AAV particle of any one of embodiments 1-73, wherein the AAV capsid variant comprises the amino acid H at position 454 and the amino acid D at position 455, numbered according to SEQ ID NO: 138 or 982.75. The AAV particle of any one of embodiments 1-74, wherein the AAV capsid variant comprises a substitution at position 454 (e.g., S454H) and / or a substitution at position 455 (e.g., G455D), numbered according to SEQ ID NO: 138.76. The AAV particle of any one of embodiments 1-75, wherein the AAV capsid variant comprises the amino acid II at position 454 and the amino acid D at position 455, and further comprises the amino acid sequence SPHSKA (SEQ ID NO: 941) immediately subsequent to position 455, numbered according to SEQ ID NO: 138.77. The AAV particle of any one of embodiments 1-76, wherein the AAV capsid variant comprises the amino acid H at position 454 and the amino acid D at position 455, numbered according to SEQ ID NO: 982.78. The AAV particle of any one of embodiments 1-77, wherein the AAV capsid variant comprises the amino acid H at position 454 and the amino acid I) at position 455, and fiirther composes the amino acid sequence SPHSKA (SEQ ID NO: 941) immediately subsequent to position 455, numbered according to SEQ ID NO: 982.79. The A AV particle of any one of embodiments 1-72, wherein the AAV capsid vanant comprises the amino acid S at position 454 and the amino acid G at position 455, numbered according to SEQ ID NO: 138.80. The AAV particle of any one of embodiments 1-72 or 79, wherein the AAV capsid variant comprises the amino acid S at position 454 and the amino acid G at position 455, and further comprises the amino acid sequence SPHSKA (SEQ ID NO: 941) immediately subsequent to position 455, numbered according to SEQ ID NO: 138.81. The AAV particle of any one of embodiments 1-72, 79, or 80, wherein the .AAV capsid variant comprises the amino acid S at position 454 and the amino acid G at position 455, numbered according to SEQ ID NO: 981.82. The AAV particle of any one of embodiments 1-72 or 79-81, wherein the AAV capsid variant comprises the amino acid S at position 454 and the amino acid G at position 455, and fiirther comprises the amino acid sequence SPHSKA (SEQ ID NO: 941) immediately subsequent to position 455, numbered according to SEQ ID NO: 981.83. The AAV particle of any one of embodiments 1-82, wherein [N2] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138.84. The AAV particle of any one of embodiments 1-83, wherein [N2] corresponds to positions 456-458 (e.g., S456, P457, H458) of SEQ ID NO: 981 or 982.85. The AAV particle of any one of embodiments 1-83, wherein [N2] corresponds to positions 456-458 (e.g., S456, P457, H458) of any one of SEQ ID NOs: 4 or 36-59.86. The AAV particle of any one of embodiments 1-85, wherein [N2]-[N3] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138.87. The AAV particle of any one of embodiments 1-86, wherein [N2] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 4, 36, 981 , or 982.88. The AAV particle of any one of embodiments 1-87, wherein [N2]-[N3] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 4, 36, 981, or 982.89. The AAV particle of any one of embodiments 1-88, wherein [N2]-[N3] corresponds to positions 456-461 (e.g., S456, P457, H458, S459, K460, A461) of SEQ ID NO: 981.90. The AAV particle of any one of embodiments 1-88, wherein [N2]-[N3] corresponds to positions 456-461 (e.g., S456, P457, H458, K459, S460, G461) of SEQ ID NO: 982.91. The AAV particle of any one of embodiments 1-90, wherein [N2] is present immediately subsequent to [N1] .92. The AAV particle of any one of embodiments 1-64, 66, 70, or 71, wherein [N3] is present immediately subsequent to [N2] and replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138.93. The AAV particle of any one of embodiments 1-1-64, 66, 70, 71, or 92, wherein [N3] is present immediately subsequent to [N1]-[N2] and replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138.94. lire AAV particle of any one of embodiments 39-93, wherein [N4] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138.95. The AAV particle of any one of embodiments 39-94, wherein [N4] replaces positions 456-459 (e.g., Q456, N457, Q458, and Q459), numbered according to SEQ ID NO: 138.96. The AAV particle of any one of embodiments 39-95, wherein [N4] corresponds to positions 462-465 (e.g., Q462, N463, Q464, Q465) of SEQ ID NO: 4, 36, 981, or 982.97. The AAV particle of any one of embodiments 39-96, wherein [N2]-[N3]-[N4] replaces positions 456-459 (e.g., Q456, N457, Q458, and Q459), numbered according to SEQ ID NO: 138.98. The AAV particle of any one of embodiments 39-97, wherein [N2]-[N3]-[N4] is present immediately subsequent to position 455, and wherein [N2]-[N3]-[N4] replaces positions 456- 459 (e.g., Q456, N457, Q458, and Q459), numbered according to SEQ ID NO: 138.99. The AAV particle of any one of embodiments 39-98, wherein [N2]-[N3]-[N4] corresponds to positions 456-465 (e.g., S456, P457, H458, S459, K460, A461, Q462, N463, Q464, Q465) of SEQ ID NO: 981.100. The AAV particle of any one of embodiments 39-98, wherein [N2]-[N3]-[N4] corresponds to positions 456-465 (e.g., S456, P457, H458, K459, S460, G461, Q462, N463, Q464, Q465) of SEQ ID NO: 982.101. The AAV particle of any one of embodiments 39-98, wherein [N2]-[N3]-[N4] corresponds to positions 456-465 of any one of SEQ ID NOs: 4 or 36-59.102. The AAV particle of any one of embodiments 39-101 , wherein [N1]-[N2]-[N3]-[N4] replaces positions 453-459 (e.g., G453, S454, G455, Q456, N457, Q458, and Q459), numbered according to SEQ ID NO: 138.103. The AAV particle of any one of embodiments 39-102, wherein [N1]- [N2]-[N3]-[N4] is present immediately subsequent to position 452, and wherein [N1]-[N2]-[N3]-[N4] replaces positions 453-459 (e.g., G453, S454, G455, Q456, N457, Q458, and Q459), numbered according to SEQ ID NO: 138.104. The AAV particle of any one of embodiments 39-99, 102, or 103, wherein [N1]-[N2]- [N3]-[N4] corresponds to positions 453-465 (e.g., G453, S454, G455, S456, P457, H458, S459, K460, A461, Q462, N463, Q464, Q465) of SEQ ID NO: 981.105. The AAV particle of any one of embodiments 39-98, 100, 102, or 103, wherein [N1] [N2]-[N3]-[N4] corresponds to positions 453-465 (e.g., G453, H454, D455, S456, P457, H458, K459, S460, G461, Q462, N463, Q464, Q465) of SEQ ID NO: 982.106. The AAV particle of any one of embodiments 39-98, 102, or 103, wherein [N1]-[N2] [N3]-[N4] corresponds to positions 453-465 of any one of SEQ ID NOs: 4 or 36-59.107. The AAV particle of any one of embodiments 1-99 or 102-104, wherein [N1 |-[N2]-[N3] corresponds to positions 453-461 (e.g., G453, S454, G455, S456, P457, H458, S459, K460, A461) of SEQ ID NO: 981.108. The AAV particle of any one of embodiments 1-98, 100, 102, 103, or 105, wherein [N1]-[N2]-[N3] corresponds to positions 453-461 (e.g., G453, H454, D455, S456, P457, H458, K459, S460, G461) of SEQ ID NO: 982.109. The AAV particle of any one of embodiments 39-98, 102, 103, or 106, wherein [N1]- [N2]-[N3] corresponds to positions 453-461 of any one of SEQ ID NOs: 36-59.110. The AAV particle of any one of embodiments 48-109, wherein [N0]-|N1 ]-[N2]-[N3]- [N4] replaces positions 450-459 (e.g., T450, 1451, N452, G453, S454, G455, Q456, N457, Q458, and Q459), numbered according to SEQ ID NO: 138.111. The AAV particle of any one of embodiments 48-110, wherein [N0]-[N1]-[N2]-[N3]- [N4] is present immediately subsequent to position 449, and wherein [N0]-[N1]-[N2]-[N3]- [N4] replaces positions 450-459 (e.g., T450, 1451, N452, G453, S454, G455, Q456, N457, Q458, and Q459), numbered according to SEQ ID NO: 138.112. The AAV particle of any one of embodiments 48-99, 102-104, or 106, wherein [N0]- [N1]-[N2]-[N3]-[N4] corresponds to positions 450-465 (e.g., T450, 1451 , N452, G453, S454,G455, S456, P457, H458, S459, K460, A461, Q462, N463, Q464, Q465) of SEQ ID NO: 981.113. The AAV particle of any one of embodiments 48-98, 100, 102, 103, 105, or 108, wherein [N0]-[N1J-[N2]-[N3]-[N4] corresponds to positions 450-465 (e.g., T450, 1451, N452, G453. H454, D455. S456, P457, H458, K459, S460. G461, Q462, N463, Q464, Q465) of SEQ ID NO: 982.114. The AAV particle of any one of embodiments 48-98, 102, 103, 106, or 109, wherein [N0]-[N1]-[N2]-[N3]-[N4] corresponds to positions 450-465 of any one of SEQ ID NOs: 36- 59.115. The AAV particle of any one of embodiments 39-114, wherein [N4] replaces positions 462-465 (e.g., Q462, N463, Q464, and. Q465), numbered according to SEQ ID NO: 4, 36, 981 , or 982.116. The AAV particle of any one of embodiments 39-115, wherein [N2]-|N3]-[N4| replaces positions 462-465 (e.g., Q462, N463, Q464, and Q465), numbered according to SEQ ID NO: 4, 36, 981, or 982.1 17. The AAV particle of any one of embodiments 39-1 .16, wherein [N2]-[N3]-[N4] is present immediately subsequent to position 455, and wherein [N2]-[N3]-[N4] replaces positions 462-465 (e.g., Q462, N463, Q464, and Q465 ), numbered according to SEQ ID NO: 4, 36, 981, or 982.118. The AAV particle of any one of embodiments 1-117, wherein [N3] is present immediately subsequent to [N2].1 19. The AAV particle of any one of embodiments 1 -1 18, wherein the AAV capsid variant comprises, from N-terminus to C-terminus, [N2]-[N3],120. The AAV particle of any one of embodiments .1-119, wirerein the AAV capsid, variant comprises, from N-terminus to C-terminus, [N1]-[N2]-[N3].121. The AAV particle of any one of embodiments 48-120, wherein the AAV capsid variant comprises, from N-terminus to C -terminus, |N0]-[N1]-[N2]-[N3].122. The AAV particle of any one of embodiments 39-121 , wherein the AAV capsid variant comprises, from N-terminus to C -terminus, [N1]-[N2]-[N3]-[N4J.123. The AAV particle of any one of embodiments 48-122, wherein the A AV capsid vanant comprises, from N-terminus to C -terminus, [N0]-[N1]-[N2]-[N3]-[N4].124. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid other T at position 460 (e.g., N, I, C, H, R, L, D, Y, A, M, Q, 1, E, K, P, G or S), numbered according to SEQ ID NO: 138.125. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises the amino acid N, I, C, H, R, L, D, Y, A, M, Q, I, E, K, P, G or S at position 460, numbered according to SEQ ID NO: 138.126. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid other T at position 466 (e.g., N, I, C, H, R, L, D, Y, A, M, Q, I, E, K, P, G or S), numbered according to any one of SEQ ID NOs: 36-59, 981, or 982.127. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises the amino acid N, I, C, H, R, L, D, Y, A, M, Q, I, E, K, P, G or S at position 466, numbered according to any one of SEQ ID NOs: 36-59, 981 or 982.128. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid other K at position 449 (e.g., an E, an N, or a T), numbered according to any one of SEQ ID NOs: 36-59, 138, 981 , or 982,129. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises the amino E, N, or T at position 449, numbered according to any one of SEQ ID NOs: 36-59, 138, 981 or 982.130. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises [A] [B] (SEQ ID NO: 4694), wherein:(i) [A] comprises the amino acid sequence of GSGSPH (SEQ ID NO: 4695); and(ii) [B] comprises X1 X2 X3 X4 X5 X6 X7 , wherein:(a) X1 is: S, C, F, or V;(b) X2 is: K, L, R, I, E, Y, V, or S;(c) X3 is: A, R, L, G, I, Y, S, F, or W;(d) X4 is: W, Q, R, G, L, V, S, or F;(e) X5 is: N, Y, R. C, K, or L;(f) X6 is: Q, G, K, R, T, L, or Y; and(g) X7 is: Q, L, R, or V; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(g).131. The AA V particle of embodiment 130, wherein(a) X1 is S;(b) X2 is K or L;(c) X3 is: A, R. or L;(d) X4 is: Q or R;(e) X5 is: N or R;(f) X6 is: Q or R; and(g) X7 is: Q, L, or R.132. The AAV particle of embodiment 130 or 131, wherein [B] comprises:(i) SLLWNQQ (SEQ ID NO: 5247), SKAQYYV (SEQ ID NO: 5248), SKLRRQQ (SEQ ID NO: 5249), SIWQNQQ (SEQ ID NO: 5250), SKAGCGQ (SEQ ID NO: 5251), SRAQNQQ (SEQ ID NO: 5252), SKRLRQQ (SEQ ID NO: 5253), SLRRNQQ (SEQ ID NO: 5254), SRGRNQQ (SEQ ID NO: 5255), SEIVNQQ (SEQ ID NO: 5256), SSRRNQQ (SEQ ID NO: 5257), CLLQNQQ (SEQ ID NO: 5258), SKAFRLQ (SEQ ID NO: 5259), CLAQNQQ (SEQ ID NO: 5260), FLRQNQQ (SEQ ID NO: 5261), SLRFNQQ (SEQ ID NO: 5262), SYLRNQQ (SEQ ID NO: 5263), CSLQNQQ (SEQ ID NO: 5264), VLWQNQQ (SEQID NO: 5265), SKWLLQQ (SEQ ID NO: 5266), SLWSNQQ (SEQ ID NO: 5267), SKRRLQQ (SEQ ID NO: 5268), SVYLNQQ (SEQ ID NO: 5269), SLWLNQQ (SEQ ID NO: 5270), SKAQRKL (SEQ ID NO: 5271), SKALRRQ (SEQ ID NO: 5272), SKAQRLR (SEQ ID NO: 5273), SKAQNQQ (SEQ ID NO: 5274), SKAQRRL (SEQ ID NO: 5275), SKARRQQ (SEQ ID NO: 5276), SKARRLQ (SEQ ID NO: 5277), SKSRRQQ (SEQ ID NO: 5278). SKARLRQ (SEQ ID NO: 5279), SKASKRQ (SEQ ID NO: 5280), VRRQNQQ (SEQ ID NO: 5281), SKAQLYR (SEQ ID NO: 5282), SLFRNQQ (SEQ ID NO: 5283), SKAQLTV (SEQ ID NO: 5284);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g,, any 2, 3, 4, 5, or 6 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i): or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).133. The .AAV particle of any one of embodiments 130-132, wherein [A][B] comprises:(i) GSGSPHSLLWNQQ (SEQ ID NO: 5285), GSGSPHSKAQYYV (SEQ ID NO: 2060), GSGSPHSKLRRQQ (SEQ ID NO: 2061), GSGSPHSIWQNQQ (SEQ ID NO: 5286), GSGSPHSKAGCGQ (SEQ ID NO: 2062), GSGSPHSRAQNQQ (SEQ ID NO: 2063), GSGSPHSKRLRQQ (SEQ ID NO: 2064), GSGSPHSLRRNQQ (SEQ ID NO: 2065). GSGSPHSRGRNQQ (SEQ ID NO: 2066), GSGSPHSEIVNQQ (SEQ ID NO: 5287), GSGSPHSSRRNQQ (SEQ ID NO: 2067), GSGSPHCLLQNQQ (SEQ ID NO: 5288), GSGSPHSKAFRLQ (SEQ ID NO: 2068), GSGSPHCLAQNQQ (SEQ ID NO: 5289), GSGSPHFLRQNQQ (SEQ ID NO: 2070), GSGSPHSLRFNQQ (SEQ ID NO: 2071), GSGSPHSYLRNQQ (SEQ ID NO: 5290), GSGSPHCSLQNQQ (SEQ ID NO: 52.91), GSGSPHVLWQNQQ (SEQ ID NO: 5292), GSGSPHSKWLLQQ (SEQ ID NO: 2072), GSGSPHSLWSNQQ (SEQ ID NO: 5293), GSGSPHSKRRLQQ (SEQ ID NO: 2073), GSGSPHSVYLNQQ (SEQ ID NO: 5294), GSGSPHSLWLNQQ (SEQ ID NO: 5295), GSGSPHSKAQRKL (SEQ ID NO: 2074), GSGSPHSKALRRQ (SEQ ID NO: 2075), GSGSPHSKAQRLR (SEQ ID NO: 2076), GSGSPHSKAQNQQ (SEQ ID NO: 1801), GSGSPHSKAQRRL (SEQ ID NO: 2077), GSGSPHSKARRQQ (SEQ ID NO: 2078), GSGSPHSKARRLQ (SEQ ID NO: 2079), GSGSPHSKSRRQQ (SEQ ID NO: 2080), GSGSPHSKARLRQ (SEQ ID NO: 2082), GSGSPHSKASKRQ (SEQ ID NO: 2083),GSGSPHVRRQNQQ (SEQ ID NO: 2084), GSGSPHSKAQLYR (SEQ ID NO: 2085), GSGSPHSLFRNQQ (SEQ ID NO: 5296), GSGSPHSKAQLTV (SEQ ID NO: 2086):.(li) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in ( i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i)134. The AAV particle of any one of embodiments 130-133, wherein the AAV capsid variant further comprises one, two, or all of an amino acid other than T at position 450 (e.g., S, Y, or G), an amino acid other than I at position 451 (e.g., M or L), and / or an amino acid other than N at position 452 (e.g., S), numbered according to SEQ ID NO: 138.135. The AAV particle of any one of embodiments 130-134, wherein the AAV capsid variant further comprises an S at position 450 and an M at position 451, numbered according to SEQ ID NO: 138.136. The AAV particle of any one of embodiments 130-134, wherein the .AAV capsid variant further comprises a Y at position 450, an L at position 451, and an S at position 452, numbered according to SEQ ID NO: 138.137. The AAV particle of any one of embodiments 130-134, wherein the AAV capsid variant further comprises a G at position 450, an L at position 451, and an S at position 452, numbered according to SEQ ID NO: 138.138. The AAV particle of any one of embodiments 130-137, wherein [A] [B] is present in loop IV.139. The AAV particle of any one of embodiments 130-138, wherein [A] is present immediately subsequent to position 452, numbered according to SEQ ID NO: 138.140. The AAV particle of any one of embodiments 130-139, wherein [A] replaces positions 453-455 (e.g., G453, S454, G455), numbered according to SEQ ID NO: 138.141. The AAV particle of any one of embodiments 130-140, wherein [A] is present immediately subsequent to position 452, and wherein [A] replaces positions 453-455 (e.g., G453, S454, G455), numbered according to SEQ ID NO: 138.142. The AAV particle of any one of embodiments 130-141, wherein [B] is present immediately subsequent to [A],143. The AAV particle of any one of embodiments 130-142, wherein [B] replaces positions 456-459 (e.g., Q456, N457, Q458, Q459), numbered according to SEQ ID NO: 138.144. The AAV particle of any one of embodiments 130-143, wherein [A] [B] replaces positions 453-459 (e.g., G453, S454, G455, Q456, N457, Q458, Q459), numbered according to SEQ ID NO: 138.145. The AAV particle of any one of embodiments 130-144, wherein [A] [B] is present immediately subsequent to position 452, and wherein [A][B] replaces positions 453-459 (e.g., G453, S454, G455, Q456, N457, Q458, Q459), numbered according to SEQ ID NO: 138.146. The AAV particle of any one of embodiments 130-145, wherein the AAV capsid variant comprises, from N-terminus to C-terminus, [A][B],147. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV 9 capsid vanant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises [A] [B] (SEQ ID NO; 4699), wherein:(i) [A] comprises X 1 X 2 X3 X4 X5 X6, wherein(a) X1 is T, M, A, C, I, R, L, D, F, V, Q, N, or II;(b) X2 is 1, P, E, N, D, S, A, T, M, or Q;(c) X3 is N, E, G, Y, W. M, T, I, K, Q. F. S, V, A, or L;(d) X4 is G. D, R, or E;(e) X5 is H, Q, N, or D;(f) X6 is D or R;optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(f); and(ti) [B] comprises SPHKSG (SEQ ID NO: 946).148. The AAV particle of embodiment 147, wherein(a) X1 is: T, M, A, or I;(b) X2 is: E, I or I);(c) X3 is: N, Q, Y, I, M, or V;(d) X4 is G;(e) X5 is H; and(f) X6 is D.149. The AAV particle of embodiment 147 or 148, wherein [A] comprises:(i) TINGHD (SEQ ID NO: 5297), MPEGHD (SEQ ID NO: 5298), MEGGHD (SEQ ID NO: 5299), MEYGHD (SEQ ID NO: 5300), AEWGIID (SEQ ID NO: 5301), CEWGHD (SEQ ID NO: 5302), ANNGQD (SEQ ID NO: 5303), IPEGHD (SEQ ID NO: 5304), ADMGHD (SEQ ID NO: 5305), IEYGHD (SEQ ID NO: 5306), ADYGHD (SEQ ID NO: 5307), IETGHD (SEQ ID NO: 5308), MEWGHD (SEQ ID NO: 5309), CEYGHD (SEQ ID NO: 5310), RINGHD (SEQ ID NO: 5311), MEIGHD (SEQ ID NO: 5312), LEYGHD (SEQ ID NO: 5313), ADWGHD (SEQ ID NO: 5314), IEIGHD (SEQ ID NO: 5315), TIKDND (SEQ ID NO: 5316), DIMGHD (SEQ ID NO: 5317), FEQGHD (SEQ ID NO: 5318), MEFGHD (SEQ ID NO: 5319), CDQGHD (SEQ ID NO: 5320), LPEGHD (SEQ ID NO: 5321), IENGHD (SEQ ID NO: 5322), MESGHD (SEQ ID NO: 5323), AEIGHD (SEQ ID NO: 5324), VEYGHD (SEQ ID NO: 5325), TSNGDD (SEQ ID NO: 5326). lEVGHD (SEQ ID NO: 5327), MEMGHD (SEQ ID NO: 5328), AEVGHD (SEQ ID NO: 5329), MDAGHD (SEQ ID NO: 5330), VEWGHD (SEQ ID NO: 5331), AEQGHD (SEQ ID NO: 5332), LEWGHD (SEQ ID NO: 5333), MELGHD (SEQ ID NO: 5334). METGHD (SEQ ID NO: 5335), MEAGHD (SEQ ID NO: 5336), TINRQR (SEQ ID NO: 5337), lESGHD (SEQ ID NO: 5338), TAKDIID (SEQ ID NO: 5339), MEVGHD (SEQ ID NO: 5340), CEIGHD (SEQ ID NO: 5341), ATNGHD (SEQ ID NO: 5342), MDGGHD (SEQ ID NO: 5343), QEVGHD (SEQ ID NO: 5344), ADQGHD (SEQ ID NO: 5345), NMNGHD (SEQ ID NO: 5346), TPWEHD (SEQ ID NO: 5347), lEMGHD (SEQ ID NO: 5348), TANEHD (SEQ ID NO: 5349), QQQGHD (SEQ ID NO: 5350), TPQDHD (SEQ ID NO: 5351), HDWGIID (SEQ ID NO: 5352), IEGGHD (SEQ ID NO: 5353)(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof:(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).150. The AAV particle of any one of embodiments 147-149, wherein [A][B] comprises: (i) T1NGHDSPHKR (SEQ ID NO: 5354), MPEGHDSPHKS (SEQ ID NO: 5355), MEGGHDSPHKS (SEQ ID NO: 5356), MEYGHDSPHKS (SEQ ID NO: 5357), AEWGHDSPHKS (SEQ ID NO: 5358), CEWGHDSPHKS (SEQ ID NO: 5359), ANNGQDSPHKS (SEQ ID NO: 5360), IPEGHDSPHKS (SEQ ID NO: 5361), ADMGHDSPHKS (SEQ ID NO: 5362), IEYGHDSPHKS (SEQ ID NO: 5363). ADYGHDSPHKS (SEQ ID NO: 5364), IETGHDSPHKS (SEQ ID NO: 5365), MEWGHDSPHKS (SEQ ID NO: 5366), CEYGHDSPHKS (SEQ ID NO: 5367), RINGHDSPHKS (SEQ ID NO: 5368), MEIGHDSPHKS (SEQ ID NO: 5369), LEYGHDSPHKS (SEQ ID NO: 5370), ADWGHDSPHKS (SEQ ID NO: 5371), IEIGHDSPHKS (SEQ ID NO: 5372), TIKDNDSPHKS (SEQ ID NO: 5373), DIMGHDSPHKS (SEQ ID NO: 5374), FEQGHDSPHKS (SEQ ID NO: 5375), MEFGHDSPHKS (SEQ ID NO: 5376), CDQGHDSPHKS (SEQ ID NO: 5377). LPEGHDSPHKS (SEQ ID NO: 5378), IENGHDSPHKS (SEQ ID NO: 5379), MESGHDSPHKS (SEQ ID NO: 5380), AEIGIIDSPHKS (SEQ ID NO: 5381 ), VEYGHDSPHKS (SEQ ID NO: 5382), TSNGDDSPHKS (SEQ ID NO: 5383), IEYGHDSPHKS (SEQ ID NO: 5384), MEMGHDSPHKS (SEQ ID NO: 5385), AEVGHDSPHKS (SEQ ID NO: 5386), MDAGHDSPHKS (SEQ ID NO: 5387), VEWGHDSPHKS (SEQ ID NO: 5388), AEQGHDSPHKS (SEQ ID NO: 5389), LEWGHDSPHKS (SEQ ID NO: 5390), MELGHDSPHKS (SEQ ID NO: 5391), MEIGHDSPHKS (SEQ ID NO: 5392), MEAGHDSPHKS (SEQ ID NO: 5393), TINRQRSPHKS (SEQ ID NO: 5394), IESGHDSPHKS (SEQ ID NO: 5395), TAKDHDSPHKS (SEQ ID NO: 5396), MEYGHDSPHKS (SEQ ID NO: 5397), CEIGHDSPHKS (SEQ ID NO: 5398), ATNGHDSPHKS (SEQ ID NO: 5399), MDGGHDSPHKS (SEQ ID NO: 5400), QEVGHDSPHKS (SEQ ID NO: 5401), ADQGHDSPHKS (SEQ ID NO: 5402), NMNGHDSPHKS (SEQ ID NO: 5403), TPWEHDSPHKS (SEQ ID NO: 5404), IEMGHDSPHKS (SEQ ID NO: 5405),TANEIIDSPHKS (SEQ ID NO: 5406), TINGHDSPHKS (SEQ ID NO: 5407), QQQGHDSPHKS (SEQ ID NO: 5408), TPQDHDSPHKS (SEQ ID NO: 5409), HDWGHDSPHKS (SEQ ID NO: 5410), lEGGHDSPHKS (SEQ ID NO: 5411)(li) an amino acid sequence comprising any portion of an amino acid sequence in (i). e.g., any 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, e.g., consecutive amino acids, thereof:(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).151. The AAV particle of any one of embodiments 147-150, wherein the AAV capsid variant further comprises one, two, three, four, or all of an amino acid other than Q at position 456 (e.g., R or L), N at position 457 (e.g., H, K, or R), Q at position 458 (e.g., R or T), Q at position 459 (H), and / or T at position 460 (N or S), numbered according to SEQ ID NO: 138.152. The AAV particle of any one of embodiments 147-151, wherein the AAV capsid variant further comprises an R at position 456, numbered according to SEQ ID NO: 138.153. The AAV particle of any one of embodiments 147-151, wherein the .AAV capsid variant further comprises an L at position 456, numbered according to SEQ ID NO: 138.154. The AAV particle of any one of embodiments 147-153, wherein the AAV capsid variant further comprises an H at position 457 and an R at position 458, numbered according to SEQ ID NO: 138.155. The AAV particle of any one of embodiments 147-153, wherein the AAV capsid variant further comprises a K at position 457 and an N at position 460, numbered according to SEQ ID NO: 138.156. The AAV particle of any one of embodiments 147-153, wherein the AAV capsid variant further comprises a T at position 458, an H at position 459, and an S at position 460, numbered according to SEQ ID NO: 138.157. The AAV particle of any one of embodiments 147-151, wherein the AAV capsid variant further comprises an R at position 456, an R at position 457, and an R at position 458, numbered according to SEQ ID NO: 138.158. The AAV particle of any one of embodiments 147-157, wherein [A] [B | is present in loop IV.159. The AAV particle of any one of embodiments 147-158, wherein [A] is present immediately subsequent to position 449, numbered according to SEQ ID NO: 138.160. The AAV particle of any one of embodiments 147-159, wherein [A] replaces positions 450-453 (e.g., T450, 1451, N452, G453), numbered according to SEQ ID NO: 138.161. The AAV particle of any one of embodiments 147-160, wherein [A] is present immediately subsequent to position 449, and wherein [A] replaces positions 450-453 (e.g., T450, 1451, N452, G453), numbered according to SEQ ID NO: 138.162. The AAV particle of any one of embodiments 147-161, wherein [A][B] replaces positions 450-455 (e.g., T450, 1451, N452, G453, S454, G455), numbered according to SEQ ID NO: 138.163. The AAV particle of any one of embodiments 147-162, wherein [A][B] is present immediately subsequent to position 449, and wherein [A][B] replaces positions 450-455 (e.g., T450, 1451, N452, G453, S454, G455), numbered according to SEQ ID NO: 138.164. The AAV particle of any one of embodiments 147-163, wherein [B] is present immediately subsequent [A], and replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138.165. The .AAV particle of any one of embodiments 147-164, wherein [B] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 4, 36, 981, or 982.166. The AAV particle of any one of embodiments 147-165, wherein [B] is present immediately subsequent to [A],167. The AAV particle of any one of embodiments 147-166, wherein the AAV capsid variant comprises, from N-terminus to C-terminus, [A] [B] .168. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a. viral genome comprising a nucleic acid encoding a modulator}' polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises an amino acid sequence having the following formula: [N1]-[N2]-[N3] (SEQ ID NO: 6407), wherein:(i) [N1] comprises X1, X2, and X3, wherein X2 is S and X3 is G;(ii) [N2] comprises the amino acid sequence SPH; and(iii) [N3] comprises X4, X5, and X6, wherein X5 is K.169. The AAV particle of embodiment 168, wherein:(i) X4 of [N3] is S, T. N, or A: and.(ii) X5 of [N3] is A, V, T, S, G, R, L, or N: optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid, amino acids in (i) or (ii).170. The AAV particle of embodiment 168 or 169, wherein X4 is S and / or X5 is A.171. The AA V particle of any one of embodiments 168-170, wherein [N3] comprises SK, TK, NK, AK, KA, KV, KT, KS, KG, KR, KL, or KN.172. The AAV particle of any one of embodiments 168-171, wherein [N3] is or comprises SKA, SKV, SKT, SKS, SKG, SKR, TKA, NKA, SKL, SKN, or AKA.173. The AAV particle of any one of embodiments 168-172, wherein [N3] is or comprises SKA.174. The AAV particle of any one of embodiments 168-173, wherein [N2]-[N3] comprises SPHSK (SEQ ID NO: 4701), SPHTK (SEQ ID NO: 4725), SPHNK (SEQ ID NO: 4726), or SPHAK (SEQ ID NO: 4727).175. The AAV particle of any one of embodiments 168-174, wherein [N2]-[N3] is or comprises:(i) SPHSKA (SEQ ID NO: 941), SPHSKV (SEQ ID NO: 4737), SPHSKT (SEQ ID NO: 4731 ), SPHSKS (SEQ ID NO: 962), SPHSKG (SEQ ID NO: 4732), SPHSKR (SEQ ID NO: 978), SPHTKA (SEQ ID NO: 4739), SPHNKA (SEQ ID NO: 4734), SPHSKL (SEQ ID NO: 960), SPHSKN (SEQ ID NO: 4735), or SPHAKA (SEQ ID NO: 4736):(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).176. The AA V particle of any one of embodiments 168-175, wherein [N2]-[N3] is or comprises SPHSKA (SEQ ID NO: 941).177. The AAV particle of any one of embodiments 168-176, wherein the AAV capsid variant comprises an amino acid other than G at position 453 (e.g., M, T, I, E, S, A, N, V, L, K, H P, R, W, or D), numbered according to SEQ ID NO: 138 or 981.178. The AAV particle of any one of embodiments 168-177, wherein the AAV capsid variant comprises the amino acid G at position 453, numbered according to SEQ ID NO: 138 or 981.179. The AAV particle of any one of embodiments 168-178, wherein X1 of [N1] is G, M, T, I, E, S, A, N, V, L, K, H, P, R, W, or D; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids.180. The AAV particle of any one of embodiments 168-179, wherein [N1] comprises SG, GS, MS, TS, IS, ES, SS, AS, NS, VS, LS, KS, HS, PS, RS, WS, or DS.181. The .AAV particle of any one of embodiments 168-180, wherein |N1 ] is or comprises:GSG, MSG, TSG, ISG, ESG, SSG, ASG, NSG, VSG, LSG, KSG, HSG, PSG, RSG, WSG, or DSG.182. lire AAV particle of any one of embodiments 168-181, wherein [Ml] is or comprises GSG.183. The .AAV particle of any one of embodiments 168-182, wherein |N1]-[N2| comprises SGSPH (SEQ ID NO: 4752).184. The AAV particle of any one of embodiments 168-183, wherein [N1]-[N2] is or comprises:(i) GSGSPH (SEQ ID NO: 4695), MSGSPH (SEQ ID NO: 4798), TSGSPH (SEQ ID NO: 4800), ISGSPH (SEQ ID NO: 4801 ), ESGSPH (SEQ ID NO: 4803), SSGSPH (SEQ ID NO: 4804), ASGSPH (SEQ ID NO: 4806), NSGSPH (SEQ ID NO: 4807), VSGSPH (SEQ ID NO: 4786), ESGSPH (SEQ ID NO: 4808). KSGSPH (SEQ ID NO: 4810), HSGSPH (SEQ ID NO: 4811), PSGSPH (SEQ ID NO: 4813), RSGSPH (SEQ ID NO: 4815), WSGSPH (SEQ ID NO: 4817), DSGSPH (SEQ ID NO: 4818):(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).185. The AAV particle of any one of embodiments 168-184, wherein [N1]-[N2]-[N3] is or comprises:(i) GSGSPHSKA (SEQ ID NO; 4697), GSGSPHSKV (SEQ ID NO; 4956), MSGSPHSKA (SEQ ID NO; 4957), TSGSPHSKA (SEQ ID NO: 4959), ISGSPHSKA (SEQ ID NO: 4960), GSGSPHSKT (SEQ ID NO: 4962), ESGSPHSKA (SEQ ID NO: 4963), SSGSPHSKA (SEQ ID NO: 4964), GSGSPHSKS (SEQ ID NO: 4953), ASGSPHSKA (SEQ ID NO: 4966), NSGSPHSKA (SEQ ID NO: 4967), VSGSPHSKA (SEQ ID NO: 4913), LSGSPHSKA (SEQ ID NO; 4968), KSGSPHSKA (SEQ ID NO: 4970), GSGSPHSKG (SEQID NO: 4972), GSGSPHSKR (SEQ ID NO: 4945), HSGSPHSKA (SEQ ID NO: 4973), PSGSPHSKA (SEQ ID NO: 4975), RSGSPHSKA (SEQ ID NO: 4977), GSGSPHTKA (SEQ ID NO: 4978), WSGSPHSKA (SEQ ID NO: 4980), DSGSPHSKA (SEQ ID NO: 4981), GSGSPHNKA (SEQ ID NO: 4983), GSGSPHSKL (SEQ ID NO: 4943), GSGSPHSKN (SEQ ID NO: 4994), or GSGSPHAKA (SEQ ID NO: 4995):(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, or 9 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).186. The AAV particle of any one of embodiments 168-185, wherein [N1]-[N2]-[N3] is or composes GSGSPHSKA (SEQ ID NO: 4697).187. The AAV capsid variant of any one of embodiments 168-186, which comprises an amino acid other than Q at position 456 (e.g., R, P, H, L, K, I, G, S, M, or E), an amino acid other than N at position 457 (e.g., D, V, S, P, T, G, ¥, W, E, R, H, K, F, A, I, L, or M), an amino acid other than Q at position 458 (e.g., R, L, A, P, H, T, I, F, K, V, M, G, W, Y, S, E, N, or D), an amino acid other than Q at position 459 (e.g., H, K, A, L, P, E, M, I, S, N, R, Y, C, V, T, W, D, G), and / or an amino acid other than T at position 460 (e.g., I, N, S, H, R, L, D, Y, A, or Q), numbered according to SEQ ID NO: 138.188. The AAV particle of any one of embodiments 168-187, wherein the AAV capsid variant comprises an amino acid other than Q at position 462 (e.g., R, P, H, L, K, I, G, S, M, or E), an amino acid other than N at position 463 (e.g., D, V, S, P, T, G, Y, W, E, R, H, K, F, A, I, L, or M), an amino acid other than Q at position 464 (e.g., R, L, A, P, H, T, I, F, K, V, M, G, W, Y, S, E, N, or D), an amino acid other than Q at. position 465 (e.g,, H, K, A, L, P, E, M, I, S, N, R, Y, C, V, T, W, D, G), and / or an amino acid other than T at position 466 (e.g., I, N, S, FI, R, L, D, Y, A, or Q), numbered according to SEQ ID NO: 981 .189. The AAV particle of any one of embodiments 168-188, wherein the AAV capsid variant comprises the amino acid Q at position 456, the amino acid N at. position 457, the amino acidQ at position 458, the amino acid Q at position 459, and / or the amino acid T at position 460, numbered according to SEQ ID NO: 138.190. The AAV particle of any one of embodiments 168-189, wherein the AAV capsid variant comprises the amino acid Q at position 462, the amino acid N at position 463, the amino acid Q at position 464, the amino acid Q at position 465, and / or the amino acid T at position 466, numbered according to SEQ ID NO: 981.191. The .AAV particle of any one of embodiments 168-190, wherein the AAV capsid variant further comprises [N4] wherein [N4] comprises X7, X8, X9, X10, and. X11, wherein:(a) X7 is Q, R, P, II, L, K, I, G, S, M, or E;(b) X8 is N, D, V, S, P, T, G, Y, W, E, R, H, K, F, A, I, L, or M;(c) X9 is Q, R. L, A, P, H, T, I, F, K, V, M, G, W, Y, S, E, N, D;(d) X10 is Q, H, K, A, L, P, E, M, I, S, N, R, Y, C, V, T, W, D, G; and.(e) X11 is T, I, N, S, II, R L, D, Y, A, Q; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(e).192. The AAV particle of embodiment 191, wherein [N4] is or comprises:(i) QNQQT (SEQ ID NO: 5412), QNRHT (SEQ ID NO: 5413), RDQQT (SEQ ID NO: 5414), PNLQT (SEQ ID NO: 5415), HVRQT (SEQ ID NO: 5416), PNQHT (SEQ ID NO: 5417), QSQQT (SEQ ID NO: 5418), QNQQI (SEQ ID NO: 5419), QPAKT (SEQ ID NO: 5420), QTQQN (SEQ ID NO: 5421), QNLAT (SEQ ID NO: 5422), QNQLT (SEQ ID NO: 5423), QGQQT (SEQ ID NO: 5424), LNRQS (SEQ ID NO: 5425), HNQQT (SEQ ID NO: 5426), QNPPT (SEQ ID NO: 5427), QNLQT (SEQ ID NO: 5428), QYQQT (SEQ ID NO: 5429), QDQET (SEQ ID NO: 5430), QNIIQT (SEQ ID NO: 5431), QDQQT (SEQ ID NO: 5432), HWQQT (SEQ ID NO: 5433). PNQQT (SEQ ID NO: 5434), QNQLI (SEQ ID NO: 5435), PEQQT (SEQ ID NO: 5436), QRTMT (SEQ ID NO: 5437), QNQQH (SEQ ID NO: 5438), LFIQIIT (SEQ ID NO: 5439), QHRIT (SEQ ID NO: 5440), QYIHT (SEQ ID NO: 5441), QKFET (SEQ ID NO: 5442), QFPST (SEQ ID NO: 5443), HNQQR (SEQ ID NO: 5444), QAIKT (SEQ ID NO: 5445). QNRQT (SEQ ID NO: 5446), QYQHT (SEQ ID NO: 5447), QN.PQS (SEQ ID NO: 5448), QHQLT (SEQ ID NO: 5449), QSPPT (SEQ ID NO: 5450), QAKLT (SEQ ID NO: 5451), KSQQT (SEQ ID NO: 5452), QDRPT (SEQ ID NO: 5453), QSQQL (SEQ ID NO: 5454), QAFHT (SEQ ID NO: 5455), QKQQD (SEQ IDNO: 5456), QNAQT (SEQ ID NO: 5457), HNQLT (SEQ ID NO: 5458), QNQQY (SEQ ID NO: 5459), QKLNT (SEQ ID NO: 5460), QNVQT (SEQ ID NO: 5461), QAQQT (SEQ ID NO: 5462), QNLQA (SEQ ID NO: 5463), QTPPT (SEQ ID NO: 5464), QYQHA (SEQ ID NO: 5465), QGQQA (SEQ ID NO: 5466), QPPAT (SEQ ID NO: 5467), QERPT (SEQ ID NO: 5468), QDLQT (SEQ ID NO: 5469), QAMHT (SEQ ID NO: 5470), LNQQT (SEQ ID NO: 5471), QHPST (SEQ ID NO: 5472), PGLQT (SEQ ID NO: 5473), QGIRT (SEQ ID NO: 5474), QAPAT (SEQ ID NO: 5475), QSQQI (SEQ ID NO: 5476), QIPPT (SEQ ID NO: 5477), QTQLT (SEQ ID NO: 5478), QAPST (SEQ ID NO: 5479), QNTYA (SEQ ID NO: 5480), QNQHI (SEQ ID NO: 5481), QNHLT (SEQ ID NO: 5482), QIGMT (SEQ ID NO: 5483), LNKQT (SEQ ID NO: 5484), QLQQT (SEQ ID NO: 5485), QRMST (SEQ ID NO: 5486), QGILT (SEQ ID NO: 5487), QDRQT (SEQ ID NO: 5488), RDWQT (SEQ ID NO: 5489), QNTHD (SEQ ID NO: 5490), PNLQI (SEQ ID NO: 5491), QERST (SEQ ID NO: 5492). QNYQT (SEQ ID NO: 5493), QRTCT (SEQ ID NO: 5494), QIGHT (SEQ ID NO: 5495), QGAIT (SEQ ID NO: 5496), QVPPT (SEQ ID NO: 5497), QVQQI (SEQ ID NO: 5498), LMRQT (SEQ ID NO: 5499), QYSVT (SEQ ID NO: 5500), QAITT (SEQ ID NO: 5501), QKTLT (SEQ ID NO: 5502), QNQWT (SEQ ID NO: 5503), QLHHT (SEQ ID NO: 5504), QNIII (SEQ ID NO: 5505), QGHHT (SEQ ID NO: 5506), QSKVT (SEQ ID NO: 5507), QLPST (SEQ ID NO: 5508), IGKQT (SEQ ID NO: 5509), QAIHT (SEQ ID NO: 5510), QHGLT (SEQ ID NO: 5511), QFMCT (SEQ ID NO: 5512), QHLQT (SEQ ID NO: 5513). QNHQN (SEQ ID NO: 5514), QPART (SEQ ID NO: 5515), QSLQT (SEQ ID NO: 5516), QSQLT (SEQ ID NO: 5517), QDRQS (SEQ ID NO: 5518), QMPST (SEQ ID NO: 5519), QGSLT (SEQ ID NO: 5520), QVPAT (SEQ ID NO: 5521), QDKQT (SEQ ID NO: 5522), I1YQQT (SEQ ID NO: 5523), QVPST (SEQ ID NO: 5524), RGEQT (SEQ ID NO: 5525), PGQQT (SEQ ID NO: 5526). QSLQI (SEQ ID NO: 5527), LEQQT (SEQ ID NO: 5528), QNQST (SEQ ID NO: 5529), QKVIT (SEQ ID NO: 5530), QNNDQ (SEQ ID NO: 5531), QSVHT (SEQ ID NO: 5532), QPLGT (SEQ ID NO: 5533), IINQET (SEQ ID NO: 5534). QNLQI (SEQ ID NO: 5535), QIQQT (SEQ ID NO: 5536), QVRNT (SEQ ID NO: 5537), PSNQT (SEQ ID NO: 5538), QVGHT (SEQ ID NO: 5539), QRDIT (SEQ ID NO: 5540), QMPNT (SEQ ID NO: 5541), RGEQT (SEQ ID NO: 5542), QKQQT (SEQ ID NO: 5543), PSLQT (SEQ ID NO: 5544), QRDQT (SEQ ID NO: 5545), QAKGT (SEQ ID NO: 5546), QSAHT (SEQ ID NO: 5547). QSTMT (SEQ ID NO: 5548), QREMT (SEQ ID NO: 5549), QYRAT (SEQ ID NO: 5550), QWQQT (SEQ ID NO: 5551), QRMNT (SEQ ID NO: 5552), GDSQT (SEQ ID NO: 5553), QKIST (SEQ ID NO: 5554), PSMQT (SEQ ID NO: 5555), SPRQT (SEQ ID NO: 5556), MEQQT (SEQ ID NO: 5557), QYQNT (SEQ ID NO:5558), QIIQQT (SEQ ID NO; 5559), INQQT (SEQ ID NO: 5560), PNQQH (SEQ ID NO: 5561), ENRQT (SEQ ID NO; 5562), QTQQA (SEQ ID NO: 5563), or QNQAT (SEQ ID NO: 5564);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i). e.g., any 2, 3, or 4 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).193. The AAV particle of embodiment 191 or 192, wherein [N1]-[N2]-[N3]-[N4] is or comprises:(i) the amino acid sequence of any of SEQ ID NOs: 2.00 or 2887-3076;(ii) an amino acid sequence comprising any portion of an amino acid, sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, or 13 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).194. The AAV particle of any one of embodiments 191 -193, wherein [N1]-[N2]-[N3]-[N4] is or composes GSGSPHSKAQNQQT (SEQ ID NO: 200).195. The AAV particle of any one of embodiments 191-193, wherein [N1]-[N2]-[N3]-[N4] is or comprises VSGSPHSKAQNQQT (SEQ ID NO: 903).196. The AAV particle of any one of embodiments 168-195, wherein the AAV capsid variant comprises an amino acid other than K at position 449 (e.g., T, E, or N), T at position 450 (e.g., S, E, A, N, V, Q, or G), an amino acid other than I at position 451 (e.g., F, E, V, L, D, S, C, T, A, N, H, R, G, or W), and / or an amino acid other than N at position 452 (e.g., I, P, K, R, H, S, M, Q, I), T, L, A, Y, V, F, E, W, or G), numbered, according to SEQ ID NO: 138 or 981.197. The AAV particle of any one of embodiments 168-196, wherein the AAV capsid variant comprises the amino acid K at position 449, the amino acid T at position 450, the amino acid I at position 451, and / or the amino acid N at position 452, numbered according to SEQ ID NO: 138 or 981.198. The AAV particle of any one of embodiments 168-197, wherein the AAV capsid variant further composes [N0], wherein [N0] comprises XA, XB, XC, and XD, wherein:(a) XAis K, T, E, or N;(b) XBIS T, S, E, A, N, V, Q, or G.(c) XCis I, F, E, V, L. D. S. C, T, A. N. H. R, G, or W; and(d) XDis N, I, P, K, R, H, S, M, Q, D, T, L, A, ¥, V, F, E, W, or G; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids m (a)-(d).199. The AAV particle of embodiment 198, wherein [N0] is or comprises:(i) KTII (SEQ ID NO: 5565), KTFP (SEQ ID NO: 5566), KTEK (SEQ ID NO: 5567), KTVN (SEQ ID NO: 5568), KTFN (SEQ ID NO: 5569), KT1N (SEQ ID NO: 5570), TTIN (SEQ ID NO: 5571), KSIN (SEQ ID NO: 5572), KTER (SEQ ID NO: 5573), KELH (SEQ ID NO: 5574), KAIN (SEQ ID NO: 5575), KTDN (SEQ ID NO: 5576), KTFH (SEQ ID NO: 5577). KTSN (SEQ ID NO: 5578), ETIN (SEQ ID NO: 5579), NTIN (SEQ ID NO: 5580). KTEN (SEQ ID NO: 5581), KTSS (SEQ ID NO: 5582), KTCN (SEQ ID NO: 5583), KTEH (SEQ ID NO: 5584), KAEM (SEQ ID NO: 5585), KATN (SEQ ID NO: 5586), KAIK (SEQ ID NO: 5587), KTDK (SEQ ID NO: 5588), KTFK (SEQ ID NO: 5589), KSDQ (SEQ ID NO: 5590), KTEI (SEQ ID NO: 5591), KTID (SEQ ID NO: 5592), KNTN (SEQ ID NO: 5593), KTET (SEQ ID NO: 5594), KIEL (SEQ ID NO: 5595), KNTN (SEQ ID NO: 5596), KTEA (SEQ ID NO: 5597), KT AN (SEQ ID NO: 5598), NTIY (SEQ ID NO: 5599), KTFS (SEQ ID NO: 5600), KTES (SEQ ID NO: 5601), KTT'N (SEQ ID NO: 5602), KTED (SEQ ID NO: 5603), KTNN (SEQ ID NO: 5604), KEVH (SEQ ID NO: 5605), KTIS (SEQ ID NO: 5606), KTVR (SEQ ID NO: 5607), KTDR (SEQ ID NO: 5608), ETIK (SEQ ID NO: 5609), KNHI (SEQ ID NO: 5610), KESD (SEQ ID NO: 5611), KTIK (SEQ ID NO: 5612), KTDL (SEQ ID NO: 5613), KTVP (SEQ ID NO: 5614), KTVI (SEQ ID NO: 5615), KAEH (SEQ ID NO: 5616), KNCL (SEQ ID NO: 5617), KTVK (SEQ ID NO: 5618), KNAD (SEQ ID NO: 5619), KTIT (SEQ ID NO: 5620), KNCV (SEQ ID NO: 5621), KNAL (SEQ ID NO: 5622), KVIN (SEQ ID NO: 5623), KTEF (SEQ ID NO: 5624), KTRE (SEQ ID NO: 5625),KQGE (SEQ ID NO: 5626), KSEK (SEQ ID NO: 5627), KNVN (SEQ ID NO: 5628), KGGE (SEQ ID NO: 5629), KEFV (SEQ ID NO: 5630), KSDK (SEQ ID NO: 5631), KTEQ (SEQ ID NO: 5632), KEVQ (SEQ ID NO: 5633), KTEY (SEQ ID NO: 5634), KNCW (SEQ ID NO: 5635), KTDV (SEQ ID NO: 5636), KSDI (SEQ ID NO: 5637), KNSI (SEQ ID NO: 5638), KNSL (SEQ ID NO: 5639), KEVV (SEQ ID NO: 5640), KTEP (SEQ ID NO: 5641), KSEL (SEQ ID NO: 5642), KTWQ (SEQ ID NO: 5643), KIEV (SEQ ID NO: 5644), KAVN (SEQ ID NO: 5645), KGVL (SEQ ID NO: 5646), KTEG (SEQ ID NO: 5647), KTRD (SEQ ID NO: 5648), KTGN (SEQ ID NO: 5649), KNAI (SEQ ID NO: 5650), KAEN (SEQ ID NO: 5651), KAET (SEQ ID NO: 5652), KTVH (SEQ ID NO: 5653), KETA (SEQ ID NO: 5654), KNNL (SEQ ID NO: 5655), EAIN (SEQ ID NO: 5656), KSLN (SEQ ID NO: 5657), KTIP (SEQ ID NO: 5658), or KTIH (SEQ ID NO: 5659);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, or 3 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).200. The AAV particle of embodiment 198 or 199, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises:(i) the amino acid sequence of any one of SEQ ID NOs: 3239-3526 or 3591-3605;(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 amino acids, e.g., consecutive amino acids, thereof;(lii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).201. The AAV particle of any one of embodiments 198-200, wherein [N0]-[N1]-[N2]-[N3] [N4] is or comprises KTINGSGSPHSKAQNQQT (SEQ ID NO: 5660).202. The AAV particle of any one of embodiments 198-200, wherein [N0]-[N1]-[N2]-[N3]- [N4] is or comprises KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589).203. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises an amino acid sequence having the following formula: [N1]-[N2]-[N3] (SEQ ID NO: 6408), wherein:(i) [N1] comprises X1, X2, and X3, wherein X2 is an amino acid other than S and X3 is an amino acid other than G;(ii) [N2] comprises the amino acid sequence SPH; and(iii) [N3] comprises X4, X5, and X6, wherein X4 is K.204. The AAV particle of embodiment 203, wherein:(i) X5 of [N3] is S, I, T. R. H, Y, L, or M; and(ii) X6 of [N3] is G, A, L, E, V, R, W, N, Q, or K; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (i) or (ii).205. The AAV particle of embodiment 203 or 204, wherein X5 is S and / or X6 is G.206. The AAV particle of any one of embodiments 203-205, wherein [N3] comprises KS, KI,KT, KR, KH, KY, KL, KM, SG, IG, TG, RG, SA, SL, SE, SV, SR, SW, SN, IIG, YG, SQ, IV, SK, LW, MG, or MA.207. The AAV particle of any one of embodiments 203-206, wherein [N3] is or comprisesKSG, KIG, KTG, KRG, KSA, KSL, KSE, KSV, KSR, KSW, KSN, KIIG, KYG, KSQ, KIV, KSK, KLW, KMG, or KMA.208. The AAV particle of any one of embodiments 203-207, wherein [N3] is or comprises KSG.209. The AA V particle of any one of embodiments 203-208, wherein [N2]-[N3] comprises SPHKS (SEQ ID NO: 4704), SPIIKI (SEQ ID NO: 4713), SPIIKT (SEQ ID NO: 471 1),SPHKR (SEQ ID NO: 4717), NPHKS (SEQ ID NO: 5661), SPHKH (SEQ ID NO: 4728),SPHKY (SEQ ID NO: 4715), SPHKL (SEQ ID NO: 4714), or SPHKM (SEQ ID NO: 4729).210. The AAV particle of any one of embodiments 203-209, wherein [N2]-[N3] is or comprises:(i) SPHKSG (SEQ ID NO: 946), SPHKIG (SEQ ID NO: 958), SPHKTG (SEQ ID NO: 4738), SPHKRG (SEQ ID NO: 974), NPHKSG (SEQ ID NO: 5662), SPHKSA (SEQ ID NO: 977), SPHKSL (SEQ ID NO: 4740), SPHKSE (SEQ ID NO: 4741), SPHKSV (SEQ ID NO: 4742), SPHKSR (SEQ ID NO: 951), SPHKSW (SEQ ID NO: 4743), SPHKSN (SEQ ID NO: 4744), SPHKHG (SEQ ID NO: 4745), SPHKYG (SEQ ID NO: 966), SPHKSQ (SEQ ID NO: 4746), SPHKIV (SEQ ID NO: 5663), SPHKSK (SEQ ID NO: 4747), SPHKLW (SEQ ID NO: 4748), SPHKMG (SEQ ID NO: 4750), or SPHKAIA (SEQ ID NO: 4751);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).211. The AAV particle of any one of embodiments 203-210, wherein [N2'|-[N3] is or composes SPHKSG (SEQ ID NO: 946).212. The AAV particle of any one of embodiments 203-211, wherein the AAV capsid variant comprises an amino acid other than G at position 453 (e.g.. A, K, W, R, L, I, M, N, T, E, Q, Y, H, F, or V), numbered, according to SEQ ID NO: 138 or 981 .213. The AAV particle of any one of embodiments 203-212, wherein the AAV capsid variant composes the amino acid G at position 453, numbered according to SEQ ID NO: 138 or 981.214. The AAV particle of any one of embodiments 203-214, wherein:(i) X1 of [N1] is G, A, K, W, R, L, I, M, N, T, E, Q, Y, H, F, or V;(li) X2 of [N1] is H, Y, R . Q. N, P, or D;(iii) X3 of [N1] is D, E, G, V, or N;optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (i), (ii), or (iii).215. The AAV particle of any one of embodiments 203-214, wherein X2 of [N1] is II and X3 of [N1] is D.2.16. The AAV particle of any one of embodiments 203-215, wherein X1 of [N1] is G, X2. of [N1] is H and X3 of [N1] is D.217. The AA V particle of any one of embodiments 203-216, wherein [N1] comprises GH, HD, GY, GR, GQ, AH, GN, KH, GP, WH, RH, LH, TH, MH, GD, NH, TH, EH, QH, YH, HH , F H , VH, YD, HE, RG, QI). RD, ND, PI). Q V. DD, HN, or NG.2.18. The AAV capsid variant, of any one of embodiments 203-217, wherein [N1] is or comprises GHD, GYD, GHE, GRG, GQD, GRD, AHD, GND, KHD, GPD, WHD, RHD, LHD, GQV, IHD, MHD, GDD, GHN, NHD, THD, GNG, EHD, QHD, YHD, HHD, FHD, or VHD.219. The AAV particle of any one of embodiments 203-218, wherein [N1] is or comprises GHD.220. The AAV particle of any one of embodiments 203-219, wherein [N1]-[N2] comprises HDSPH (SEQ ID NO: 4703).221. The AA V particle of any one of embodiments 203-22.0, wherein [N1]-[N2] is or composes:(i) GHDSPH (SEQ ID NO: 4784). GYDSPH (SEQ ID NO: 4829), GHESPH (SEQ ID NO: 4793), GRGSPH (SEQ ID NO: 4788), GHDNPH (SEQ ID NO: 5664), GQDSPH (SEQ ID NO: 4785), GRDSPH (SEQ ID NO: 4831), AHDSPH (SEQ ID NO: 5665), GNDSPH (SEQ ID NO: 4832), KHDSPH (SEQ ID NO: 5666), GPDSPH (SEQ ID NO: 4833), WHDSPH (SEQ ID NO: 5667), RHDSPH (SEQ ID NO: 5668), LHDSPH (SEQ ID NO: 5669), GQVSPH (SEQ ID NO: 4835), IHDSPH (SEQ ID NO: 5670), MHDSPH (SEQ ID NO: 5671), GDDSPH (SEQ ID NO: 4792), GHNSPH (SEQ ID NO: 4836), NHDSPH (SEQ ID NO: 5672), THDSPH (SEQ ID NO: 5673), GNGSPH (SEQ ID NO: 4805), EHDSPH(SEQ ID NO: 5674), QHDSPH (SEQ ID NO: 5675), YHDSPH (SEQ ID NO: 5676), HHDSPH (SEQ ID NO: 5677), FHDSPH (SEQ ID NO: 5678), or VHDSPH (SEQ ID NO: 5679);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i). e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an ami no acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).222. The AAV particle of any one of embodiments 203-221 , wherein [N1]-[N2]-[N3] is or comprises:(i) GHDSPHKSG (SEQ ID NO: 4698), GHDSPHKIG (SEQ ID NO: 4996), GYDSPHKSG (SEQ ID NO: 4997), GHESPHKSG (SEQ ID NO: 4998), GHDSPHKTG (SEQ ID NO: 4999), GRGSPHKRG (SEQ ID NO: 5000), GHDNPHKSG (SEQ ID NO: 5680), GQDSPHKSG (SEQ ID NO: 4908), GHDSPHKSA (SEQ ID NO: 4940), GHDSPHKSL (SEQ ID NO: 5001), GHDSPHKSE (SEQ ID NO: 5003), GRDSPHKSG (SEQ ID NO: 5004), AHDSPHKSG (SEQ ID NO: 5681), GNDSPHKSV (SEQ ID NO: 5005), AHDSPHKIG (SEQ ID NO: 5682), GHESPHKSA (SEQ ID NO: 4939), GQDSPHKIG (SEQ ID NO: 5006), GHDSPHKSV (SEQ ID NO: 5007), GHDSPHKSR (SEQ ID NO: 4942), KHDSPHKSG (SEQ ID NO: 5683), GPDSPHKIG (SEQ ID NO: 5008), GPDSPHKSG (SEQ ID NO: 5009), GHDSPHKSW (SEQ ID NO: 5010), WHDSPHKSG (SEQ ID NO: 5684), RHDSPHKSG (SEQ ID NO: 5685), GHDSPHKSN (SEQ ID NO: 5011), GHDSPHKRG (SEQ ID NO: 4937). GHDSPHKHG (SEQ ID NO: 5013), EHDSPHKSG (SEQ ID NO: 5686), GQVSPHKSG (SEQ ID NO: 5014), IHDSPHKSG (SEQ ID NO: 5687), MHDSPHKSG (SEQ ID NO: 5688), GDDSPHKSV (SEQ ID NO: 5015). GHNSPHKSG (SEQ ID NO: 5016), NHDSPHKSG (SEQ ID NO: 5689), THDSPHKSG (SEQ ID NO: 5690), GNGSPHKRG (SEQ ID NO: 5017), EHDSPHKSG (SEQ ID NO: 5691), GIIDSPHKYG (SEQ ID NO: 5018), GHDSPHKSQ (SEQ ID NO: 5019), QHDSPHKSG (SEQ ID NO: 5692), RHDSPHKIV (SEQ ID NO: 5693), YHDSPHKSG (SEQ ID NO: 5694). GNDSPHKIG (SEQ ID NO: 5020), HHDSPHKSG (SEQ ID NO: 5695), GHDSPHKSK (SEQ ID NO: 5021), EHDSPHKSG (SEQ ID NO: 5696), GHDSPHKLW (SEQ ID NO: 5022), YHDSPHKSG (SEQ ID NO: 5697),GIIDSPHKMG (SEQ ID NO: 5024), GHDSPHKMA (SEQ ID NO: 5025), or GDDSPHKSG (SEQ ID NO: 4938);(li) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, or 9 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).223. The AAV particle of any one of embodiments 203-22.2, wherein [N1]-[N2]-[N3] is or comprises GIIDSPHKSG (SEQ ID NO: 4698).224. The AAV particle of any one of embodiments 203-223, wherein the AAV capsid variant comprises an amino acid other than Q at position 456 (e.g., R, P, H, K, L, V, A, E, or I), an amino acid other than N at position 457 (e.g., I, K, S, H, R, T, D, Y, L, W, F, A, Q, or M), an amino acid other than Q at position 458 (e.g., R, V, K, P, Y, H, L, I, E, or M), an amino acid other than Q at position 459 (e.g., H, L, E, P, W, D, I, V, S, K, R, C, M, or N), and / or an amino acid other than T at position 460 (e.g.. A, E, K, S, I, P, G, or N), numbered according to SEQ ID NO: 138.225. The AAV particle of any one of embodiments 203-224, wherein the AAV capsid variant comprises an amino acid other than Q at position 462 (e.g., R, P, II, K, L, V, A, E, or I), an amino acid other than N at position 463 (e.g., I, K, S, H, R, T, D, Y, L, W, F, A, Q, or M), an amino acid other than Q at position 464 (e.g., R, V, K, P, Y, H, L, I, E, or M), an amino acid other than Q at position 465 (e.g., H, L, E, P, W, D, I, V, S, K, R, C, M, or N), and / or an amino acid other than T at position 466 (e.g., A, E, K, S, I, P, G, or N), numbered according to SEQ ID NO: 982.226. The AAV particle of any one of embodiments 203-225, wherein the AAV capsid variant comprises the amino acid Q at position 456, the amino acid N at position 457, the amino acid Q at position 458, the amino acid Q at position 459, and / or the amino acid T at position 460, numbered according to SEQ ID NO: 138.227. The AAV particle of any one of embodiments 203-226, wherein the AAV capsid variant comprises the amino acid Q at position 462, the amino acid N at position 463, the amino acid Q at position 464, the amino acid Q at position 465, and / or the amino acid T at position 466, numbered according to SEQ ID NO; 138.228. The AAV particle of any one of embodiments 203-227, wherein the AAV capsid variant further composes [N4], wherein [N4] comprises X7, X8, X9, X10, and X11, wherein:(a) X7 is Q, R, P, H , L, K, I, G, S, M, or E;(b) X8 is N, D, V, S, P, T, G, Y, W, E, R, H, K, F, A, 1, L, or M:(c) X9 is Q, R, L, A, P, H, T, I, F, K, V, M, G, W, Y, S, E, N, D;(d) X10 is Q, H , K, A, L, P, E, M, I, S, N, R, Y, C, V, T, W, D, G; and(e) X11 is T, I, N, S, H, R, L, D, Y, A, Q; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid, amino acids in (a)-(e).229. The AAV particle of embodiment 228, wherein [N4] is or comprises;(i) QNQQT (SEQ ID NO: 5412), Q1RQT (SEQ ID NO: 5698), QNQHA (SEQ ID NO: 5699), QKQQT (SEQ ID NO: 5543), QSVQT (SEQ ID NO: 5700), RSQQT (SEQ ID NO: 5701), QNKLE (SEQ ID NO: 5702), QNQQK (SEQ ID NO: 5703), QHQQA (SEQ ID NO: 5704), QIQHT (SEQ ID NO: 5705), PRQQT (SEQ ID NO: 5706), HTQQT (SEQ ID NO: 5707), QRQHT (SEQ ID NO: 5708), QSQQT (SEQ ID NO: 5418), QNQQS (SEQ ID NO: 5709), RNQET (SEQ ID NO: 5710), QTQLT (SEQ ID NO: 5478), KNQQT (SEQ ID NO: 5711), QDQQT (SEQ ID NO: 5432), HNQQT (SEQ ID NO: 5426), QNQLT (SEQ ID NO: 5423), QTQQT (SEQ ID NO: 5712), QTQQI (SEQ ID NO: 5713), QSKQA (SEQ ID NO: 5714), QNQPP (SEQ ID NO: 5715), QSPQT (SEQ ID NO: 5716), QNYQT (SEQ ID NO: 5493), QNHQT (SEQ ID NO: 5431), QNRQT (SEQ ID NO: 5446), QNQQG (SEQ ID NO: 5717), QNHLT (SEQ ID NO: 5482). QYQHT (SEQ ID NO: 5447), QNQWT (SEQ ID NO: 5503), QNQHT (SEQ ID NO: 5718), QTRQT (SEQ ID NO: 5719), QNLHT (SEQ ID NO: 5720), LNQQT (SEQ ID NO: 5471), QNQET (SEQ ID NO: 5721), QHLQT (SEQ ID NO: 5513), LNQPT (SEQ ID NO: 5722), QNQDT (SEQ ID NO: 5723), RNQQT (SEQ ID NO: 5724), QNLLT (SEQ ID NO: 5725). QLVIT (SEQ ID NO: 5726), RTQET (SEQ ID NO: 5727), QTHQT (SEQ ID NO: 5728), QNQPA (SEQ ID NO: 5729), QDQHT (SEQ ID NO: 5730), QSQHT (SEQ ID NO: 5731), RNQQI (SEQ ID NO: 5732), VRQQT (SEQ ID NO: 5733), QNQHS (SEQ ID NO: 5734), AWQQT (SEQ ID NO: 5735), QSVPT (SEQ IDNO: 5736), QNIQP (SEQ ID NO: 5737), QNHLN (SEQ ID NO: 5738), LDQQT (SEQ ID NO: 5739), PDQQS (SEQ ID NO: 5740), ESQQT (SEQ ID NO: 5741), QNKQT (SEQ ID NO: 5742), QRQLT (SEQ ID NO: 5743), QIIVT (SEQ ID NO: 5744), QKQST (SEQ ID NO: 5745), QSHQT (SEQ ID NO: 5746), QFVVT (SEQ ID NO: 5747), QNLQT (SEQ ID NO: 5428), QNQQI (SEQ ID NO: 5419), QSQPT (SEQ ID NO: 5748), QNEQT (SEQ ID NO: 5749). QSLQT (SEQ ID NO: 5516). RNRQT (SEQ ID NO: 5750), QSKQT (SEQ ID NO: 5751), QNPLT (SEQ ID NO: 5752), RDQKT (SEQ ID NO: 5753), HNQQN (SEQ ID NO: 5754), QWKRT (SEQ ID NO: 5755), QSQQI (SEQ ID NO: 5476), QAQQT (SEQ ID NO: 5462), QNHQI (SEQ ID NO: 5756), QNQQA (SEQ ID NO: 5757), QNQLN (SEQ ID NO: 5758), QTQPT (SEQ ID NO: 5759), INQQT (SEQ ID NO: 5560), QKQLT (SEQ ID NO: 5760), RNQLA (SEQ ID NO: 5761), RNQQS (SEQ ID NO: 5762), ISIQT (SEQ ID NO: 5763), QNQQN (SEQ ID NO: 5764), QSQQS (SEQ ID NO: 5765), QTVCT (SEQ ID NO: 5766). QYQQI (SEQ ID NO: 5767), QQIMT (SEQ ID NO: 5768), QNEQS (SEQ ID NO: 5769), LNHQT (SEQ ID NO: 5770), QMIHT (SEQ ID NO: 5771), RNHQS (SEQ ID NO: 5772), QKMNT (SEQ ID NO: 5773), QSQQN (SEQ ID NO: 5774), QYQIIA (SEQ ID NO: 5465);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g,, any 2, 3, or 4 amino acids, e.g,, consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in ( i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).230. The AAV particle of embodiment 228 or 229, wherein [N1]-[N2]-[N3]-[N4] is or comprises:(i) the amino acid sequence of any of SEQ ID NOs: 201 or 3160-3237;(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, .10, 11, 12, or 13 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).231. The AAV particle of any one of embodiments 228-230, wherein [N1]-[N2]-[N3]-[N4] is or comprises GHDSPHKSGQNQQT (SEQ ID NO; 201).232. The AAV particle of any one of embodiments 203-231, wherein the AAV capsid variant comprises an amino acid other than K at position 449 (e.g., T), T at position 450 (e.g.. A, S, I, V, N, E, Y, C, G, W, or Q), an amino acid other than I at position 451 (e.g., E, V, S, T, N, D, C, G, Q, L, P, A), and / or an amino acid other than N at position 452 (e.g., S, Y, I, K, F, T, D, E, G, V, L, A, M, Q, II, P, or R), numbered according to SEQ ID NO: 138 or 982.233. The AAV particle of any one of embodiments 203-232, wherein the AAV capsid variant comprises the amino acid K at position 449, the amino acid T at position 450, the amino acid 1 at position 45 I , and / or the amino acid N at position 452, numbered according to SEQ ID NO: 138 or 982.234. The AAV particle of any one of embodiments 203-233, wherein the AAV capsid variant further comprises [N0], wherein [N0] comprises XA, XB, XC, and XD, wherein:(a) XAis K or T;(b) XBis T, A, S, I, V, N, E, Y, C, G, W, or Q;(c) XCis I, E, V, S, T, N, D, C, G, Q, L, P, A; and(d) XDIS N, S, Y, I, K, F, T, D, E, G, V. L, A, M, Q, H, P, or R; optionally wherein the AAV capsid, variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(d).235. The AAV particle of embodiment 234, wherein [N0] is or comprises:(i) KAIN (SEQ ID NO: 5575), KTIN (SEQ ID NO: 5570), KTES (SEQ ID NO: 5601), TTIN (SEQ ID NO: 5571), KSIN (SEQ ID NO: 5572), KTVN (SEQ ID NO: 5568), KSIY (SEQ ID NO: 5775), KTSN (SEQ ID NO: 5578). KTTN (SEQ ID NO: 5602), KIIN (SEQ ID NO: 5776), KITS (SEQ ID NO: 5606), KA.II (SEQ ID NO: 5777), KTIK (SEQ ID NO: 5612), KTEF (SEQ ID NO: 5624), KITT (SEQ ID NO: 5620), KTNN (SEQ ID NO: 5604), KTID (SEQ ID NO: 5592), KAIS (SEQ ID NO: 5778), KTVD (SEQ ID NO: 5779), KTIE (SEQ ID NO: 5780), KTEG (SEQ ID NO: 5647), KVIN (SEQ ID NO: 5623), KAVN (SEQ ID NO: 5645), KTIY (SEQ ID NO: 5781), KTDN (SEQ ID NO: 5576), KTCN (SEQ ID NO: 5583), KNVV (SEQ ID NO: 5782), KTEL (SEQ ID NO: 5595), KTDA (SEQ ID NO: 5783), KIEV (SEQ ID NO: 5644), KSEL (SEQ ID NO: 5642), KTEM (SEQ ID NO:5784), KTEQ (SEQ ID NO: 5632), KTII (SEQ ID NO: 5565), KIVN (SEQ ID NO: 5785), KTEK (SEQ ID NO: 5567), KTEN (SEQ ID NO: 5581), KIGN (SEQ ID NO: 5786), KEVM (SEQ ID NO: 5787), KYQV (SEQ ID NO: 5788), KTEA (SEQ ID NO: 5597), KATN (SEQ ID NO: 5586), KTEH (SEQ ID NO: 5584), KTVE (SEQ ID NO: 5789), KAID (SEQ ID NO: 5790), KTIM (SEQ ID NO: 5791), KEVG (SEQ ID NO: 5792), KSEM (SEQ ID NO: 5793), KAQQ (SEQ ID NO: 5794), KCGE (SEQ ID NO: 5795), KASN (SEQ ID NO: 5796). KTET (SEQ ID NO: 5594), KTIG (SEQ ID NO: 5797), KTDP (SEQ ID NO: 5798), KELV (SEQ ID NO: 5799), KELM (SEQ ID NO: 5800), KNEI (SEQ ID NO: 5801), KTPN (SEQ ID NO: 5802), KITN (SEQ ID NO: 5803), KTDI (SEQ ID NO: 5804), KTDQ (SEQ ID NO: 5805), KGIN (SEQ ID NO: 5806), KSEI (SEQ ID NO: 5807), KSEK (SEQ ID NO: 5627), KWSA (SEQ ID NO: 5808), KELA (SEQ ID NO: 5809), KQTQ (SEQ ID NO: 5810), KGAD (SEQ ID NO: 5811), KVGE (SEQ ID NO: 5812), KANE (SEQ ID NO: 5813), KTDT (SEQ ID NO: 5814), KTCI (SEQ ID NO: 5815). KELR (SEQ ID NO: 5816), KCQI (SEQ ID NO: 5817), KGVM (SEQ ID NO: 5818), KA CD (SEQ ID NO: 5819), KNEE (SEQ ID NO: 5820), KAAE (SEQ ID NO: 5821), KGQN (SEQ ID NO: 5822), KNEE (SEQ ID NO: 5823), KTSI (SEQ ID NO: 5824), KAEH (SEQ ID NO: 5616), KCDQ (SEQ ID NO: 5825), KEIL (SEQ ID NO: 5826), KIER (SEQ ID NO: 5573), KNAI (SEQ ID NO: 5650), KTDK (SEQ ID NO: 5588), KTPD (SEQ ID NO: 5827), KTIH (SEQ ID NO: 5659), or KTEI (SEQ ID NO: 5591);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, or 3 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).236. The AAV particle of embodiment 234or 235, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises:(i) the amino acid sequence of any one of SEQ ID NOs: 3606-3836;(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).237. The AAV particle of any one of embodiments 234-236, wherein [N0]-[N1]-[N2]-[N3]- [N4] is or comprises KTINGHDSPFIKSGQNQQT (SEQ ID NO: 5828).2.38. The AAV particle of any one of embodiments 234-236, wherein [N0]-[N1]-[N2]-[N3]- [N4] is or comprises KAEIGHDSPHKSGQNQQT (SEQ ID NO: 1754).239. The AA V particle of any one of embodiments 234-236, wherein [N0]-[N1]-[N2]-[N3]- [N4] is or comprises KTEKMSGSPHSKAQNQQT (SEQ ID NO: 3241).240. The AAV particle of any one of embodiments 168-239, wherein [N1]-[N2]-[N3] is present in loop IV, e.g., numbered according to SEQ ID NO: 4, 36, 138, 981 , or 982,241. The AAV particle of any one of embodiments 198-202 or 234-240, wherein [N0] and [N4] are present in loop IV, e.g., numbered according to SEQ ID NO: 4, 36, 138, 981, or 982.242. The AAV particle of any one of embodiments 198-202 or 234-241, wherein [N0] is present immediately subsequent to position 448, numbered according to SEQ ID NO: 4, 36, 138, 981, or 982.243. The AAV particle of any one of embodiments 198-202 or 234-242, wherein [N0] replaces positions 449-452 (e.g., K449, T450, 1451, and N452), numbered according to SEQ ID NO: 4, 36, 138, 981, or 982.244. The AAV particle of any one of embodiments 198-202 or 234-243, wherein [N0] is present immediately subsequent to position 448 and wherein [N0] replaces positions 449-452 (e.g., K449, T450, 1451, and N452), numbered according to SEQ ID NO: 4, 36, 138, 981, or 982.245. The AAV particle of any one of embodiments 198-202 or 234-244, wherein [N0] corresponds to positions 449-452 (e.g., K449, T450, 1451 , and N452) of any one of SEQ ID NOs: 4, 36, 138, 981, or 982.246. The AAV particle of any one of embodiments 168-245, wherein [N1] is present immediately subsequent to position 452, numbered according to SEQ ID NO: 4, 36, 138, 981 , or 982.247. The AAV particle of any one of embodiments 168-246, wherein [N1] replaces positions 453-455 (e.g., G453, S454, and G455), numbered according to SEQ ID NO: 4, 36, 138, 981, or 982.248. The AAV particle of any one of embodiments 168-246, wherein [N1] replaces position453 (e.g., G453), numbered according to SEQ ID NO: 4, 36, 138, 981, or 982.249. The AAV particle of any one of embodiments 168-177, 179-181, 183-185, 187-193, 195-200, 202, or 240-246, wherein:(i) X1 of [N1] replaces position 453 (e.g., G453);(ii) X2 of [N1] corresponds to position 454 (e.g., S454); and(iii) X3 of [N1] corresponds to position 455 (e.g., G455), wherein (i), (ii), and (iii) are numbered according to SEQ ID NO: 138 or SEQ ID NO:981.250. The AAV particle of any one of embodiments 168-176, 178-201, or 240-246, wherein :(i) X1 of [N1] corresponds to position 453 (e.g., G453);(ii) X2 of [N1] corresponds to position 454 (e.g., S454); and(iii) X3 of [N1] corresponds to position 455 (e.g., G455); wherein (i), (ii), and (iii) are numbered according to SEQ ID NO: 138 or SEQ ID NO:981.251. The AAV particle of any one of embodiments 203-248, wherein:(i) X1 of [N1] corresponds to position 453 (e.g., G453);(ii) X2 of [N1] replaces position 454 (e.g., S454); and(iii) X3 of [N1] replaces position 455 (e.g., G455), wherein (i), (ii), and (iii) are numbered according to SEQ ID NO: 138 or SEQ ID NO:982.252. The AAV particle of any one of embodiments 203-248 or 251, wherein [N1] corresponds to positions 453-455 (e.g., G453, H454, D455) of SEQ ID NO 982.253. The AAV particle of any one of embodiments 168-176, 178-201, 240-247, or 250, wherein [N1] corresponds to positions 453-455 (e.g., G453, S454, G455) of SEQ ID NO: 138 or 981.254. The AAV particle of any one of embodiments 168-253, wherein [N2] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 4, 36, 138, 981, or 982.255. The AAV particle of any one of embodiments 168-254, wherein [M2] corresponds to positions 456-458 (e.g., S456, P457, and H458) of SEQ ID NO: 981 or 982.256. The AAV particle of any one of embodiments 168-254, wherein [N2] corresponds to positions 456-458 (e.g., S456, P457, and H458) of any one of SEQ ID NOs: 4 or 36-59.257. The AA V particle of any one of embodiments 168-256, wherein [N2] is present immediately subsequent to [N1].258. The AAV particle of any one of embodiments 168-202, 240-247, or 249-257, wherein [N3] corresponds to positions 459-460 (e.g., S459, K460, A461) of SEQ ID NO: 981 .259. The AAV particle of any one of embodiments 168-202, 240-247, or 249-257, wherein [N3] corresponds to positions 459-460 (e.g., S459, K460, A461) of SEQ ID NO: 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 57, or 59.260. The AAV particle of any one of embodiments 168-259, wherein [N2]-[N3] is present immediately subsequent to position 455, numbered according to any one of SEQ ID NOs: 4, 36, 138, 981, or 982.261. The AA V particle of any one of embodiments 168-259, wherein [N2]-[N3] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 981.262. The AAV particle of any one of embodiments 168-261, wherein [N2]-[N3] corresponds to positions 456-461 (e.g., S456, P457, H458, S459, K460, A461) of SEQ ID NO: 981.263. The AAV particle of any one of embodiments 168-262, wherein [N2]-[N3] corresponds to positions 456-461 (e.g., S456, P457, H458, S459, K460, A461) of any one of SEQ ID NOs: 36, 38, 39. 40, 41, 42, 43, 44, 45, 46. 47, 48, 49, 50, 51, 52, 53. 54, 55, 57, or 59.264. The AAV particle of any one of embodiments 203-257 or 259-261, wherein [N3] corresponds to positions 459-460 (e.g., K459, S460, G461) of SEQ ID NO: 982.265. The AAV particle of any one of embodiments 203-257 or 259-261, wherein [N3] corresponds to positions 459-460 (e.g., K459, S460, G461) of SEQ ID NO: 37.2.66. The AAV particle of any one of embodiments 203-265, wherein [N2.]-[N3] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 982.267. The AAV particle of any one of embodiments 203-246, 248, 252, 255, 2.57, 260, 263266, wherein [N3] replaces positions 454 and. 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138.2.68. The AAV particle of any one of embodiments 203-246, 2.48, 252, 255, 257, 260, 263-267, wherein [N3] is present immediately subsequent to [N2] and replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138.269. The AA V particle of any one of embodiments 203-246, 248, 252, 255, 2.57, 260, 263-268, wherein [N3] is present immediately subsequent to [N1]-[N2] and replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138.270. The AAV particle of any one of embodiments 203-257, 260, 264-269, wherein [N2]- [N3] corresponds to positions 456-461 (e.g., S456, P457, H458, K459, S460, G461) of SEQ ID NO: 982.271 . The AAV particle of any one of embodiments 203-257, 260, 264-270, wherein [N2]- [N3] corresponds to positions 456-461 (e.g., S456, P457, H458, K459, S460, G461) of SEQ ID NO: 37.272. The AAV particle of any one of embodiments 191-202 or 228-271, wherein [N4] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138.273. The AAV particle of any one of embodiments 191-202 or 228-272, wherein [N4] replaces positions 456-460 (e.g., Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138.274. The AAV particle of any one of embodiments 191-202 or 228-273, wherein [N4] corresponds to positions 462-466 (e.g., Q462, N463, Q464, Q465, and T466) of SEQ ID NO: 981 or 982.275. The AAV particle of any one of embodiments 191-202 or 228-273, wherein [N4] corresponds to positions 462-466 of any one of SEQ ID NOs; 4 or 36-59.276. The AAV particle of any one of embodiments 191-202 or 228-274, wherein [N4] corresponds to positions 456-460 (e.g., Q456, N457, Q458. Q459, and T460) of SEQ ID NO: 138.277. The .AAV particle of any one of embodiments 191-202 or 228-276, wherein [N2]-[N3] [N4] replaces positions 456-460 (e.g., Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138.278. The AAV particle of any one of embodiments 191-202 or 228-277, wherein [N2]-[N3j- [N4] is present immediately subsequent to position 455, and wherein [N2]-[N3]-[N4] replaces positions 456-460 (e.g., Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138.279. The AA V particle of any one of embodiments 191-202 or 228-278, wherein [N1 ]-[N2]- [N3]-[N4] replaces positions 453-460 (e.g., G453, S454, G455, Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138.280. The AAV particle of any one of embodiments 191-202 or 228-279, wherein [N1]-[N2] [N3]-[N4] is present immediately subsequent to position 452, and wherein [N1]-[N2]-[N3]- [N4] replaces positions 453-460 (e.g., G453, S454, G455, Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138.281. The AAV particle of any one of embodiments 191-202, 2.40-247, 249, 250, 253-263,266, or 272-280, wherein [N1]-[N2]-[N3]-[N4] corresponds to positions 453-466 (e.g., G453, S454, G455, S456, P457, H458, S459, K460, A461, Q462, N463, Q464, Q465, and T466) of SEQ ID NO: 981.282. The AAV particle of any one of embodiments 168-202, 240-247, 249, 250, 253-263,266, or 272-280, wherein [N1]-[N2]-[N3] corresponds to positions 453-461 (e.g., G453, S454, G455, S456, P457, H458, S459, K460, A461) of SEQ ID NO: 981 .283. The AAV particle of any one of embodiments 228-257, 260, 261, 264-282, wherein [N1]-[N2]-[N3]-[N4] corresponds to positions 453-466 (e.g.. G453, H454, D455, S456, P457, H458, K459, S460, G461, Q462, N463, Q464, Q465, T466) of SEQ ID NO: 982.284. The AAV particle of any one of embodiments 203-257, 260, 261, 264-283, wherein [N1]-[N2]-[N3] corresponds to positions 453-461 (e.g., G453, H454, D455, S456, P457, H458, K459, S460, G461) of SEQ ID NO: 982.285. The AAV particle of any one of embodiments 228-257, 260, 261, 264-282, wherein [N1]-[N2]-[N3]-[N4] corresponds to positions 453-466 of any one of SEQ ID NOs: 4 or 36- 59.2.86. The AAV particle of any one of embodiments 198-202 or 234-286, wherein [N0]-[N1]- [N2]-[N3]-[N4] replaces positions 449-460 (e.g., K449, T450, 1451, N452, G453, S454, G455, Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138.287. The AA V particle of any one of embodiments 198-202 or 234-286, wherein [N0]-[N1]- [N2]-[N3]-[N4] is present immediately subsequent to position 448, and wherein [N0]-[N1]-[N2]-[N3]-[N4] replaces positions 449-460 (e.g., K449, T450, 1451, N452, G453, S454, G455, Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138.288. The AAV particle of any one of embodiments 198-202, 240-247, 249, 250, 253-263, 266, 272-281, 286, or 287 , wherein [N0]- [N1]-[N2]-[N3]-[N4] corresponds to positions 449- 466 (e.g., K449, T450, 1451, N452, G453, S454, G455, S456, P457, H458, S459, K460, A461 , Q462, N463, Q464, Q465, T466) of SEQ ID NO: 981.289. The AAV particle of any one of embodiments 234-257, 260, 261, 264-284, 286, or 287, wherein [N0]-[N1]-[N2]-[N3]-[N4] corresponds to positions 449-466 (e.g., K449, T450, 1451, N452, G453, H454, D455, S456, P457, II458, K459, S460, G461 , Q462, N463, Q464, Q465, T466) of SEQ ID NO: 982.2.90. The AAV particle of any one of embodiments 234-257, 2.60, 261, 264-284, 2.86, or 287, wherein [N0]-[N1]-[N2]-[N3]-[N4] corresponds to positions 449-466 of any one of SEQ ID NOs: 4 or 36-59.291. The AA V particle of any one of embodiments 191-202 or 228-290, wherein [N4] is present immediately subsequent to position 461, numbered according to SEQ ID NO; 4, 36, 981, or 982.292. The AAV particle of any one of embodiments 191 -202 or 228-291 , wherein [N4] replaces positions 462-466 (e.g., Q462, N463, Q464, Q465, and T466), numbered according to SEQ ID NO: 4, 36, 981, or 982.293. The AAV particle of any one of embodiments 191-202 or 228-292, wherein [N2]-[N3]- [N4] replaces positions 462-466 (e.g., Q462, N463, Q464, Q465, and T466), numbered according to SEQ ID NO: 4, 36, 981 , or 982,294. The AAV particle of any one of embodiments 191-202 or 228-293, wherein [N2]-[N3]- [N4] is present immediately subsequent to position 455, and wherein [N2]-[N3]-[N4] replaces positions 462-466 (e.g., Q462, N463, Q464, Q465, and T466), numbered according to SEQ ID NO: 4, 36, 981, or 982.295. The AAV particle of any one of embodiments 168-294, wherein the AAV capsid variant comprises, from N-terminus to C-terminus, [N2]-[N3],296. The AAV particle of any one of embodiments 168-295, wherein the AAV capsid variant comprises, from N-terminus to C-tenninus, [N1]-[N2]-[N3|.297. The AAV particle of any one of embodiments 168-296, wherein the AAV capsid variant comprises, from N-terminus to C-terminus, [N0]-[N1]-[N2]-[N3].298. The AAV particle of any one of embodiments 168-297, wherein the AAV capsid variant comprises, from N-terminus to C-terminus, [N1]-[N2]-[N3]-[N4],299. The AAV particle of any one of embodiments 168-298, wherein the AAV capsid variant composes, from N-terminus to C-tenninus, [N0]-[N1]-[N2.]-[N3]-[N4].300. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV 9 capsid vanant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises the formula [A|-[B] (SEQ ID NO: 4696), wherein:(i) [A] comprises GSGSPH (SEQ ID NO: 4695); and(ii) [B] comprises X1, X2, X3, X4, and X5, wherein:(a) X1 is S, I, F, V, C, Y, W, R, P, L, Q, M, K, or G;(b) X2 is K, M, R, F, V, C. P, Y, L, W, G, N, S. T, I, or A:(c) X3 is A, Y, L, R, W, C, T, F, H, I, P, M, K, S, V, G, Q, or N;(d) X4 is Q, M, F, K, H, R, C, W, P, V, L, G, S, Y, I, A, T, D, N, or E; and(e) X5 is A, N, Y, R, K, L. I, M, Q, S, C, W, F, T, G, V, or P; optionally wherein the AAV capsid, variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(e).301. The AAV particle of embodiment 300, wherein:(a) X1 is S, L, R, V, or P;(b) X2 is K, C, F, L, P, R, S, or V;(c) X3 is A, C, F, I, K, L, M, P, R, T, W, or Y:(d) X4 is Q, R, S, T, C, F, K, L, P or Y ; and(e) X5 is N, R, S, T, K, M, Q or Y; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a. conservative substitution, of any of the aforesaid amino acids in (a)-(e).302. The AAV particle of embodiment 300 or 301, wherein [B] comprises SKA, SMY, SKL, SKR, SKW, SRC, SFT, SKF, IVW, SKY, SCH, FPW, SKI, VYY, SLY, SKP, SRF, SRM, SVK, SWA, SLW, SFR, SKK, SYA, SCS, SGA, SFP, SFF, SMC, SKT, SGK, FYR, CRV, YGI, VNC, SLA, WSY, RWL, PSC, SSW, SKG, VPW, SGC, STT, PKR, SKC, WVP, SFW, RIK, SKM, LRW, LPT, SYM, LLC, RCC, LCV, SYL, QGC, MAF, SFQ, SLC, RPW, RPR, SCP, SVR, SLP, VYII, SYT, LVY, YRY, SWL, CPA, SPP, RWT, PRK, PFV, SKS, WVA, SKV, CAL, SSC, SKN, LCT, STC, SKQ, KSG, SYY, SLT, SCQ, FPF, SVF, GRY, AQA, AQN. YMN, AFY, LKR, RHR, AQK, WRL, CRN, TCN, FFI, AQY, WQN. YFM, ARQ, HQN, IRR, YQN, YWN, APS, FWN, AQC, MRN, K.KN, APN, WKN, ARW. RPN, KVF, AFN, ACS, RLW, SRN, CPN, ACN, FRQ, PEN, FGN, CQN, LFW, TRK, KRN, RQN, VQN, IQN, AQR, PFR, AWN, RSY, LQN, WLN, RRA, AQT, GCT, RYT, TPN, ARM, CFL, PQN, WSN, FKN, KQN. APR. RYN, MIC, TQN, WKS, AAR, LTR, IRG. LVN, FQN, ACQ, WGL, IL R. QIN, ACI, ALR, AHA, CLN, AFV, AQF, RC.N, MPC, KTS, PYN, AQS, TRN, LKN, AQM, CTN, PDN, RNY, ACR, CSV, ARI, LPK, SEQ, VRM, NSR, RKR, ARN, QRP, RVV, GQN. YSN, QSN, AKG, CIS, FEN, AKK. KAQ, MYM, KAF, KLK, KRH, KWR, RCR, FTC, KFF, VWQ, KYF, KAR, CHQ, PWQ, KIR, YYQ, LYW, KPK, RFW, RMR, VKK, WAP, LWK, FRP, KKV, YAF, KAC, KRL, CSR, RCP, GAC, KFR, FFG, MCQ, KEF, KTR, GKR, YRQ, RVQ, GIQ, NCQ, KPF, LAW, KRS, SYQ, WLQ, KRR, KGC, KRY, GCQ, FTP, ITC. KRQ, KCF, VPQ, FWS, KFK, IKQ, K AP. FRY, KM1, RWQ, PTQ, KWK, YMR, KAA, LCQ, CCQ, CVQ, KLT, KLC, YLV, AFQ, KWG, KIL, FQI, KAL, KAH, LCL, PRQ, CPQ, VRY, VRC, KMP, KKT, LPY, YHQ, YTR, VYQ, RYQ, WLK, PAQ, MCT, PPD, WTQ, RKQ, KCS, FVQ, KLP, KSE. VAQ, LYQ, KVR, ALQ, SCT, KNS, KRK, CTQ, TCL, YAR, KQR, KRV, SGQ, YYS, LTC, CQS, KAK, KPQ, PFQ, KCT, or VFE.303. The AAV particle of any one of embodiments 300-302, wherein [B] comprises SKAQ (SEQ ID NO: 5829), SMYM (SEQ ID NO: 5830), SKAF (SEQ ID NO: 5831), SKLK (SEQ ID NO: 5832), SKRTI (SEQ ID NO: 5833), SKWR (SEQ ID NO: 5834), SRCR (SEQ ID NO: 5835), SFTC (SEQ ID NO: 5836), SKFF (SEQ ID NO: 5837), IVWQ (SEQ ID NO:5838), SKYF (SEQ ID NO: 5839), SKAR (SEQ ID NO: 5840), SCIIQ (SEQ ID NO: 5841), FPWQ (SEQ ID NO: 5842), SKIR (SEQ ID NO: 5843), VYYQ (SEQ ID NO: 5844), SLYW (SEQ ID NO: 5845), SKPK (SEQ ID NO: 5846), SKEW (SEQ ID NO: 5847), SRMR (SEQ ID NO: 5848), SVKK (SEQ ID NO: 5849), SWAP (SEQ ID NO: 5850), SLWK (SEQ ID NO: 5851), SFRP (SEQ ID NO: 5852), SKKV (SEQ ID NO: 5853), SYAF (SEQ ID NO: 5854). SK U' (SEQ ID NO: 5855), SKRL (SEQ ID NO: 5856), SCSR (SEQ ID NO: 5857), SRCP (SEQ ID NO: 5858), SGAC (SEQ ID NO: 5859), SKFR (SEQ ID NO: 5860), SFPF (SEQ ID NO: 5861), SFFG (SEQ ID NO: 5862), SMCQ (SEQ ID NO: 5863), SKLF (SEQ ID NO: 5864), SKTR (SEQ ID NO: 5865), SGKR (SEQ ID NO: 5866), FYRQ (SEQ ID NO: 5867), CRVQ (SEQ ID NO: 5868), YGIQ (SEQ ID NO: 5869), VNCQ (SEQ ID NO: 5870), SKPF (SEQ ID NO: 5871), SLAW (SEQ ID NO: 5872), SKRS (SEQ ID NO: 5873), WSYQ (SEQ ID NO: 5874), RWLQ (SEQ ID NO: 5875), PSCQ (SEQ ID NO: 5876), SSWL (SEQ ID NO: 5877), SKRR (SEQ ID NO: 5878), SKGC (SEQ ID NO: 5879), VPWQ (SEQ ID NO: 5880), SKRY (SEQ ID NO: 5881), SGCQ (SEQ ID NO: 5882), Sl i p (SEQ ID NO: 5883), STIC (SEQ ID NO: 5884), PKRQ (SEQ ID NO: 5885), SKCF (SEQ ID NO: 5886), WVPQ (SEQ ID NO: 5887), SEWS (SEQ ID NO: 5888), SKFK (SEQ ID NO: 5889), RIKQ (SEQ ID NO: 5890), SKAP (SEQ ID NO: 5891), SFRY (SEQ ID NO: 5892), SKMI (SEQ ID NO: 5893), LRWQ (SEQ ID NO: 5894), LPTQ (SEQ ID NO: 5895), SKWK (SEQ ID NO: 5896), SYMR (SEQ ID NO: 5897), SKAA (SEQ ID NO: 5898), LLCQ (SEQ ID NO: 5899), RCCQ (SEQ ID NO: 5900), LCVQ (SEQ ID NO: 5901), SKLT (SEQ ID NO: 5902), SKLC (SEQ ID NO: 5903), SYLV (SEQ ID NO: 5904), QGCQ (SEQ ID NO: 5905), MAFQ (SEQ ID NO: 5906), SKWG (SEQ ID NO: 5907), SKIL (SEQ ID NO: 5908), SFQI (SEQ ID NO: 5909), SKAL (SEQ ID NO: 5910), SKAH (SEQ ID NO: 5911), SLCL (SEQ ID NO: 5912), RPWQ (SEQ ID NO: 5913), RPRQ (SEQ ID NO: 5914), SCPQ (SEQ ID NO: 5915), SVRY (SEQ ID NO: 5916), SVRC (SEQ ID NO: 5917), SKMP (SEQ ID NO: 5918), SKKT (SEQ ID NO: 5919), SLPY (SEQ ID NO: 5920), VYIIQ (SEQ ID NO: 5921), SYTR (SEQ ID NO: 5922). LVYQ (SEQ ID NO: 5923), YRYQ (SEQ ID NO: 5924), SWLK (SEQ ID NO: 5925), CPAQ (SEQ ID NO: 5926), SMCT (SEQ ID NO: 5927), SPPD (SEQ ID NO: 5928), SKRN (SEQ ID NO: 5929), RWTQ (SEQ ID NO: 5930), PRKQ (SEQ ID NO: 5931), SKCS (SEQ ID NO: 5932), PFVQ (SEQ ID NO: 5933), SKLP (SEQ ID NO: 5934), SKSE (SEQ ID NO: 5935), WVAQ (SEQ ID NO: 5936), SLYQ (SEQ ID NO: 5937), SKVR (SEQ ID NO: 5938). CALQ (SEQ ID NO: 5939), SSCT (SEQ ID NO: 5940), SKNS (SEQ ID NO: 5941), SKRK (SEQ ID NO: 5942), LCTQ (SEQ ID NO: 5943), STCL (SEQ ID NO: 5944), SY AR (SEQ ID NO: 5945), SKQR (SEQ ID NO: 5946), SKRY (SEQ ID NO: 5947), KSGQ (SEQ ID NO:5948), SYYS (SEQ ID NO: 5949), SLTC (SEQ ID NO: 5950), SCQS (SEQ ID NO: 5951), SKAK (SEQ ID NO: 5952), SKPQ (SEQ ID NO: 5953), FPFQ (SEQ ID NO: 5954), SKCT (SEQ ID NO: 5955), SAFE (SEQ ID NO: 5956), GRYQ (SEQ ID NO: 5957), KAQA (SEQ ID NO: 5958), KAQN (SEQ ID NO: 5959), MYMN (SEQ ID NO: 5960), KAFY (SEQ ID NO: 5961), KLKR (SEQ ID NO: 5962), KRHR (SEQ ID NO: 5963), KAQK (SEQ ID NO: 5964). KWRL (SEQ ID NO: 5965), RCRN (SEQ ID NO: 5966), FTCN (SEQ ID NO: 5967), KFFI (SEQ ID NO: 5968), KAQY (SEQ ID NO: 5969), VWQN (SEQ ID NO: 5970), KYFM (SEQ ID NO: 5971), KARQ (SEQ ID NO: 5972), CHQN (SEQ ID NO: 5973), PWQN (SEQ ID NO: 5974), KIRR (SEQ ID NO: 5975), YYQN (SEQ ID NO: 5976), LYWN (SEQ ID NO: 5977), KPKR (SEQ ID NO: 5978), KAFS (SEQ ID NO: 5979), RFWN (SEQ ID NO: 5980), KAQC (SEQ ID NO: 5981), RMRN (SEQ ID NO: 5982), VKKN (SEQ ID NO: 5983), WAPN (SEQ ID NO: 5984), LWKN (SEQ ID NO: 5985), KARW (SEQ ID NO: 5986). FRPN (SEQ ID NO: 5987), KKVF (SEQ ID NO: 5988), YAFN (SEQ ID NO: 5989), KACS (SEQ ID NO: 5990), KRLW (SEQ ID NO: 5991), CSRN (SEQ ID NO: 5992), RCPN (SEQ ID NO: 5993), GACN (SEQ ID NO: 5994), KFRQ (SEQ ID NO: 5995), FPFN (SEQ ID NO: 5996), FFGN (SEQ ID NO: 5997), MCQN (SEQ ID NO: 5998), KLFW (SEQ ID NO: 5999), KTRK (SEQ ID NO: 6000), GKRN (SEQ ID NO: 6001), YRQN (SEQ ID NO: 6002), RVQN (SEQ ID NO: 6003), GIQN (SEQ ID NO: 6004), KAQR (SEQ ID NO: 6005), NCQN (SEQ ID NO: 6006), KPFR (SEQ ID NO: 6007), LAWN (SEQ ID NO: 6008), KRSY (SEQ ID NO: 6009), SYQN (SEQ ID NO: 6010), WLQN (SEQ ID NO: 6011), SCQN (SEQ ID NO: 6012), SWEN (SEQ ID NO: 6013), KRRA (SEQ ID NO: 6014), KAQT (SEQ ID NO: 6015), KGCT (SEQ ID NO: 6016), KRYT (SEQ ID NO: 6017), GCQN (SEQ ID NO: 6018), FTPN (SEQ ID NO: 6019), TTCN (SEQ ID NO: 6020), KARM (SEQ ID NO: 6021), KRQN (SEQ ID NO: 6022). KCFL (SEQ ID NO: 6023), VPQN (SEQ ID NO: 6024), FWSN (SEQ ID NO: 6025), KFKN (SEQ ID NO: 6026), IKQN (SEQ ID NO: 6027), KAPR (SEQ ID NO: 6028), FRYN (SEQ ID NO: 6029), KMIC (SEQ ID NO: 6030), RWQN (SEQ ID NO: 6031), PTQN (SEQ ID NO: 6032), KWKS (SEQ ID NO: 6033). YMRN (SEQ ID NO: 6034), KAAR (SEQ ID NO: 6035), LCQN (SEQ ID NO: 6036), CCQN (SEQ ID NO: 6037), CVQN (SEQ ID NO: 6038), KLTR (SEQ ID NO: 6039), KLCT (SEQ ID NO: 6040), KIRG (SEQ ID NO: 6041), YLVN (SEQ ID NO: 6042), AFQN (SEQ ID NO: 6043), KACQ (SEQ ID NO: 6044), KWGL (SEQ ID NO: 6045), KIER (SEQ ID NO: 6046), FQ1N (SEQ ID NO: 6047), KACI (SEQ ID NO: 6048), KALR (SEQ ID NO: 6049), KARA (SEQ ID NO: 6050), LCLN (SEQ ID NO: 6051), KAFV (SEQ ID NO: 6052), PRQN (SEQ ID NO: 6053), CPQN (SEQ ID NO: 6054), KAQF (SEQ ID NO: 6055), VRYN (SEQ ID NO: 6056), VRCN (SEQID NO: 6057), KMPC (SEQ ID NO: 6058), KKTS (SEQ ID NO: 6059), LPYN (SEQ ID NO: 6060), YHQN (SEQ ID NO: 6061), KAQS (SEQ ID NO: 6062), YTRN (SEQ ID NO: 6063), VYQN (SEQ ID NO: 6064), RYQN (SEQ ID NO: 6065), WLKN (SEQ ID NO: 6066), KAQM (SEQ ID NO: 6067), PAQN (SEQ ID NO: 6068), MCTN (SEQ ID NO: 6069), PPDN (SEQ ID NO: 6070), KRNY (SEQ ID NO: 6071), WTQN (SEQ ID NO: 6072), KACR (SEQ ID NO: 6073), RKQN (SEQ ID NO: 6074), ROSY (SEQ ID NO: 6075), KARI (SEQ ID NO: 6076), FVQN (SEQ ID NO: 6077), KLPK (SEQ ID NO: 6078), KSEQ (SEQ ID NO: 6079), VAQN (SEQ ID NO: 6080), LYQN (SEQ ID NO: 6081), KVRM (SEQ ID NO: 6082), ALQN (SEQ ID NO: 6083), SCTN (SEQ ID NO: 6084), KNSR (SEQ ID NO: 6085), KRKR (SEQ ID NO: 6086), CTQN (SEQ ID NO: 6087), TCLN (SEQ ID NO: 6088), YARN (SEQ ID NO: 6089), KQRP (SEQ ID NO: 6090), KRVV (SEQ ID NO: 6091), SGQN (SEQ ID NO: 6092), YYSN (SEQ ID NO: 6093), ETON (SEQ ID NO: 6094), CQSN (SEQ ID NO: 6095), KAKG (SEQ ID NO: 6096), KPQN (SEQ ID NO: 6097), PFQN (SEQ ID NO: 6098), KCTS (SEQ ID NO: 6099), VEEN (SEQ ID NO: 6100), or KAKK (SEQ ID NO: 6101).304. The AAV particle of any one of embodiments 300-303, wherein [B] is or comprises:(i) SKAQA (SEQ ID NO: 6102), SKAQN (SEQ ID NO: 6103), SMYMN (SEQ ID NO: 6104), SKAFY (SEQ ID NO: 6105), SKLKR (SEQ ID NO: 6106), SKRHR (SEQ ID NO: 6107), SKAQK (SEQ ID NO: 6108), SKWRL (SEQ ID NO: 6109). SRCRN (SEQ ID NO: 61 10), SFTCN (SEQ ID NO: 6111.), SKFFI (SEQ ID NO: 6112), SKAQY (SEQ ID NO: 6113), IVWQN (SEQ ID NO: 6114), SKYFM (SEQ ID NO: 6115), SKARQ (SEQ ID NO: 6116), SCHQN (SEQ ID NO: 6117), FPWQN (SEQ ID NO: 6118), SKIRR (SEQ ID NO: 6119), VYYQN (SEQ ID NO: 6120), SLYWN (SEQ ID NO: 6121), SKPKR (SEQ ID NO: 6122), SKAFS (SEQ ID NO: 6123), SRFWN (SEQ ID NO: 6124), SKAQC (SEQ ID NO: 6125), SRMRN (SEQ ID NO: 6126), SVKKN (SEQ ID NO: 6127), SWAPN (SEQ ID NO: 6128). SLWKN (SEQ ID NO: 6129), SKARW (SEQ ID NO: 6130), SFRPN (SEQ ID NO: 6131), SKKVF (SEQ ID NO: 6132), SYAFN (SEQ ID NO: 6133), SKACS (SEQ ID NO: 6134), SKRLW (SEQ ID NO: 6135), SCSRN (SEQ ID NO: 6136), SRCPN (SEQ ID NO: 6137), SGACN (SEQ ID NO: 6138), SKFRQ (SEQ ID NO: 6139), SFPFN (SEQ ID NO: 6140), SFFGN (SEQ ID NO: 6141), SMCQN (SEQ ID NO: 6142), SKLFW (SEQ ID NO: 6143), SKTRK (SEQ ID NO: 6144), SGKRN (SEQ ID NO: 6145), FYRQN (SEQ ID NO: 6146), CRVQN (SEQ ID NO: 6147), YGIQN (SEQ ID NO: 6148), SKAQR (SEQ ID NO: 6149), VNCQN (SEQ ID NO: 6150), SKPFR (SEQ ID NO: 6151), SLAWN (SEQ ID NO:6152), SKRSY (SEQ ID NO: 6153), WSYQN (SEQ ID NO: 6154), RWLQN (SEQ ID NO: 6155), PSCQN (SEQ ID NO: 6156), SSWLN (SEQ ID NO: 6157), SKRRA (SEQ ID NO: 6158), SKAQT (SEQ ID NO: 6159), SKGCT (SEQ ID NO: 6160), VPWQN (SEQ ID NO: 6161), SKRYT (SEQ ID NO: 6162), SGCQN (SEQ ID NO: 6163), SFTPN (SEQ ID NO: 6164), STTCN (SEQ ID NO: 6165), SKARM (SEQ ID NO: 6166), PKRQN (SEQ ID NO: 6167). SKCFL (SEQ ID NO: 6168), WVPQN (SEQ ID NO: 6169), SFWSN (SEQ ID NO: 6170), SKFKN (SEQ ID NO: 6171), RIKQN (SEQ ID NO: 6172), SKAPR (SEQ ID NO: 6173), SFRYN (SEQ ID NO: 6174), SKMIC (SEQ ID NO: 6175), LRWQN (SEQ ID NO: 6176), LPTQN (SEQ ID NO: 6177), SKWKS (SEQ ID NO: 6178), SYMRN (SEQ ID NO: 6179), SKAAR (SEQ ID NO: 6180), LLCQN (SEQ ID NO: 6181), RCCQN (SEQ ID NO: 6182), LCVQN (SEQ ID NO: 6183), SKLTR (SEQ ID NO: 6184), SKLCT (SEQ ID NO: 6185), SKIRG (SEQ ID NO: 6186), SYLVN (SEQ ID NO: 6187), QGCQN (SEQ ID NO: 6188). MAFQN (SEQ ID NO: 6189), SKACQ (SEQ ID NO: 6190). SKWGL (SEQ ID NO: 6191), SKIER (SEQ ID NO: 6192), SFQIN (SEQ ID NO: 6193), SKACI (SEQ ID NO: 6194), SKALR (SEQ ID NO: 6195), SKAHA (SEQ ID NO: 6196), SLCLN (SEQ ID NO: 6197), SKAFV (SEQ ID NO: 6198), RPWQN (SEQ ID NO: 6199), RPRQN (SEQ ID NO: 6200), SCPQN (SEQ ID NO: 6201), SKAQF (SEQ ID NO: 6202), SVRYN (SEQ ID NO: 6203), SVRCN (SEQ ID NO: 6204), SKMPC (SEQ ID NO: 6205), SKKTS (SEQ ID NO: 6206), SLPYN (SEQ ID NO: 6207), VYHQN (SEQ ID NO: 6208), SKAQS (SEQ ID NO: 6209). SYTRN (SEQ ID NO: 6210), LVYQN (SEQ ID NO: 6211), YRYQN (SEQ ID NO: 6212), SWLKN (SEQ ID NO: 6213), SKAQM (SEQ ID NO: 6214), CPAQN (SEQ ID NO: 6215), SMCTN (SEQ ID NO: 6216), SPPDN (SEQ ID NO: 6217), SKRNY (SEQ ID NO: 6218), RWTQN (SEQ ID NO: 6219), SKACR (SEQ ID NO: 6220), PRKQN (SEQ ID NO: 6221), SKCSV (SEQ ID NO: 6222), SKARI (SEQ ID NO: 6223). PFVQN (SEQ ID NO: 6224), SKLPK (SEQ ID NO: 6225), SKSEQ (SEQ ID NO: 6226), WVAQN (SEQ ID NO: 6227), SLYQN (SEQ ID NO: 6228), SKVRM (SEQ ID NO: 6229), CALQN (SEQ ID NO: 6230). SSCTN (SEQ ID NO: 6231), SKNSR (SEQ ID NO: 6232), SKRKR (SEQ ID NO: 6233), LCTQN (SEQ ID NO: 6234), STCLN (SEQ ID NO: 6235), SYARN (SEQ ID NO: 6236), SKQRP (SEQ ID NO: 6237), SKRVV (SEQ ID NO: 6238), KSGQN (SEQ ID NO: 6239), SYYSN (SEQ ID NO: 6240), SLTCN (SEQ ID NO: 6241), SCQSN (SEQ ID NO: 6242), SKAKG (SEQ ID NO: 6243), SKPQN (SEQ ID NO: 6244), FPFQN (SEQ ID NO: 6245), SKCTS (SEQ ID NO: 6246), SVFEN (SEQ ID NO: 6247), SKAKK (SEQ ID NO: 6248), or GRYQN (SEQ ID NO: 6249);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, or 4 amino acids, e.g., consecutive amino acids, thereof;(lii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).305. The AAV particle of any one of embodiments 300-304, wherein [A]-[B] is or comprises:(i) GSGSPHSKAQA (SEQ ID NO: 6250), GSGSPHSKAQN (SEQ ID NO: 6251), GSGSPHSMYMN (SEQ ID NO: 6252), GSGSPHSKAFY (SEQ ID NO: 6253), GSGSPHSKLKR (SEQ ID NO: 6254), GSGSPHSKRHR (SEQ ID NO: 6255), GSGSPHSKAQK (SEQ ID NO: 6256), GSGSPHSKWRL (SEQ ID NO: 6257), GSGSPHSRCRN (SEQ ID NO: 6258). GSGSPHSFTCN (SEQ ID NO: 6259), GSGSPHSKFFI (SEQ ID NO: 6260), GSGSPHSKAQY (SEQ ID NO: 6261), GSGSPHTVWQN (SEQ ID NO: 6262), GSGSPHSKYFM (SEQ ID NO: 6263), GSGSPHSKARQ (SEQ ID NO: 6264), GSGSPHSCHQN (SEQ ID NO: 6265), GSGSPHFPWQN (SEQ ID NO: 6266), GSGSPHSKIRR (SEQ ID NO: 6267), GSGSPHVYYQN (SEQ ID NO: 6268), GSGSPHSLYWN (SEQ ID NO: 62.69), GSGSPHSKPKR (SEQ ID NO: 6270), GSGSPHSKAFS (SEQ ID NO: 6271), GSGSPHSRFWN (SEQ ID NO: 6272), GSGSPHSK AQC (SEQ ID NO: 6273), GSGSPHSRMRN (SEQ ID NO: 6274), GSGSPHSVKKN (SEQ ID NO: 6275), GSGSPHSWAPN (SEQ ID NO: 6276), GSGSPHSLWKN (SEQ ID NO: 6277), GSGSPHSKARW (SEQ ID NO: 6278), GSGSPHSFRPN (SEQ ID NO: 6279), GSGSPHSKKVF (SEQ ID NO: 6280), GSGSPHSYAFN (SEQ ID NO: 6281), GSGSPHSKACS (SEQ ID NO: 62.82), GSGSPHSKRLW (SEQ ID NO: 6283), GSGSPHSCSRN (SEQ ID NO: 6284), GSGSPHSRCPN (SEQ ID NO: 6285), GSGSPHSGACN (SEQ ID NO: 6286), GSGSPHSKFRQ (SEQ ID NO: 6287), GSGSPHSFPFN (SEQ ID NO: 62.88), GSGSPHSFFGN (SEQ ID NO: 6289), GSGSPHSMCQN (SEQ ID NO: 6290), GSGSPHSKLFW (SEQ ID NO: 6291 ), GSGSPHSKTRK (SEQ ID NO: 6292), GSGSPHSGKRN (SEQ ID NO: 6293), GSGSPHFYRQN (SEQ ID NO: 6294), GSGSPHCRVQN (SEQ ID NO: 6295), GSGSPHYGIQN (SEQ ID NO: 62.96), GSGSPHSKAQR (SEQ ID NO: 6297), GSGSPHVNCQN (SEQ ID NO: 6298), GSGSPHSKPFR (SEQ ID NO: 6299), GSGSPHSLAWN (SEQ ID NO: 6300), GSGSPHSKRSY (SEQ ID NO: 6301),GSGSPHWSYQN (SEQ ID NO: 6302), GSGSPHRWLQN (SEQ ID NO: 6303), GSGSPHPSCQN (SEQ ID NO: 6304), GSGSPHSSWLN (SEQ ID NO: 6305), GSGSPHSKRRA (SEQ ID NO: 6306), GSGSPHSKAQT (SEQ ID NO: 6307), GSGSPHSKGCT (SEQ ID NO: 6308), GSGSPHVPWQN (SEQ ID NO: 6309), GSGSPHSKRYT (SEQ ID NO: 6310), GSGSPHSGCQN (SEQ ID NO: 6311 ), GSGSPHSFTPN (SEQ ID NO: 6312), GSGSPHSITCN (SEQ ID NO: 6313), GSGSPHSKARM (SEQ ID NO: 6314), GSGSPHPKRQN (SEQ ID NO: 6315), GSGSPHSKCFL (SEQ ID NO: 6316), GSGSPHWVPQN (SEQ ID NO: 6317), GSGSPHSFWSN (SEQ ID NO: 6318), GSGSPHSKFKN (SEQ ID NO: 6319), GSGSPHRIKQN (SEQ ID NO: 6320), GSGSPHSKAPR (SEQ ID NO: 6321), GSGSPHSFRYN (SEQ ID NO: 6322), GSGSPHSKMIC (SEQ ID NO: 6323), GSGSPHLRWQN (SEQ ID NO: 6324), GSGSPHLPTQN (SEQ ID NO: 6325), GSGSPHSKWKS (SEQ ID NO: 6326), GSGSPHSYMRN (SEQ ID NO: 6327). GSGSPHSKAAR (SEQ ID NO: 6328), GSGSPHELCQN (SEQ ID NO: 6329), GSGSPHRCCQN (SEQ ID NO: 6330), GSGSPHLCVQN (SEQ ID NO: 6331), GSGSPHSKLTR (SEQ ID NO: 6332), GSGSPHSKLCT (SEQ ID NO: 6333), GSGSPHSKIRG (SEQ ID NO: 6334), GSGSPHSYLVN (SEQ ID NO: 6335), GSGSPHQGCQN (SEQ ID NO: 6336), GSGSPHMAFQN (SEQ ID NO: 6337), GSGSPHSKACQ (SEQ ID NO: 6338), GSGSPHSKWGL (SEQ ID NO: 6339), GSGSPHSKILR (SEQ ID NO: 6340), GSGSPHSFQLN (SEQ ID NO: 6341), GSGSPHSKACI (SEQ ID NO: 6342), GSGSPHSKALR (SEQ ID NO: 6343), GSGSPHSKAHA (SEQ ID NO: 6344), GSGSPHSLCLN (SEQ ID NO: 6345), GSGSPHSKAFV (SEQ ID NO: 6346), GSGSPHRPWQN (SEQ ID NO: 6347), GSGSPHRPRQN (SEQ ID NO: 6348), GSGSPHSCPQN (SEQ ID NO: 6349), GSGSPHSKAQF (SEQ ID NO: 6350), GSGSPHSVRYN (SEQ ID NO: 6351), GSGSPHSVRCN (SEQ ID NO: 6352), GSGSPHSKMPC (SEQ ID NO: 6353), GSGSPHSKKTS (SEQ ID NO: 6354), GSGSPHSLPYN (SEQ ID NO: 6355), GSGSPHVYHQN (SEQ ID NO: 6356), GSGSPHSKAQS (SEQ ID NO: 6357), GSGSPHSYTRN (SEQ ID NO: 6358), GSGSPHLVYQN (SEQ ID NO: 6359), GSGSPHYRYQN (SEQ ID NO: 6360), GSGSPHSWLKN (SEQ ID NO: 6361), GSGSPHSKAQM (SEQ ID NO: 6362), GSGSPHCPAQN (SEQ ID NO: 6363), GSGSPHSMCTN (SEQ ID NO: 6364), GSGSPHSPPDN (SEQ ID NO: 6365), GSGSPHSKRNY (SEQ ID NO: 6366), GSGSPHRWTQN (SEQ ID NO: 6367), GSGSPHSKACR (SEQ ID NO: 6368), GSGSPHPRKQN (SEQ ID NO: 6369),GSGSPHSKCSV (SEQ ID NO: 6370), GSGSPHSKARI (SEQ ID NO: 6371 ), GSGSPHPFVQN (SEQ ID NO: 6372), GSGSPHSKLPK (SEQ ID NO: 6373), GSGSPHSKSEQ (SEQ ID NO: 6374), GSGSPHWVAQN (SEQ ID NO: 6375), GSGSPHSLYQN (SEQ ID NO: 6376), GSGSPHSKVRM (SEQ ID NO: 6377), GSGSPHCALQN (SEQ ID NO: 6378), GSGSPHSSCTN (SEQ ID NO: 6379), GSGSPHSKNSR (SEQ ID NO: 6380), GSGSPHSKRKR (SEQ ID NO: 6381), GSGSPHLCTQN (SEQ ID NO: 6382), GSGSPHSTCLN (SEQ ID NO: 6383), GSGSPHSYARN (SEQ ID NO: 6384), GSGSPHSKQRP (SEQ ID NO: 6385), GSGSPHSKRVV (SEQ ID NO: 6386), GSGSPHKSGQN (SEQ ID NO: 6387), GSGSPHSYYSN (SEQ ID NO: 6388), GSGSPHSLTCN (SEQ ID NO: 6389), GSGSPHSCQSN (SEQ ID NO: 6390), GSGSPHSKAKG (SEQ ID NO: 6391 ), GSGSPHSKPQN (SEQ ID NO: 6392), GSGSPHFPFQN (SEQ ID NO: 6393), GSGSPHSKCTS (SEQ ID NO: 6394). GSGSPHSVFEN (SEQ ID NO: 6395), GSGSPHSKAKK (SEQ ID NO: 6396), or GSGSPHGRYQN (SEQ ID NO: 6397);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i)306. The AAV particle of any one of embodiments 300-305, wherein [A]-[B] does not comprise the amino acid sequence of GSGSPHSKAQN (SEQ ID NO: 6251).307. The AAV particle of any one of embodiments 300-306, w herein the AAV capsid variant comprises one, two, or all of an amino acid other than Q at position 458 (e.g., R, C, S, W, L, F, Y, H, I, V, A, or P), an amino acid other than Q at position 459 (e.g., K, I, R, L or S), and / or an amino acid other than T at position 460 (e.g., R), numbered according to SEQ ID NO: 138.308. The AAV particle of any one of embodiments 300-307, wherein the AAV capsid variant comprises:(i) the amino acid R at position 458;(ii) the amino acid W at position 458;(iii) the amino acid Y at position 458;(iv) the amino acid F at position 458;(v) the amino acid. S at position 458;(vi) the amino acid C at position 458;(vii) the amino acid I at position 458;(viii) the amino acid L at position 458;(ix) the amino acid P at position 458;(x) the amino acid I at position 459;(xi) the amino acid FI at position 458; or(xii) the amino acid V at position 458; wherein (i)-(xii) are numbered according to SEQ ID NO: 138.309. The AAV particle of any one of embodiments 300-307, wherein the AAV capsid variant composes:(i) the amino acid R at position 458 and the amino acid K at position 459;(ii) the amino acid C at position 458 and the amino acid I at position 459;(lii) the amino acid S at position 458 and the amino acid R at position 459;(iv) tire amino acid L at position 458 and tire amino acid K at position 459;(v) the amino acid F at position 458 and the amino acid K at position 459;(vi) the amino acid C at position 458 and the amino acid R at position 459;(vii) the amino acid H at position 458 and the amino acid R at position 459;(viii) the amino acid I at position 458 and the amino acid L at position 459;(ix) the amino acid V at position 458 and the amino acid R at position 459;(x) the amino acid A at position 458 and the amino acid K at position 459;(xi) tire amino acid I at position 458 and the amino acid. K at position 459;(xii) the amino acid C at position 458 and the amino acid S at. position 459; or(xiii) the amino acid C at position 458 and the amino acid L at position 459; wherein (i)-(xiii) are numbered, according to SEQ ID NO: 138.310. The AAV particle of any one of embodiments 300-307, wherein the AAV capsid variant comprises the amino acid F at position 458, the amino acid K at position 459, and the amino acid R at position 460, numbered according to SEQ ID NO: 138.31 1. The AAV particle of any one of embodiments 300-310, wherein the AAV capsid variant comprises one, two, or all of an amino acid other than T at position 450 (e.g., Y, P, W, R, K, S, or F), an amino acid other than I at position 451 (e.g., R, S, Y, I.,, V, H, P, A, or F), and / or an amino acid other than N at position 452 (e.g., V, W, A, T, F, Y, L, R, H, S, or M), numbered according to SEQ ID NO: 138.312. The AAV particle of any one of embodiments 300-311, wherein the AAV capsid variant comprises the amino acid V at position 452, numbered according to SEQ ID NO: 138.313. The AAV particle of any one of embodiments 300-312, wherein the AAV capsid variant comprises the amino acid Y at position 450 and the amino acid V at position 452, numbered according to SEQ ID NO: 138.314. The AAV particle of any one of embodiments 300-312, wherein the AAV capsid variant comprises the amino acid R at position 450 and the amino acid Y at position 451 , numbered according to SEQ ID NO: 138.315. The AAV particle of any one of embodiments 300-31 1, wherein the AAV capsid variant comprises:(i) the amino acid P at position 450, the amino acid R at position 451, and the amino acid W at position 452;(ii) the amino acid Y at. position 450, the amino acid S at position 451 , and the amino acid A at position 452;(iii) the amino acid Y at position 450, the amino acid Y at position 451, and the amino acid T at position 452;(iv) the amino acid P at: position 450, the amino acid R at. position 451, and the amino acid F at position 452;(v) the amino acid W at. position 450, the amino acid L at position 451 , and the amino acid T at position 452;( vi) the amino acid R at position 450, the amino acid S at position 451 , and the amino acid Y at position 452;(vii) the amino acid Y at position 450, the amino acid V at position 451, and the amino acid F at position 452;(viii) the amino acid K at position 450, the amino acid H at position 451, and the amino acid L at position 452;(ix) the amino acid P at position 450, the amino acid. P at position 451, and the amino acid L at position 452;(x) the amino acid P at position 450, the amino acid A at position 451, and the amino acid R at position 452;(xi) the amino acid S at position 450, the amino acid R at position 451 , and the amino acid R at position 452;(xii) the amino acid F at position 450, the amino acid F at position 451 , and the amino acid H at position 452;(xiii) the amino acid R at position 450, the amino acid F at position 451, and the amino acid S at position 452;(xiv) the amino acid Y at position 450, the amino acid S at position 451, and the amino acid M at position 452; or(xv) the amino acid P at position 450, the amino acid F at position 451, and the amino acid L at position 452; wherein (i)-(xv) is numbered according to SEQ ID NO: 138.316. The AAV particle of any one of embodiments 300-315, wherein the .AAV capsid variant comprises:(i) the amino acid sequence of any one of SEQ ID NOs: 3849-3982, 2984-4010, 4681- 4693;(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).317. The AAV particle of any one of embodiments 300-316, wherein the AAV capsid variant does not comprise the amino acid sequence of GSGSPHSKAQNQQ (SEQ ID NO: 1801) or GSGSPHSKAQNQQT (SEQ ID NO: 200).318. The AAV particle of any one of embodiments 300-317, wherein [A]-[B] is present in loop IV.319. The AAV particle of any one of embodiments 300-318, wherein [A] is present immediately subsequent to position 452, numbered according to SEQ ID NO: 138 or 981.320. The AAV particle of any one of embodiments 300-319, wherein [A] replaces positions 453-455 (e.g., G453, S454, G455), numbered according to SEQ ID NO: 138 or 981.321. The AAV particle of any one of embodiments 300-320, w-herein [A] is present immediately subsequent to position 452, and wherein [A] replaces positions 453-455 (e.g., G453, S454, G455), numbered according to SEQ ID NO: 138 or 981.322. The AAV particle of any one of embodiments 300-321, wherein [B] is present immediately subsequent to [A],323. The AAV particle of any one of embodiments 300-322, wherein [B] replaces positions 456 and 457 (e.g., Q456, N457), numbered according to SEQ ID NO: 138.324. The AAV particle of any one of embodiments 300-323, wherein [A]-[B] replaces positions 453-457 (e.g,, G453, S454, G455, Q456, N457), numbered according to SEQ ID NO: 138.325. The AAV particle of any one of embodiments 300-324, wherein [A]-[B] is present immediately subsequent to position 452, and wherein [A]-[B] replaces positions 453-457 (e.g., G453, S454, G455, Q456, N457), numbered according to SEQ ID NO: 138.32.6. The AAV particle of any one of embodiments 300-325, wherein the AAV capsid variant comprises, from N-terminus to C -terminus, [A][B],327. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises at least one, at least two, at least three, or at least four (e.g., from 1 -4 to 1 - 5) charged amino acid residues (e.g., acidic and / or basic amino acid residues) relative to SEQ ID NO: 138, which is present N-terminal to the amino acid sequence of SPH (e.g., within 1,2, 3, 4, 5, or 6 amino acids from the start of the SPH amino acid sequence (e.g., within positions 450-455 numbered according to SEQ ID NO: 138)), optionally wherein the amino acid sequence of SPH is present at positions 456-458 numbered according to any one of SEQ ID NOs: 36-59, 981, or 982.328. The AAV particle of embodiment 327, wherein the amino acid sequence of SPH is present at positions 456-458 numbered according to any one of SEQ ID NOs: 36-59, 981 , or 982.329. The AA V particle of embodiment 327 or 328, wherein the AAV capsid variant comprises less than tour, less than three, less than two (e.g., two or one) charged amino acid residues (e.g., acidic and / or basic amino acid residues) relative to SEQ ID NO: 138.330. The AAV particle of any one of embodiments 327-329, wherein the AA V capsid variant comprises one charged amino acid residues (e.g., an acidic or basic amino acid residue) relative to SEQ ID NO: 138, optionally at any one of positions 450-455 numbered relative to SEQ ID NO: 138.331. The AAV particle of any one of embodiments 327-330, wherein the charged amino acid residue is an acidic amino acid (e.g., D or E).332. The AAV particle of any one of embodiments 327-331, wherein the charged amino acid residue is a negatively charged amino acid (e.g., D or E).333. The AAV particle of any one of embodiments 327-332, wherein the charged amino acid residue is D.334. The AAV particle of any one of embodiments 32.7-333, wherein the charged amino acid residue is E.335. The AAV particle of any one of embodiments 327-334, wherein the charged amino acid residue is a basic amino acid (e.g., K, R, or H),336. Hre AAV particle of any one of embodiments 327-335, wherein the charged amino acid residue is a positively charged amino acid (e.g., K, R, or H).337. The AAV particle of any one of embodiments 327-336, wherein the charged amino acid residue is H.338. lire AAV particle of any one of embodiments 327-337, wherein the charged amino acid residue is R.339. The AAV particle of any one of embodiments 327-338, wherein tire charged amino acid residue is K.340. lire AAV particle of any one of embodiments 327-339, wherein the AAV capsid variant comprises an acidic amino acid (e.g., E or D) and a basic amino acid (e.g., R, K, or H).341 . The .AAV particle of any one of embodiments 327-340, wherein at least one, two, three or four charged amino acid residues is present within 1, 2, 3, 4, 5, or 6 (e.g., 1-6) amino acids from the start, of the SPH amino acid sequence.342. lire AAV particle of any one of embodiments 327-341, wherein the AAV capsid variant composes two charged amino acid residues immediately preceding the amino acid sequence of SPH (e.g., at. positions 454 and 455, numbered according to SEQ ID NO: 138 or SEQ ID NO: 982).343. The AAV particle of any one of embodiments 327-342, wherein the AAV capsid variant comprises a charged amino acid residue (e.g., E) within 1 , 2, 3, 4, 5 (e.g., 5) amino acids from the start of the SPH amino acid sequence.344. Hre AAV particle of any one of embodiments 327-343, wherein the AAV capsid variant comprises a charged amino acid residue (e.g., E) at position 451, numbered according to any one of SEQ ID NO: 138, 981. or 982.345. The AAV particle of any one of embodiments 327-344, wherein the AAV capsid variant comprises E at position 451, numbered according to any one of SEQ ID NOs: 138, 981, or 982.346. The AAV particle of any one of embodiments 327-345, wherein the .AAV capsid variant comprises a charged amino acid residue (e.g., R or K) at position 452, numbered according to any one of SEQ ID NOs: 138, 981 , or 982,347. The AAV particle of any one of embodiments 327-346, wherein the AAV capsid variant comprises R at position 452, numbered according to SEQ ID NO: 138 or SEQ ID NO: 982.348. The AAV particle of any one of embodiments 327-347, wherein the .AAV capsid variant comprises E at position 451 and R at position 452, numbered according to SEQ ID NO: 138 or SEQ ID NO: 982.349. The AAV particle of any one of embodiments 327-348, wherein the AAV capsid variant has decreased tropism for a liver cell or tissue, relative to the tropism of an AAV capsid comprising the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 981.350. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises at least one, at least two, at least three, or at least four (e.g., from 1-4 to 1- 5) charged amino acid residues (e.g., basic amino acid residues) relative to SEQ ID NO: 138, which is present C -terminal to the amino acid sequence of SPH (e.g., within 1, 2, 3, 4, 5, 6, or 7 amino acids from the end of the SPH amino acid sequence (e.g., within positions 459-465 numbered according to any one of SEQ ID NOs: 36-59, or 981)), optionally wherein the amino acid sequence of SPH is present at positions 456-458 numbered according to any one of SEQ ID NOs: 36-59, 981, or 982.351 . The AAV particle of embodiment 350, wherein the amino acid sequence of SPH is present at positions 456-458 numbered according to any one of SEQ ID NOs: 36-59, 981, or 982.352. The AAV particle of embodiment 350 or 351, wherein the AAV capsid variant comprises less than four, less than three, less than two (e.g., two or one) charged amino acid residues (e.g,, basic amino acid residues) relative to SEQ ID NO: 138.353. The AAV particle of any one of embodiments 350-352, wherein the .AAV capsid variant comprises one charged amino acid residues (e.g., a basic amino acid residue) relative to SEQ ID NO: 138, optionally at any one of positions 456-460 numbered according to SEQ ID NO: 138, or at positions 462-466 numbered according to any one of SEQ ID NOs: 36-59, 981, or 982.354. The AAV particle of any one of embodiments 350-353, wherein the charged amino acid residue is a basic amino acid (e.g., R or K).355. The AAV particle of any one of embodiments 350-354, wherein the charged amino acid residue is a positively charged amino acid (e.g., R or K).356. The AAV particle of any one of embodiments 350-355, wherein the charged amino acid residue is R.357. The AAV particle of any one of embodiments 350-355, wherein the charged amino acid residue is K,358. The AAV particle of any one of embodiments 350-357, wherein at least one, two, three or four charged amino acid residues is present within 1, 2, 3, 4, 5, 6, 7 (e.g., 1-7) amino acids from the end of the SPH amino acid sequence.359. The AAV particle of any one of embodiments 350-358, wherein the AAV capsid variant comprises a. charged amino acid, residue (e.g., K or R) immediately after the SPH sequence (e.g., at position 459 numbered according to SEQ ID NO: 981).360. The AAV particle of any one of embodiments 350-359, wherein the AAV capsid variant comprises a charged amino acid residue (e.g., K or R) at position 459, numbered according to SEQ ID NO: 138 or SEQ ID NO: 982.361 . The AAV particle of any one of embodiments 350-360, wherein the AAV capsid variant comprises K at position 459, numbered according to SEQ ID NO: 981.362. The AAV particle of any one of embodiments 350-360, wherein the AAV capsid variant comprises R at position 459, numbered according to SEQ ID NO: 981.363. The AAV particle of any one of embodiments 350-362, wherein the AAV capsid variant comprises a. charged amino acid residue (e.g., R or K) at one, two three, four, five, or all of positions 460, 461, 462, 463, 464, and / or 465, numbered according to SEQ ID NO: 138 or 981.364. The AAV particle of any one of embodiments 300-326 or 350-363, wherein the AAV capsid variant has increased tropism for a liver cell or tissue, relative to the tropism of an AAV capsid, comprising the amino acid sequence of SEQ ID NO: 138.365. The .AAV particle of any one of embodiments 300-326 or 350-364, wherein the AAV capsid variant is enriched at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 105, at least 110, at least 115, at least 120, at least 125, at least 130, at least 135, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, or at least. 200-fold, in the liver compared to an AAV capsid comprising the amino acid sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 4.366. The AAV particle of any one of embodiments 300-326, 364, or 365, wherein the AAV capsid variant has reduced tropism for a CNS cell or tissue, e.g., a brain cell, brain tissue, spinal cord cell, or spinal cord tissue, relative to the tropism of an AAV capsid comprising the amino acid sequence of SEQ ID NO: 138.367. The .AAV particle of any one of embodiments 300-326 or 364-366, wherein the AAV capsid variant shows preferential transduction in a liver region relative to the transduction in the brain and / or dorsal root ganglia (DRG).368. The AAV particle of any one of embodiments 300-326 or 364-367, wherein the AAV capsid variant shows preferential transduction in a liver region relative to the transduction in the heart and / or muscle (e.g., quadriceps).369. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises:(a) the amino acid sequence of any of the sequences provided in Tables 1, 2A, 2B, or 15-21 ;(b) an amino acid sequence comprising at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 consecutive amino acids from any one of the sequences provided in Tables 1, 2A, 2B, or 15-21; or(c) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids, relative to any one of the sequences provided in Tables 1, 2A, 2B. or 15-21; or(d) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of any one of the sequences provided in Tables 1, 2A, 2B, or 15-21.370. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid, variant comprises:(a) the amino acid sequence of any of SEQ ID NOs: 945-980 or 985-986;(b) an amino acid sequence comprising at least 3, at least 4, or at least 5 consecutive amino acids from any one of SEQ ID NOs: 945-980 or 985-986; or(c) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 945-980 or 985-986;(d) an amino sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of any one of SEQ ID NOs: 945-980 or 985-986.371. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises:(a) the amino acid sequence of any of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909;(b) an amino acid sequence comprising at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, or at least 13 consecutive amino acids from any one of SEQ ID NOs: 2, 200, 2.01, 941 , 943, 204, 208, 404, or 903-909;(c) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 2, 200, 201, 941. 943, 204, 208, 404, or 903-909: or(d) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909.372. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (c.g., an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises:(a) the amino acid sequence of any of SEQ ID NOs: 3849-4051 or 4681-4693;(b) an amino acid sequence comprising at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16 or at least 17 consecutive amino acids from any one of SEQ ID NOs: 3849- 4051 or 4681-4693;(c) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 3849-4051 or 4681-4693; or(d) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of any one of SEQ ID NOs: 3849-4051 or 4681 -4693.373. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (AT.XN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises:(a) the amino acid sequence of any of SEQ ID NOs: 4052-4092;(b) an amino acid sequence comprising at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16 or at least 17 consecutive amino acids from any one of SEQ ID NOs: 4052- 4092;(c) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 4052-4092; or(d) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid, sequence of any one of SEQ ID NOs: 4052-4092.374. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRMA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises:(a) the amino acid sequence of any of SEQ ID NOs: 4056, 4058, 4059, 4062-4064, 4066, 4067, 4080, 4084, 4090, or 4095-4097;(b) an amino acid sequence comprising at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16 or at least 17 consecutive amino acids from any one of SEQ ID NOs: 4056, 4058, 4059, 4062-4064, 4066, 4067, 4080, 4084, 4090, or 4095-4097;(c) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 4056, 4058, 4059, 4062-4064, 4066, 4067, 4080, 4084, 4090, or 4095-4097; or(d) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of any one of SEQ ID NOs: 4056, 4058, 4059, 4062-4064, 4066, 4067, 4080, 4084, 4090, or 4095-4097.375. The AAV particle of embodiment 369 or 371, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, or at least 13 consecutive amino acids from any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909.376. The AAV particle of any one of embodiments 369-375, wherein the at least 3 consecutive amino acids comprise SPH.377. The AAV particle of any one of embodiments 369-371 or 376, wherein the at least 4 consecutive amino acids comprise SPHS (SEQ ID NO: 4700).378. The AAV particle of any one of embodiments 369-371, 376, or 377, wherein the at least5 consecutive amino acids comprise SPHSK (SEQ ID NO: 4701).379. The AAV particle of any one of embodiments 369-371 or 376-378, wherein the at least6 consecutive amino acids comprise SPHSKA (SEQ ID NO: 941).380. The AA V particle of embodiment 369-371, wherein the at least 3 consecutive amino acids comprise HDS.381. The AAV particle of any one of embodiments 369-371 or 380, wherein the at least 4 consecutive amino acids comprise HDSP (SEQ ID NO; 4702).382. The AAV particle of any one of embodiments 369-371, 380, or 381, wherein the at least5 consecutive amino acids comprise HDSPH (SEQ ID NO: 4703).383. The AAV particle of any one of embodiments 369-371 or 380-382, wherein the at least6 consecutive amino acids comprise HDSPHK (SEQ ID NO: 2).384. The AAV particle of any one of embodiments 369-371, wherein:(i) the at least 3 consecutive amino acids comprise SPH;(ii) the at least 4 consecutive amino acids comprise SPHK (SEQ ID NO: 6398);(iii) the at least 5 consecutive amino acids comprise SPHKY (SEQ ID NO; 4715); and / or(iv) the at least 6 consecutive amino acids comprise SPHKYG (SEQ ID NO: 966).385. The AA V particle of embodiment 369 or 371, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909.386. The AAV particle of any one of embodiments 369, 371, or 385, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of SPHSKA (SEQ ID NO: 941).387. The AAV particle of any one of embodiments 369, 371, or 385, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2).388. The AA V particle of any one of embodiments 369-371, 384, or 385, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of SPHKYG (SEQ ID NO: 966).389. The AAV particle of embodiment 370, wherein the AAV capsid variant comprises:(i) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications, relative to the amino acid, sequence of KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589);(ii) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications, relative to the amino acid sequence of KAEIGHDSPHKSGQNQQT (SEQ ID NO: 1754)(iii) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications, relative to the amino acid sequence of KTEKMSGSPHSKAQNQQT (SEQ ID NO: 3241);(iv) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications, relative to the amino acid sequence of KTINGHDSPHSKAQNLQT (SEQ ID NO: 4100); or(v) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications, relative to the amino acid sequence of KTVNGHDSPHSKAQNQQT (SEQ ID NO: 4062).390. The AAV particle of embodiment 369 or 371, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 2, 200, 201, 941 , 943, 204, 208, 404, or 903-909.391. The AAV particle of any one of embodiments 369, 371, or 390, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of SPHSKA (SEQ ID NO: 941).392. The AA V particle of any one of embodiments 369, 371, or 390, wherein the AA V capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2).393. The AAV particle of any one of embodiments 369, 371, 384, or 390, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of SPHKYG (SEQ ID NO: 966).394. The AAV particle of embodiment 369, wherein the AAV capsid variant comprises:(i) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589);(ti) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of KAEIGHDSPHKSGQNQQT (SEQ ID NO: 1754);(iii) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of KTEKMSGSPHSKAQNQQT (SEQ ID NO: 3241);(iv) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of KTINGHDSPHSKAQNLQT (SEQ ID NO: 4100); or(v) an amino acid sequence comprising at least one, at least two, or at least three but. no more than four different amino acids relative to the amino acid sequence of KTVNGHDSPHSKAQNQQT (SEQ ID NO: 4062).395. The AAV particle of any one of embodiments 1-129, 269, 271 , 375-388, or 390-394, wherein the .AAV capsid variant comprises the amino acid sequence of any one of SEQ ID NOs: 2. 200, 201, 941, 943, 204, 208, 404, or 903-909.396. The AAV particle of any one of embodiments 295-297, 301-305, 313, 314, 318, 319, or323, wherein the .AAV capsid variant comprises the amino acid sequence ofERVSGSPHSKA (SEQ ID NO: 6399), optionally wherein the amino acid sequence is present immediately subsequent to position 450 and replaces positions 451-455 (e.g., 1451, N542, G453, S454, G455), numbered according to SEQ ID NO: 138.397. The AAV particle of any one of embodiments 369-371, 375-379, 385, 386, 389-391 , or 394-396, wherein the AAV capsid variant comprises the amino acid sequence of KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589), optionally wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, 1451, N452, G453, S454, G455, Q456, N457, Q458, Q459, T460), numbered according to SEQ ID NO: 138.398. The AAV particle of any one of embodiments 269-371, 375, 380-383, 385, 387, 389, 390, 393, or 394, wherein the AAV capsid variant comprises the amino acid sequence of AEIGHDSPHKSG (SEQ ID NO: 6400), optionally wherein the amino acid sequence is present immediately subsequent to position 449 and replaces positions 450-455 (e.g., T450, 1451, N452, G453, S454, G455), numbered according to SEQ ID NO: 138.399. The AAV particle of any one of embodiments 369-371, 375, 380-383, 385, 387, 389, 390, 393, 394, or 398, wherein the AAV capsid variant comprises the amino acid sequence of KAEIGHDSPHKSGQNQQT (SEQ ID NO: 1754), optionally wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, 1451, N452, G453, S454, G455, Q456, N457, Q458, Q459, T460), numbered according to SEQ ID NO: 138.400. The AAV particle of any one of embodiments 369-371, 375-379, 390, 391 , or 395, wherein the AAV capsid variant comprises the amino acid sequence of EKMSGSPHSKA (SEQ ID NO: 6401), optionally wherein the amino acid sequence is present immediately subsequent to position 450 and replaces positions 451-455 (e.g., 1451 , N452, G453, S454, G455), numbered according to SEQ ID NO: 138.401. The AAV particle of any one of embodiments 369-371, 375-379, 390, 391 , or 395, wherein the AAV capsid variant comprises the amino acid sequence of KTEKMSGSPHSKAQNQQT (SEQ ID NO: 3241), optionally wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, 1451, N452, G453, S454, G455, Q456, N457, Q458, Q459, T460), numbered according to SEQ ID NO: 138.402. The AAV particle of any one of embodiments 369-371, 375-379, 390, 391 , or 395, wherein the AAV capsid variant comprises the amino acid sequence of HDSPHSKAQNL (SEQ ID NO: 6402), optionally wherein the amino acid sequence is present immediately subsequent to position 453 and replaces positions 456-458 (e.g., Q456, N457, Q458), numbered according to SEQ ID NO: 138.403. lire AAV particle of any one of embodiments 369-371, 375-379, 390, 391, or 395, wherein the AAV capsid variant comprises the amino acid sequence of KTTNGHDSPHSKAQNLQT (SEQ ID NO: 4100), optionally wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, 1451, N452, G453, S454, G455, Q456. N457, Q458, Q459, T460), numbered according to SEQ ID NO: 138.404. The AAV particle of any one of embodiments 369-371, 375-379, 390, 391 , or 395, wherein the AAV capsid variant comprises the amino acid sequence of VNGHDSPHSKA (SEQ ID NO: 6403), optionally wherein the amino acid sequence is present immediately subsequent to position 450 and replaces positions 451-455 (e.g., 1451 , N452, G453, S454, G455), numbered according to SEQ ID NO: 138.405. The AAV particle of any one of embodiments 369-371, 375-379, 390, 391 , or 395, wherein the AAV capsid variant comprises the amino acid sequence of KTVNGHDSPHSKAQNQQT (SEQ ID NO: 4062), optionally wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, 1451, N452, G453, S454, G455, Q456, N457, Q458, Q459, T460), numbered according to SEQ ID NO: 138.406. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51 , 54-72, 69- 89, 91, 94-99, 102-104, 107, 1 10-112, 115-129, 168-202, 02, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-299, 327-363, 369-371, 375-379, 385, 386, 390, 391, or 395, wherein the AAV capsid variant comprises an amino acid sequence encoded by: the nucleotide sequence of SEQ ID NO: 942; a nucleotide sequence comprising at least one, at least two, at least three, at least four, at least five, at least six, or at least seven modifications, e.g., substitutions (e.g., conservative substitutions), but no more than ten modifications, e.g., substitutions (e.g., conservative substitutions), relative to the nucleotide sequence of SEQ ID NO: 942; or a nucleotide sequence comprising at least one, at least two, at least three, at least four, at least five, at least six, or at least seven, but no more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 942.407. The AAV particle of any one of embodiments 1-9, 11 , 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-77, 83-88, 90-97, 100-103, 105. 110, 111. 113-129, 203-248, 251, 252, 2.54-257, 2.60, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, or 395, wherein the AAV capsid variant comprises an amino acid sequence encoded by: the nucleotide sequence of SEQ ID NO: 3; a nucleotide sequence comprising at least one, at least two, at least three, at least four, at least five, at least six, or at least seven modifications, e.g., substitutions (e.g., conservative substitutions), but no more than ten modifications, e.g., substitutions (e.g., conservative substitutions), relative to the nucleotide sequence of SEQ ID NO: 3; or a nucleotide sequence comprising at least one, at least two, atleast three, at least four, at least five, at least six, or at least seven, but no more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 3.408. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-72, 69- 89, 91, 94-99, 102-104, 107, 110-112, 115-129, 168-202, 02, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288. 291-299, 327-363, 369-371, 375-379, 385, 386, 390. 391, 395, or 406, wherein the nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NO: 942; a nucleotide sequence comprising at least one, at least two, at least three, at least four, at least five, at least six, or at least seven modifications, e.g., substitutions (e.g., conservative substitutions), but no more than ten modifications, e.g., substitutions (e.g., conservative substitutions), relative to the nucleotide sequence of SEQ ID NO: 942; or a nucleotide sequence comprising at least one, at least two, at least three, at least four, at least five, at least six, or at least seven, but no more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 942.409. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-77, 83-88. 90-97, 100-103, 105, 110. 111, 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, or 407, wherein the nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NO: 3; a nucleotide sequence comprising at least one, at least two, at least three, at least four, at least five, at least six, or at least seven modifications, e.g., substitutions (e.g., conservative substitutions), but no more than ten modifications, e.g., substitutions (e.g., conservative substitutions), relative to the nucleotide sequence of SEQ ID NO: 3; or a nucleotide sequence comprising at least one, at least two, at least three, at least four, at least five, at least six, or at least seven, but no more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 3.410. The AAV particle of any one of embodiments 369-409, wherein the amino acid. sequence is present in loop IV, e.g., relative to the amino acid sequence of SEQ ID NO: 138.411. The AAV particle of any one of embodiments 369-410, wherein the amino acid sequence is present immediately subsequent to position 448, 449, 450, 451, 452, 453, 454, or 455, numbered according to SEQ ID NO: 138.412. The AAV particle of any one of embodiments 369-411, wherein the amino acid sequence replaces amino acids 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, and / or 460 (e.g., K449, T450, 1451, N452, G453, S454, G455, Q456, N457, Q458, Q459, and / or T460), numbered according to SEQ ID NO: 138.413. The AAV particle of any one of embodiments 369-412, wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138.414. The AAV particle of any one of embodiments 369-413, wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to SEQ ID NO: 138.415. The AAV particle of any one of embodiments 1-2.3, 26-2.9, 32, 35-43, 46-51 , 54-72, 69- 89, 91, 94-99, 102-104, 107, 1 10-112, 115-129, 168-202, 02, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-299, 327-363, 369-371, 375-379, 385, 386, 390, 391, 395, 406, 408, or 410-413, wherein the AAV capsid variant comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138.416. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51 , 54-72, 69- 89, 91, 94-99, 102-104, 107, 1 10-112, 115-129, 168-202, 02, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-299, 327-363, 369-371, 375-379, 385, 386, 390, 391, 395, 406, 408, 410-413, or 415, wherein the AAV capsid variant the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 981.417. The AAV particle of embodiment 415 or 416, wherein the AA V capsid variant further comprises an amino acid other than I at position 451 , an amino acid other than N at position 452, and an amino acid oilier than G at position 453, numbered according to any one of SEQ ID NOs: 36, 138, or 981.418. The AAV particle of any one of embodiments 415-417, wherein the AAV capsid variant further comprises E at position 451, R at position 452, and V at position 453, numbered according to any one of SEQ ID NOs: 36, 138, or 981 .419. The AAV particle of any one of embodiments 415-418, wherein the .AAV capsid variant further comprises the substitutions I451E, N452R, and G453V, numbered according to any one of SEQ ID NOs: 36, 138, or 981 .420. The AAV particle of any one of embodiments 415-419, wherein the AAV capsid variant comprises:(i) E at position 451, R at position 452, and V at position 453, numbered according to any one of SEQ ID NOs: 36, 138, or 981; and(ii) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to any one of SEQ ID NOs: 36, 138, or 981 (at amino acids 456-461, numbered according to SEQ ID NO: 36 or 981).421. The AA V particle of embodiment 415 or 416, wherein the AAV capsid variant further comprises an amino acid other than I at position 451, an amino acid other than N at position 452, and / or G at position 453, numbered according to SEQ ID NO: 39 or 138.422. The AAV particle of any one of embodiments 415, 416, or 421 , wherein the AAV capsid variant further comprises E at position 451, K at position 452, and / or M at position 453, numbered according to SEQ ID NO: 138 or 39.423. The AAV particle of any one of embodiments 415, 416, 421, or 422, wherein the AAV capsid variant further comprises the substitutions I451E, N452K, and G453M, numbered according to SEQ ID NO: 39 or 138.424. The .AAV particle of any one of embodiments 415, 416, or 421-423, wherein the AAV capsid variant comprises:(i) E at position 451, K at position 452, and M at position 453, numbered according to SEQ ID NO: 39 or 138; and(ii) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 39 or 138.425. The AAV particle of embodiment 415 or 416, wherein the .AAV capsid variant further comprises an amino acid other than S at position 454, an amino acid other than G at position 455, and / or Q at position 458, numbered according to SEQ ID NO: 138.426. The .AAV particle of any one of embodiments 415, 416, or 425, wherein the AAV capsid variant further comprises H at position 454, D at position 455, and / or L at position 458, numbered according to SEQ ID NO: 138.427. The AAV particle of any one of embodiments 415, 416, 425, or 426, wherein the AAV capsid variant further comprises the substitutions S454H, G455I), and Q458L, numbered according to SEQ ID NO: 138.428. The AAV particle of any one of embodiments 415, 416, or 425-427, wherein the AAV capsid variant comprises:(i) H at position 454, D at position 455, and / or L at position 458, numbered according to SEQ ID NO: 138; and(ii) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138.429. The AA V particle of embodiment 415 or 416, wherein the AAV capsid variant further comprises an amino acid other than I at position 451, an amino acid other than S at position 454, and / or an amino acid other than G at position 455, numbered according to SEQ ID NO: 52 or 138.430. The .AAV particle of any one of embodiments 415, 416, or 429, wherein the AAV capsid variant further comprises V at position 451, H at position 454, and / or D at position 455, numbered according to SEQ ID NO: 52 or 138.431 . The AAV particle of any one of embodiments 415, 416, 429, or 430, wherein the AAV capsid variant further comprises the substitutions I451V, S454H, and / or G455D, numbered according to SEQ ID NO: 52 or 138.432. The AAV particle of any one of embodiments 415, 416, or 429-431, wherein the .AAV capsid variant comprises:(i) V at position 451, H at position 454, and / or D at position 455, numbered according to SEQ ID NO: 52 or 138; and(ii) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 52 or 138.433. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 111, 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, or 414, wherein the AAV capsid variant the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to the amino acid sequence of SEQ ID NO: 138.434. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 1 11, 113-129, 203-248, 251 , 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, or 433, comprising the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid, sequence is present immediately subsequent to position 453, numbered according to the amino acid sequence of SEQ ID NO: 982.435. The AAV particle of any one of embodiments 1 -9, 11, 12-2.2, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 1 11, 113-129, 203-248, 251 , 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433, or 434, wherein the AAV capsid variant the amino acid sequence of SPHKSG (SEQ ID NO: 946), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 982.436. The AAV particle of any one of embodiments 369-435, wherein the AAV capsid variant composes:(i) the amino acid sequence of HDSPHSKA (SEQ ID NO: 4486), which is present immediately subsequent to position 453; and(ii) a deletion of amino acids SG at position 454 and 455; wherein (i) and (ii) are numbered according to SEQ ID NO: 138.437. The AAV particle of any one of embodiments 369-436, wherein the AAV capsid variant comprises the amino acids HD at position 454 and 455, and further comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941), which is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138.438. The AAV particle of any one of embodiments 433-435, wherein the AAV capsid variant further composes an amino acid other than T at position 450, an amino acid other than I at position 451, and an amino acid other than N at position 452, numbered according to SEQ ID NO: 138 or 982.439. The AAV particle of any one of embodiments 433-435 or 438, wherein the AAV capsid variant further comprises A at position 450, E at position 451, and I at position 452, numbered according to SEQ ID NO: 138 or 982.440. The AAV particle of any one of embodiments 433-435, 438, or 439, wherein the AAV capsid variant further comprises the substitutions T450A, I451E, and N452I, numbered according to SEQ ID NO: 138 or 982.441. The AAV particle of any one of embodiments 433, 434, or 438-440, wherein the AAV capsid variant comprises:(i) A at position 450, E at position 451, and. I at position 452, numbered according to SEQ ID NO: 138 or 982; and(ii) the amino acid sequence of HDSPHK (SEQ ID NO: 2), which is present immediately subsequent to positions 453, numbered according to SEQ ID NO: 138 or 982.442. The AAV particle of any one of embodiments 1-22, 25-27, 31 , 34-42, 45-50, 53-63, 69, 79, 83-86, 91-98, 102, 103, 110, 111, 118-129, 369-371, 384, 385, 390, 393, 395, 410-413,wherein the AAV capsid variant the amino acid sequence of SPHKYG (SEQ ID NO: 966), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to the amino acid sequence of SEQ ID NO: 138.443. An adeno-associated virus (AAV) particle comprising an .AAV capsid variant comprising the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to the amino acid sequence of SEQ ID NO: 982, wherein the AAV particle further comprises viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein.444. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a. viral genome comprising a nucleic acid encoding a modulatory polynucleotide tor reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to the amino acid sequence of SEQ ID NO: 981 .445. An adeno-associated virus (AAV) particle comprising an AAV capsid variant comprising the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to the amino acid sequence of SEQ ID NO: 37, and optionally further comprising:(i) one, two, or all of an amino acid other than T at position 450, an amino acid other than I at position 541, and / or an amino acid other than N at position 452, numbered according to SEQ ID NO: 138 or 37;(ii) one, two, or all of A at position 450, E at position 451, and / or I at position 452, numbered according to SEQ ID NO: 138 or 37; wherein the AAV particle further comprises a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein.446. An adeno-associated virus (AAV) particle comprising an AAV capsid variant comprising the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to the amino acid sequence of any one of SEQ ID NO: 36, 38-55, 57, or 59, wherein the AAV particle further comprises a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein.447. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant further comprises:(i) a modification in loop I, II, VI and / or VIII; and / or(ii) a substitution at position K449, e.g., a K449R substitution, numbered according to SEQ ID NO: 138.448. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three modifications, e.g., substitutions (e.g., conservative substitutions), but not more than 30, not more than 20, or not more than 10 modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 138.449. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three, but no more than 30, not more than 20, or not more than 10 different amino acids relative to the amino acid sequence of SEQ ID NO: 138.450. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to SEQ ID NO: 138.451. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid, sequence with at least 98% identity to SEQ ID NO: 138.452. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid sequence encoded by a sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at. least. 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to SEQ ID NO: 137.453. The AAV particle of any one of the preceding embodiments, wherein the nucleotide sequence encoding the capsid vanant comprises at least 80% (e.g., at least 80%, at. least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to SEQ ID NO: 137.454. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises a VP 1 protein, a VP2 protein, a VP3 protein, or a combination thereof.455. The AAV particle of any one of embodiments 1-454, wherein the AAV capsid variant comprises the amino acid sequence corresponding to positions 138-742, e.g., a VP2, of SEQ ID NO: 981, 982, 36, or 4, or a sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity thereto.456. The AAV particle of any one of embodiments 1-455, wherein the AAV capsid variant comprises the amino acid sequence corresponding to positions 203-742, e.g., a VP3, of SEQ ID NO: 981, 982, 36, or 4, or a sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity thereto.457. The AAV particle of any one of embodiments 1-456, wherein the AAV capsid variant comprises an amino acid sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to SEQ ID NO: 138.458. The AAV particle of any one of embodiments 1-457, wherein the AAV capsid variant comprises an amino acid sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to SEQ ID NO: 138.459. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-72, 69- 89, 91 , 94-99, 102-104, 107, 110-112, 115-129, 168-202, 240-247, 249, 250, 253-263, 266, 272-281 , 286, 288, 291 -299, 327-363, 369-371, 375-379, 385, 386, 390, 391 , 395, 406, 408, 410-413, 415-432, 444, or 446-458, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, at least 4, at least 5, or at least 6 consecutive amino acids from the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein:(i) the at least 3 consecutive amino acids comprise SPH;(ii) the at least 4 consecutive amino acids comprise SPHS (SEQ ID NO: 4700):(lii) the at least 5 consecutive amino acids comprise SPHSK (SEQ ID NO: 4701); or (iv) the at least 6 consecutive amino acids comprise SPHSKA (SEQ ID NO: 941); wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 981; (b) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 981; (c) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 981 ; or (d) an amino acid sequence with at least 90% (e.g., at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to any of the amino acid sequences in (a)-(c).460. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-72, 69- 89, 91, 94-99, 102-104, 107, 110-112, 115-129, 168-202, 240-247, 249, 250. 253-2.63. 266, 272-281, 286, 288, 291-299, 327-363, 369-371 , 375-379, 385, 386, 390, 391, 395, 406, 408, 410-413, 415-432, 444, or 446-459, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, at least 4, at least 5, or at least 6 consecutive amino acids from the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein:(i) the at least 3 consecutive amino acids comprise SPH;(ii) the at least 4 consecutive amino acids comprise SPHS (SEQ ID NO: 4700);(iii) the at least 5 consecutive amino acids comprise SPHSK (SEQ ID NO: 4701); or(iv) the at. least 6 consecutive amino acids comprise SPHSKA (SEQ ID NO: 941); wherein the AAV capsid variant comprises an amino acid sequence has at least 90%(e.g., at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to the amino acid sequence of SEQ ID NO: 981.461. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-72, 69- 89, 91, 94-99, 102-104, 107, 110-112, 115-129, 168-202, 240-247, 249, 250, 253-263, 266,272-281, 286, 288, 291-299, 327-363, 369-371 , 375-379, 385, 386, 390, 391, 395, 406, 408, 410-413, 415-432, 444, or 446-460, wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of SPHSKA (SEQ ID NO: 941 ), wherein the AAV capsid variant comprises:(a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 981;(b) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQID NO: 981:(c) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 981; or(d) an amino acid sequence with at least 90% (e.g,, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to any of the amino acid sequences in (a)-(c).462. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51 , 54-72, 69- 89, 91, 94-99, 102-104, 107, 1 10-112, 115-129, 168-202, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-299, 327-363, 369-371, 375-379, 385, 386, 390, 391, 395, 406, 408, 410-413, 415-432, 444, or 446-461, wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the AAV capsid variant comprises an amino acid sequence at least 90% (e.g., at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 981 ,463. The AAV particle of any one of embodiments 459-462, wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138 or 981.464. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 111, 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435, 438-441, 443, 445, or 447-458, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, at least 4, at least 5, or at least 6 consecutive amino acids from the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein:(i) the at least 3 consecutive amino acids comprise HDS;(ii) the at least 4 consecutive amino acids comprise IIDSP (SEQ ID NO: 4702);(iii) the at least 5 consecutive amino acids comprise HDSPH (SEQ ID NO: 4703); or(iv) tire at least 6 consecutive amino acids comprise HDSPHK (SEQ ID NO: 2); wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO; 982; (b) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982; (c) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982; or (d) an amino acid sequence with at least 90% (e.g., at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to any of the amino acid sequences in (a)-(c).465. The AAV particle of any one of embodiments 1-9, 1 1 , 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 111, 113-129, 203-248, 251, 252, 254-257, 260, 261, 2.64-280, 2.83-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435, 438-441, 443, 445, 447-458, or 464, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, at least 4, at least 5, or at least 6 consecutive amino acids from the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein:(i) the at least 3 consecutive amino acids comprise HDS;(ii) the at least 4 consecutive amino acids comprise HDSP (SEQ ID NO: 4702);(iii) the at least 5 consecutive amino acids comprise HDSPH (SEQ ID NO: 4703); or(iv) the at. least 6 consecutive amino acids comprise HDSPHK (SEQ ID NO: 2); wherein the AAV capsid variant comprises an amino acid sequence at: least 90% (e.g., at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequence of SEQ ID NO: 982.466. The AAV particle of any one of embodiments 1-9, 1 1, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-77, 83-88, 90-97, 100-103, 105. 110, 111. 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435, 438-441, 443, 445, 447-458, 464, or 465, wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the AAV capsid variant comprises:(a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982;(b) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982;(c) a VP3 protein comprising the amino acid, sequence of positions 203-742. of SEQ ID NO: 982; or(d) an amino acid sequence with at least 90% (e.g., at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to any of the amino acid sequences m (a)-(c).467. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 111 , 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435, 438-441, 443, 445, 447-458, or 464-466, wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the AAV capsid variant comprises an amino acid sequence at least 90% (e.g., at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequence of SEQ ID NO: 982.468. The AAV particle of any one of embodiments 464-468, wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to SEQ ID NO: 138 or 982.469. The AAV particle of any one of embodiments 1-468, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981 or 982, or an amino acid sequence with at least 80% (e.g., at least 80%, at least. 85%, at. least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity- thereto.470. The AAV particle of any one of embodiments 1-469, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two or at least three modifications, e.g., substitutions (e.g., conservative substitutions), but not more than 30, not more than 20 or not more than 10 modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 981 or 982.471 . The AAV particle of any one of embodiments, 1-470, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two or at least three, but not more than 30, not more than 20 or not more than 10 different amino acids, relative to the amino acid sequence of SEQ ID NO: 981 or 982.472. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-72, 69- 89, 91, 94-99, 102-104, 107, 110-112, 115-129, 168-202, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-299, 327-363, 369-371 , 375-379, 385, 386, 390, 391, 395, 406, 408, 410-413, 415-432, 444, 446-463, or 469-471, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981, or an amino acid, sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity thereto.473. The AAV particle of any one of embodiments 1-2.3, 26-29, 32, 35-43, 46-51 , 54-72, 69- 89, 91, 94-99, 102-104, 107, 1 10-112, 115-129, 168-202, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-299, 327-363, 369-371, 375-379, 385, 386, 390, 391, 395, 406, 408, 410-413, 415-432, 444, 446-463, or 469-472, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two or at least three modifications, e.g., substitutions (e.g., conservative substitutions), but not more than 30, not more than 20 or not more than 10 modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 981.474. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-72, 69- 89, 91, 94-99, 102-104, 107. 110-112, 115-129, 168-202, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291 -299, 327-363, 369-371, 375-379, 385, 386, 390, 391 , 395, 406, 408, 410-413, 415-432, 444, 446-463, or 469-473, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two or at least three, but not more than 30, not more than 20 or not more than 10 different amino acids, relative to the amino acid sequence of SEQ ID NO: 981.475. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 111 , 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435, 438-441, 443, 445, 447-458, or 464-471, whereinthe AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 982, or an amino acid sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity thereto.476. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 111, 113-129, 203-248, 251, 252, 254-257, 260, 261, 2.64-280, 2.83-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435, 438-441, 443, 445, 447-458, 464-471 , or 475, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two or at least three modifications, e.g., substitutions (e.g., conservative substitutions), but not more than 30, not more than 20 or not more than 10 modifications, e.g.. substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 982.477. The AAV particle of any one of embodiments 1 -9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 111, 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-2.80, 283-2.87, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435, 438-441, 443, 445, 447-458, 464-471, 475, or 476, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two or at least three, but not more than 30, not more than 20 or not more than 10 different amino acids, relative to the amino acid sequence of SEQ ID NO: 982.478. The .AAV particle of any one of embodiments 1-477, wherein the AAV capsid variant comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 983 or 984, or a nucleotide sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%), at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity thereto.479. The AAV particle of any one of embodiments 1-478, wherein the nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NOs: 983 or 984, or a nucleotide sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity thereto.480. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-72, 69- 89, 91, 94-99, 102-104, 107, 110-112, 115-129, 168-202, 02, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-299, 327-363, 369-371, 375-379, 385, 386, 390, 391, 395, 406, 408, 410-413, 415-432, 444, 446-463, 469-474, 478, or 479, wherein the nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NO: 983, or a nucleotide sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity thereto.481. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46-50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 111 , 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435, 438-441, 443, 445, 447-458, 464-471, or 475- 479, wherein the nucleotide sequence encoding the capsid variant comprises tire nucleotide sequence of SEQ ID NO: 984, or a nucleotide sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity thereto.482. The AAV particle of any one of the preceding embodiments, wherein the nucleotide sequence encoding the capsid variant is codon optimized.483. An AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51 , 54-72, 69- 89, 91, 94-99, 102-104, 107, 1 10-112, 115-129, 168-202, 02, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-299, 327-363, 369-371, 375-379, 385, 386, 390, 391, 395, 406, 408, 410-413, 415-432, 444, 446-463, 469-474, 478-480, or 482, and further comprising an amino acid sequence at least 95% identical to SEQ ID NO: 981,484. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a. viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981.485. The AAV particle of embodiment 483 or 484, wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of SEQ ID NO: 983, or a nucleotide sequence at least 90%, at least 95%, or at least 99% identical thereto.486. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42,44, 46-50, 52, 54-77, 83-88, 90-97, 100-103, 105. 110, 111. 113-129, 203-248, 251, 252,2.54-257, 2.60, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386,390, 392, 395, 407, 409-412, 414, 433-435, 438-441, 443, 445, 447-458, 464-471 , 475-479,481, or 482, and further comprising an amino acid sequence at least 95% identical to SEQ ID NO: 982.487. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 982.488. The AA V particle of embodiment 486 or 487, wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of SEQ ID NO: 984, or a nucleotide sequence at least 90%, at least 95%, or at least 99% identical thereto.489. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NOs: 983 or 984, or a nucleotide sequence at least 95% identical thereto.490. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid, variant comprises the amino acid sequence of any one of SEQ ID NOs: 4 or 36-59, optionally wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 4 or 36.491. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2) mRNA, thereby reducing or eliminating ATXN2 protein, wherein the AAV capsid variant comprises an amino acid sequence encoded by the nucleotide sequence of any one of SEQ ID NOs: 12-35, or a nucleotide sequence at least 95% identical thereto.492. The AAV particle of 490 or 491, wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of any one of SEQ ID NOs: 12-35, or a nucleotide sequence at least 95% identical thereto.493. The AAV particle of any one of embodiments 1-299, 369-371, or 375-492, which has an increased tropism for a CNS cell or ti ssue, e.g., a brain cell, brain tissue, spinal cord cell, or spinal cord tissue, relative to the tropism of an AAV particle comprising a capsid comprising the amino acid sequence of SEQ ID NO: 138.494. The AA V particle of any one of embodiments 1-129, 168-299, 369-371 , or 375-493, which transduces a brain region, e.g., a midbrain region (e.g., the hippocampus, or thalamus) or the brain stem, optionally wherein the level of transduction is at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, or at least 65 -fold greater as compared to an AAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay, e.g., an immunohistochemistry assay or a qPCR assay, e.g., as described in Example 2.495. The AAV particle of any one of embodiments 1-129, 168-299, 369-371 , or 375-494, which transduces a brain region, e.g., a midbrain region (e.g., the hippocampus, or thalamus) or the brain stem, optionally wherein the level of transduction is at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, or at least 65-fold greater as compared to an .AAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay, e.g., an immunolnstochemistiy assay or a qPCR assay, e.g., as described in Example 2.496. The AAV particle of any one of embodiments 1-129, 168-299, 369-371 , or 375-495, which is enriched at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or atleast 10-fold, in the brain compared to an AAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1.497. The AAV particle of any one of embodiments 1-129, 168-299, 369-371 , or 375-496, which is enriched at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80 or at least 85-fold, in the brain compared to an AAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1.498. The AA V particle of any one of embodiments 1-129, 168-299, 369-371 , or 375-497, which is enriched in the brain of at least two to at least three species, e.g., a non-human primate and rodent (e.g., mouse), e.g., as compared to an AAV particle comprising a capsid of SEQ ID NO: 138.499. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, or 375-498, which is enriched at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least80, at least 85, at least 90, at least 95, at least 100, at least 105, at least 115, at least 120, at least 125, at least 130, at least 135, at least 140, at least 145, at least 150, at least 155, at least160, at least 165, at least 170, at least 175, at least 180, at least 190, at least 200, at least 205, or at least 210-fold, in the brain of at least two to at least three species, e.g., a non-human primate and rodent (e.g., mouse), compared to an AAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1 or 5.500. The AA V particle of embodiment. 498 or 499, wherein the at least two to at least three species are Macaca fasciculans, Chlorocebus sabaeus, Callithrix jacchus, and / or mouse (e.g., BALB / c mice, C57B1 / 6 mice, and / or CD-I outbred mice).501. The AAV particle of any one of embodiments 130-146, 369, 410-414, 447-454, 457, 458, 482, or 493, which is enriched at least 2, at least 2.5, at least 3, at least 3.5, at least 4, at least 4.5, at least 5, at least 5.5, at least 6, at least 6.5, at least 7, at least 7.5, or at least 8-fold, in the brain compared, to an AAV particle comprising a capsid of SEQ ID NO: 981, e.g., when measured by an assay as described in Example 3.502. The AAV particle of any one of embodiments 147-167, 369, 410-414, 447-454, 457, 458, 482, or 493, which is enriched at least 2, at least 2.5, at least 3, at least 3.5, at least 4, at least 4.5, at least 5, or at least 5.5 -fold, in the brain compared, to an AAV particle comprising a capsid of SEQ ID NO; 982, e.g., when measured by an assay as described in Example 3.503. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, or 375-500, which delivers an increased level of a payload to a brain region, optionally wherein the level of the payload is increased by at least 10, at least 12, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, or at least 70-fold, as compared to an AAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay, e.g., a qRT-PCR or a qPCR assay (e.g., as described in Example 2 or 8).504. The AAV particle of any one of embodiments 1-12.9, 168-2.99, 369-371, 375-500, or 503, which delivers an increased level of viral genomes to a brain region, optionally wherein the level of viral genomes is increased by at least 5, at least 10, at least 15, at least 1.7, at least 18, at least 19, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50-fold, as compared to an AAV particle comprising a. capsid of SEQ ID NO: 138, e.g., when measured by an assay, e.g., a qRT-PCR or a qPCR assay (e.g., as described in Example 2 or 8).505. The AAV particle of embodiment 503 or 504, wherein the brain region is a midbrain region (e.g., the hippocampus or thalamus), frontal cortex, temporal cortex, motor cortex, cerebral cortex, caudate, putamen, dentate nucleus, substantia nigra, or the brainstem.506. The AAV particle of any one of embodiments 1-129, 168-299, 369-371 , 375-500, or 503-505, which is enriched at least 4, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, or at least. 35-fold, in the spinal cord compared to an AAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1 or 8, optionall y wherein the region of the spinal cord is a thoracic spinal cord region, cervical spmal cord region, C5 ventral horn region, lumbar spinal cord region, or L5 ventral horn region.507. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, 375-500, or 503-506, which shows preferential transduction in a brain region relative to the transduction in the dorsal root ganglia (DRG).508. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, 375-500, or 503-507, which shows preferential transduction in a brain region relative to the liver.509. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, 375-500, or 503-508, which shows preferential transduction in a brain region relative to the transduction in the heart.510. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, 375-500, or 503-509, which shows preferential transduction in a brain region relative to the transduction in the dorsal root ganglia. (DRG) and the heart.51 1. The AAV particle of any one of the preceding embodiments, which is capable of transducing non-neuronal cells, e.g., glial cells (e.g., oligodendrocytes or astrocytes).512. The AAV particle of embodiment 511, wherein the non-neuronal ceils comprise glial cells, oligodendrocytes (e.g., Olig2 positive oligodendrocytes), or astrocytes (e.g., Olig2 positive astrocytes).513. The .AAV particle of any one of the preceding embodiments, which is capable of transducing Olig2 positive cells, e.g., Olig2 positive astrocytes or Olig2 positive oligodendrocyte s .514. The AAV particle of any one of embodiments 369, 373, 447-454, 457, 458, or 482, which has increased tropism for a heart cell or tissue, e.g., a heart ventricle or heart atrium, relative to the tropism of an AAV particle comprising a capsid of SEQ ID NO: 138.515. The AAV particle of any one of embodiments 369, 373, 447-454, 457, 458. 482, or 514, which is enriched at least 4, at least 5, at least 8, at least 10, at least 11, at least 12, at least 13, at least 14, at least 18, at least 19, at least 20, at least 21 , at least 22, at least 24, at least 25, at least 27, at least 31, at least 33, or at least 34-fokl, in the heart compared to an AAV particlecomprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 4.516. The AAV particle of any one of embodiments 369, 374, 447-454, 457, 458, 482, which has an increased tropism for a muscle cell or tissue (e.g., a quadriceps cell or a quadriceps tissue), relative to the tropism of an AAV particle comprising a capsid comprising the amino acid sequence of SEQ ID NO: 138.517. The AAV particle of any one of embodiments 369, 374, 447-454, 457, 458, 482, which is enriched, at least 4, at least 5, at least 8, at least 12, at least 17, at least 18, at least 20, at least 26, at least 27, at least 28, at least 30, or at least 36-fold, in the muscle compared to an AAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 4.518. The AAV particle of embodiment 516 or 517, wherein the muscle cell or tissue is a heart muscle (e.g., a heart ventricle or a heart atrium, or both), a quadriceps muscle, or both.519. The AAV particle of any one of the preceding embodiments, which is isolated and / or recombinant.[Embodiments 520-576 are intentionally absent.]577. The AAV particle of any one of the preceding embodiments, wherein the encoded modulatory polynucleotide comprises an RNAi agent, optionally a dsRNA, siRNA, shRNA, pre-miRN A, pri-miRNA, miRNA, stRNA, IncRNA, piRNA, or snoRNA, or a combination thereof.[Embodiments 578-583 are intentionally absent.]584. The AAV particle of embodiment 577, wdierein the modulatory polynucleotide comprises an siRNA.[Embodiments 585 is intentionally absent.]586. The AAV particle of any one of the preceding embodiments, wherein the viral genome comprises a promoter operably linked to the nucleic acid sequence encoding the modulators' polynucleotide.587. The AAV particle of embodiment 586, wherein the promoter is a human elongation factor la-subunit (EFla) promoter, cytomegalovirus (CMV) promoter, a chicken p-actin (CBA) promoter, a CAG promoter, a CAG derivative promoter, a. CMV immediate-early enhancer and / or promoter, a CMV promoter, a β glucuronidase (GUSB) promoter, a ubiquitin C (UBC) promoter, a neuron-specific enolase (NSE) promoter, a platelet-derived growth factor (PDGF) promoter, a platelet-derived growth factor B-chain (PDGF-β) promoter, an intercellular adhesion molecule 2 (ICAM-2) promoter, a. synapsin (Syn) promoter, a methyl- CpG binding protein 2 (MeCP2) promoter, a Ca2+ / calmodulin-dependent protein kinase II (CaMKII) promoter, a metabotropic glutamate receptor 2 (mGluR2) promoter, a neurofilament light (NFL) or heavy (NFH) promoter, a P-globin minigene nβ2 promoter, a. preproenkephalin (PPE) promoter, an enkephalin (Enk) and excitatory.' amino acid transporter 2 (EAAT2) promoter , a glial fibrillary acidic protein (GFAP) promoter, a myelin basic protein (MBP) promoter, a cardiovascular promoter (e.g., aMHC, cTnT, and CMV-MLC2k), a liver promoter (e.g., hAAT, TBG), a skeletal muscle promoter (e.g., desmin, MCK, C512) or a fragment, e.g., a truncation, or a functional variant thereof.[Embodiments 588 and 589 are intentionally absent.]590. The AAV particle of any one of embodiments 586-589, wherein the viral genome further comprises a polyadenylation (poly A) sequence.591. The AAV particle of any one of embodiments 586-590, wherein the viral genome further comprises an inverted terminal repeat (ITR) sequence.592. The AAV particle of any one of embodiments 586-591, wherein the viral genome comprises an ITR sequence positioned 5’ relative to the nucleic acid sequence encoding the modulatory polynucleotide .593. The AAV particle of any one of embodiments 586-592, wherein the viral genome comprises an ITR sequence positioned 3’ relative to the nucleic acid sequence encoding the modulatory polynucleotide.594. The AAV particle of any one of embodiments 586-593, wherein the viral genome comprises an ITR sequence positioned 5" relative to the nucleic acid sequence encoding the modulatory polynucleotide and. an ITR sequence positioned 3’ relative to the nucleic acid sequence encoding the modulatory polynucleotide.595. The AA V particle of any one of embodiments 586-594, wherein the viral genome further comprises an enhancer, a Kozak sequence, an intron region, and / or an exon region.[Embodiments 596-615 are intentionally absent.]616. The AAV particle of any one of embodiments 586-595, wherein the viral genome further comprises a nucleotide sequence encoding a Rep protein, e.g., a non-structural protein, wherein the Rep protein comprises a Rep78 protein, a Rep68 protein, a Rep52 protein, and / or a. Rep40 protein (e.g,, a. R.ep78 and a. Rep52 protein).617. The AAV particle of any one of embodiments 586-615, wherein the AAV particle further composes a. nucleotide sequence encoding a. Rep protein, e.g., a non-stmctural protein, wherein the Rep protein comprises a Rep78 protein, a. Rep68 protein, a Rep52 protein, and / or a Rep40 protein (e.g., a Rep78 and a Rep52 protein).618. The AA V particle of embodiment 616 or 617, wherein the Rep78 protein, the Rep68 protein, the Rep52 protein, and / or the Rep40 protein are encoded by at least one Rep gene.619. The AAV particle of any one of embodiments 586-618, wherein the viral genome further comprises a. nucleic acid sequence encoding the AAV capsid variant of the AAV particle of any one of embodiments 1-519, 566, or 574.620. The AAV particle of any one of embodiments 575-519, wherein the AAV particle is an isolated and / or recombinant AAV particle.[Embodiment 621 is intentionally absent.]622. A cell, e.g., a host cell, comprising the AAV particle of any one of the preceding embodiments.623. lire cell of embodiment 622, wherein the cell is a mammalian cell or an insect cell.[Embodiment 624 is intentionally absent.]625. The cell of embodiment 622 or 623, wherein the cell is a cell of a brain region or a spinal cord region, optionally a cell of the brain stem, hippocampus, or thalamus.626. lire cell of embodiment 624 or 625, wherein the cell is a neuron, a sensory neuron, a motor neuron, an astrocyte, a glial cell, or an oligodendrocyte.627. A method of making an AAV particle, comprising(i) providing a host cell comprising a viral genome encoding a modulatory polynucleotide for reducing or eliminating expression of A taxin-2 (ATXN2) mRNA; and(ii) incubating the host cell under conditions suitable to encapsulate the viral genome in the AAV capsid variant as described in any one of embodiments 1-620; thereby making the AAV particle.628. The method of embodiment 627, further comprising, prior to step (i), introducing a first nucleic acid molecule comprising the viral genome into the host cell.629. The method of embodiment 628, wherein the host cell comprises a second nucleic acid encoding the capsid variant.630. The method of embodiment 629, wherein the second nucleic acid molecule is introduced into the host cell prior to, concurrently with, or after the first nucleic acid molecule.631. A pharmaceutical composition comprising the AAV particle of any one of embodiments 1-620, and a pharmaceutically acceptable excipient.632. A method of delivering a payload to a. cell or tissue (e.g., a CNS cell or CNS tissue), comprising administering an effective amount of the pharmaceutical composition of embodiment 631 or the AAV particle of any one of embodiments 1-620.[Embodiments 633-635 are intentionally absent.]636. The method of embodiment 632, wherein the cell or tissue is within a subject.637. The method of embodiment 636, wherein the subject has, has been diagnosed with having, or is at risk of having a genetic disorder, e.g,, a monogenic disorder or a polygenic disorder.638. The method of embodiment 636 or 637, wherein the subject has, has been diagnosed with having, or is at risk of a disorder associated with aberrant expression or activity of ATXN2.639. The method of any one of embodiments 636-638, wherein the subject has, has been diagnosed with having, or is at risk of having a muscular disorder or a neuromuscular disorder.640. The method of any one of embodiments 636-639, wherein the subject has, has been diagnosed with having, or is at risk of having spinocerebellar ataxia type 2 (SCA2).641. A method of treating a subject having or diagnosed with having a genetic disorder, e.g., a monogenic disorder or a. polygenic disorder, comprising administering to the subject an effective amount of the pharmaceutical composition of embodiment 631 or the AAV particle of any one of embodiments 1-620.642. A method of treating a. subject having or diagnosed with having a. muscular disorder or a neuromuscular disorder associated with aberrant expression or activity of ATXN2, comprising administering to the subject an effective amount of the pharmaceutical composition of embodiment 631 or the AAV particle of any one of embodiments 1-620.643. A method of treating a. subject having or diagnosed with having a. spinocerebellar ataxia type 2 (SCA2), comprising administering to the subject an effective amount of the pharmaceutical composition of embodiment 631 or the AAV particle of any one of embodiments 1-620.[Embodiments 644 and 645 are intentionally absent.]646. The method of any one of embodiments 641-643, where treating comprises prevention of progression of the disease or disorder in the subject.647. The method of embodiment 636-646, wherein the subject is a human.648. The method of any one of embodiments 636-647, wherein the AAV particle is administered to the subject intravenously, intrathecally, intraarterially, or intramuscularly.649. The method of any one of embodiments 636-648, wherein the AAV particle is administered to the subject via focused ultrasound (FUS), e.g., coupled with the intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS coupled with intravenous administration.650. The method of any one of embodiments 636-649, wherein the AAV particle is administered to the subject intravenously.[Embodiment 651 is intentionally absent.]652. The method of any one of embodiments 636-651 , wherein the AAV particle is administered to the subject intraarterially.653. The method of any one of embodiments 648-652, wherein administration of the AAV particle results in a decreased presence, level, and / or activity of an ATXN2 gene, mRMA, protein, or combination thereof.[Embodiment 654 is intentionally absent.]655. The pharmaceutical composition of embodiment 631 or the AAV particle of any one of embodiments 1-620 for use in a method of delivering a modulatory polynucleotide for reducing or elimination expression of ATXN2 to a. cell or tissue.656. The pharmaceutical composition of embodiment 631 or the AAV particle of any one of embodiments 1-620 for use in a method of treating a genetic disorder, a muscular disorder, or a neuromuscular disorder.657. The pharmaceutical composition of embodiment 631 or the AAV particle of any one of embodiments 1-620 for use in the manufacture of a medicament.658. Use of the pharmaceutical composition of embodiment 631 or the AAV particle of anyone of embodiments 1-620 in the manufacture of a medicament.659. Use of the pharmaceutical composition of embodiment. 631 or the AAV particle of anyone of embodiments 1-620 in the manufacture of a medicament for treating a genetic disorder, a muscular disorder, or a neuromuscular disorder.660. The AAV particle, pharmaceutical composition, cell, method, or use or any one of the preceding embodiments for reducing or eliminating expression of ATXN2 (e.g., of ATXN2 mRNA. and / or protein).[Embodiments 661 -664 are intentionally absent.]665. The AA V particle of embodiment 660, wherein the AAV capsid vanant comprises (a) a VP 1 protein comprising the amino acid sequence of SEQ ID NO: 982 or a. sequence at least 90% identical thereto; (b) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or a sequence at least 90% identical thereto; or (c) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or a sequence at least 90% identical thereto; or wherein the AAV capsid variant is encoded by the nucleotide sequence of SEQ ID NO: 984 or a sequence at least 90% identical thereto.666. The AAV particle of any one of embodiments 660-664, wherein the AAV capsid variant comprises no more than three amino acid substitutions relative to the amino acid sequence ofHDSPHK (SEQ ID NO: 2), wherein the AAV capsid variant comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 982.[Embodiments 666-674 are intentionally absent.]675. The AAV particle of any one of the preceding embodiments, wherein the encoded modulatory polynucleotide comprises a molecular scaffold, comprising a 5’ flanking region, a loop region, and a. 3' flanking region, optionally wherein(a) the 5’ flanking region comprises any one of SEQ ID NOs: 6413-6416; or a nucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 6413-6416;(b) the loop region comprises any one of SEQ ID NOs: 6417-6421; or a nucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 6417-6421; and(c) the 3’ flanking region comprises any one of SEQ ID NOs: 6422-6427; or a nucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 6422-6427.676. The AAV particle of embodiment 675, wherein:(a) the 5’ flanking region of the molecular scaffold comprises SEQ ID NO: 6414 or SEQ ID NO: 6415;(b) the loop region of the molecular scaffold comprises SEQ ID NO: 6417, SEQ ID NO: 6418, or SEQ ID NO: 6421 ; and(c) the 3’ flanking region of the molecular scaffold comprises SEQ ID NO: 6423, SEQ ID NO: 6424. or SEQ ID NO: 6425.677. The AAV particle of embodiment 675, wherein:(a) the 5’ thinking region of the molecular scaffold comprises SEQ ID NO: 6414, the loop region of the molecular scaffold comprises SEQ ID NO: 6417, and the 3" flanking region of the molecular scaffold comprises SEQ ID NO: 6423;(b) the 5’ flanking region of the molecular scaffold comprises SEQ ID NO; 6415, the loop region of the molecular scaffold comprises SEQ ID NO: 6421, and the 3’ flanking region of the molecular scaffold comprises SEQ ID NO: 6425; or(c) the 5’ flanking region of the molecular scaffold comprises SEQ ID NO: 6414, the loop region of the molecular scaffold comprises SEQ ID NO: 6417, and the 3’ flanking region of the molecular scaffold comprises SEQ ID NO: 6424; or(d) the 5’ flanking region of the molecular scaffold comprises SEQ ID NO: 6414, the loop region of the molecular scaffold comprises SEQ ID NO: 6418, and the 3’ flanking region of the molecular scaffold comprises SEQ ID NO: 6423.677a. The AAV particle of embodiment 677, wherein the modulatory polynucleotide comprises an siRNA comprising a passenger strand and a guide strand, wherein the passenger and guide strands are substantially complementary, and wherein the guide strand targets (e.g., reduces expression or silences expression of) ATXN2 mRNA, thereby reducing or eliminating ATXN2 protein.677b. The AAV particle of embodiment 677a, wherein the passenger strand and the guide strand, are located, respectively, on a 5’ arm and a 3’ arm of a stem loop structure, wherein the passenger strand is located between the 5 ’ flanking region of the molecular scaffold and the loop region of the molecular scaffold and the guide strand is located between the loop region of the molecular scaffold and the 3’ flanking region of the molecular scaffold.677c. The AAV particle of embodiment 677a, wherein the guide strand and the passenger strand are located, respectively; on a 5’ arm and a 3’ arm of a stem loop structure, wherein the guide strand is located between the 5’ flanking region of the molecular scaffold, and the loop region of the molecular scaffold and the passenger strand is located between the loop region of the molecular scaffold and the 3’ flanking region of the molecular scaffold.677d. The AAV particle of any one of embodiments 677a-677c, wherein the passenger strand is 15-30 nucleotides in length, optionally 21-25 nucleotides in length.677e. The AAV particle of any one of embodiments 677a-677d, wherein the guide strand is 15-30 nucleotides in length, optionally 21-25 nucleotides in length.677f. Tlte AAV particle of embodiment 677e, wherein the passenger strand and guide strand are at least 70% complementary.677g. The AAV particle of any one of embodiments 677a-677f, wherein the modulatory polynucleotide (e.g., the guide strand of the modulatory polynucleotide) binds to a coding region of ATXN2 mRNA.677h. Tlte AAV particle of any one of embodiments 677a-677g, wherein the modulatory polynucleotide (e.g., the guide strand of the modulatory polynucleotide) binds to a noncoding region of ATXN2 mRNA,678. The AAV particle of any one of embodiments 667-677h, wherein the viral genome further comprises a promoter operably linked to the nucleic acid sequence encoding the modulatory polynucleotide .679. The AAV particle of any one of embodiments 667-678, wherein the viral genome further comprises an enhancer.[Embodiments 680 and 681 are intentionally absent.]682. The AAV particle of embodiment 678 or 679, wherein the promoter comprises a tissue- specific promoter.683. The AAV particle of embodiment 678 or 679, wherein the promoter comprises a ubiquitous promoter.684. lire AAV particle of any one of embodiments 678-683, wherein the promoter composes:(i) an EF-la promoter, a CB promoter, a chicken β -actin (CBA) promoter, a CAG promoter, a CMV immediate-early enhancer and / or promoter, a CMV promoter, an Hl promoter, a β glucuronidase (GUSB) promoter, a ubiquitin C (UBC) promoter, a neuron- specific enolase (NSE), a platelet-derived growth factor (PDGF) promoter, a platelet-derived growth factor B-chain (PDGF-β) promoter, an intercellular adhesion molecule 2 (ICAM-2) promoter, a synapsin (Syn) promoter, a methyl-CpG binding protein 2 (MeCP2) promoter, aCa2+ / calmodul in-depen dent protein kinase II (CaMKII) promoter, a metabotropic glutamate receptor 2 (mGluR2) promoter, a neurofilament light (NFL) or heavy (NFH) promoter, a p- globin minigene np2 promoter, a preproenkephalin (PPE) promoter, an enkephalin (Enk) and. excitatory amino acid transporter 2 (EAAT2) , a glial fibrillary acidic protein (GFAP) promoter, a myelin basic protein (MBP) promoter, a cardiovascular promoter (e.g., aMHC, cTnT, and CMV-MLC2k), a liver promoter (e.g., hAAT, TEG), a skeletal muscle promoter (e.g., desmin, MCK, C512) or a fragment, e.g., a truncation, or a functional variant thereof.713. The AAV particle of any one of embodiments 667-713, wherein the viral genome further comprises an inverted terminal repeat (ITR) sequence.714. The AAV particle of embodiment 713, wherein the ITR sequence is positioned 5’ relative to the nucleic acid encoding the modulatory polynucleotide.715. The AAV particle of embodiment 713 or embodiment 714, wherein the ITR sequence is positioned 3’ relative to the nucleic acid encoding the modulatory polynucleotide.716. The AA V particle of any one of embodiments 713-715, wherein the viral genome comprises an ITR positioned 5' relative to the nucleic acid encoding the modulatory polynucleotide and an ITR positioned 3 ’ relative to the nucleic acid encoding the modulatory polynucleotide.717. The AAV particle of any one of embodiments 667-716, wherein the viral genome further comprises a polyadenylation (polyA) sregion.718. The AAV particle of any one of embodiments 667-717, wherein the viral genome further comprises an intron region.[Embodiments 719-726 are intentionally absent.]727. The AAV particle of any one of embodiments 667-718, wherein the viral genome further comprises an exon region, e.g., at least one, at least two, or at least three exon regions.728. The AAV particle of any one of embodiments 667-727, wherein the viral genome further comprises a Kozak sequence.[Embodiments 729-748 are intentionally absent.]749. An AAV particle comprising an AAV capsid variant and a viral genome, wherein the capsid variant comprises:(a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or a sequence at least 90% identical thereto:(b) a VP2 protein composing the amino acid sequence of positions 138-742 of SEQID NO: 982 or a sequence at least 90% identical thereto; and / or(c) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQID NO: 982 or a sequence at least 90% identical thereto and wherein the viral genome encodes a modulatory polynucleotide (e.g... siRNA) comprising a stem-loop structure comprising;(i) a 5’ flanking region, a passenger strand, a loop region, a guide strand that targets ATXN2 mRNA, and a 3 ’ flanking region; or(ii) a 5’ flanking region, a guide strand that targets ATXN2 mRNA, a loop region, a passenger strand, and a 3’ flanking region.750. The AAV particle of embodiment 749, w herein the AAV capsid variant comprises no more than three amino acid substitutions relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the AAV capsid variant comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 982.751. The AAV particle of embodiment 749, wherein the AAV capsid variant is encoded by the nucleotide sequence of SEQ ID NO: 984 or a sequence at least 90% identical (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical) thereto.[Embodiments 752-761 are intentionally absent.]762. The AAV particle of any one of embodiments 660-751, further comprising a nucleic acid encoding a Rep protein, wherein the Rep protein comprises a Rep78 protein, a Rep68 protein, a. Rep52 protein, and / or a Rep40 protein.763. The AAV particle of embodiment 762, wherein the Rep78 protein, the Rep68 protein, the Rep52 protein, and / or the Rep40 protein are encoded by at least one Rep gene.764. A vector encoding the AAV particle of any one of embodiments 660-763.765. A cell comprising the AAV particle of any one of embodiments 660-763 or the vector of embodiment 764.766. The cell of embodiment 765, which is a mammalian cell, e.g., an HEK293 cell, an insect cell, e.g., an Sf9 cell, or a bacterial cell.767. A method of making a recombinant AAV particle, the method comprising(i) providing a host cell comprising a viral genome comprising the nucleotide sequence encoding a modulatory polynucleotide of the disclosure; and(ii) incubating the host cell under conditions suitable to enclose the viral genome in a capsid variant comprising the amino acid sequence of SEQ ID NO: 982; thereby making the recombinant AAV particle.768. The method of embodiment 767, further comprising, prior to step (i), introducing a first nucleic acid molecule comprising the viral genome into the host cell.769. The method of embodiment 767 or embodiment 768, wherein the host cell comprises a second nucleic acid encoding the capsid variant.770. The method of embodiment 769, further comprising introducing the second nucleic acid into the cell.771. The method, of embodiment 769 or embodiment 770, wherein the second nucleic acid molecule is introduced into the host cell prior to, concurrently with, or after the first nucleic acid molecule.772. The method of any one of embodiments 767-772, wherein the host cell comprises a mammalian cell, e.g., an HEK293 cell, an insect cell, e.g,, an Sf9 cell, or a bacterial cell .773. A pharmaceutical composition comprising the AAV particle of any one of embodiments 660-763 and a pharmaceutically acceptable excipient.774. A method of delivering a modulatory polynucleotide to a subject comprising administering an effective amount of the pharmaceutical composition of embodiment 773 or the AAV particle of any one of embodiments 660-763, thereby delivering the nucleic acid encoding a modulatory polynucleotide to the subject.775. The method of embodiment 774, wherein the subject has, has been diagnosed with having, or is at risk of having a. disease associated with aberrant expression or activity of ATXN2, e.g., of a ATXN2 gene, ATXN2 mRNA, and / or ATXN2 protein.776. The method of embodiment 774 or embodiment 775, wherein the subject has, has been diagnosed with having, or is at risk of having a spinocerebellar ataxia, type 2 (SCA2).777. A method of treating a subject having or diagnosed with having a disease associated with aberrant ATXN2. protein expression or activity or mutant ATXN2 protein, composing administering an effective amount of the pharmaceutical composition of embodiment 773 or the AAV particle of any one of embodiments 1-751, thereby treating the disease associated with aberrant ATXN2 protein expression or activity or mutant ATXN2 protein in the subject.[Embodiments 778-779 are intentionally absent.]780. A method of treating a. subject having or diagnosed with having SCA2, comprising administering an effective amount, of the pharmaceutical composition of embodiment 773 or the AAV particle of any one of embodiments 1-751, thereby treating SCA2 in the subject.781. The method, of embodiment 779 or embodiment 780, wherein the subject has one or more mutations in ATXN2.[Embodiments 782-785 are intentionally absent]786. The method, of embodiment 781, wherein the subject’s ATXN2 gene has 32 or more CAG repeats (SEQ ID NO: 6435).787. The method of embodiment 781, wherein the subject’s ATXN2 gene has 35 or more CAG repeats (SEQ ID NO: 6436).788. The method of embodiment 781, w'herein the subject’s ATXN2 gene has 45 or more CA.G repeats (SEQ ID NO: 6434).789. The method of any one of embodiments 774-789, wherein the subject has an increased level of ATXN2 activity as compared to a reference level.790. The method of embodiment 789, wherein the reference level comprises the level of ATXN2 activity in a subject that does not have a disease associated with aberrant ATXN2 protein expression or activity or mutant ATXN2 protein.791. The method of any one of embodiments 777-790, wherein treating results in amelioration of at least one biomarker or symptom of the disease associated with aberrant AT.XN2 protein expression or activity or mutant AT.XN2 protein.792. The method of embodiment 791, w'herein the at least one biomarker or symptom comprises progressive cerebellar ataxia, nystagmus, slow saccadic eye movements, ophthalmoparesis, parkinsonism, or a. combination thereof.793. The method of any one of embodiments 774-792, wherein tire subject is a human.794. The method of any one of embodiments 774-793, wherein the subject is a juvenile, e.g., between 6 years of age to 20 years of age.795. The method, of any one of embodiments 774-793, wherein the subject is an adult, e.g., above 20 years of age.796. The method of any one of embodiments 774-795. wherein the subject has one or more mutations in a ATXN2 gene, ATXM2 mRNA, and / or ATXN2 protein.797. The method of any one of embodiments 774-796, wherein the AAV particle is administered to the subject intravenously, intracerebrally, via intrathalamic (ITH) administration, intramuscularly, intrathecally, intracerebroventricularly, via intraparenchymal administration, via focused ultrasound (FUS), e.g., coupled, with the intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS coupled with intravenous administration, or via intra-cisterna magna injection (ICM).798. The method of any one of embodiments 774-796, wherein the AAV particle is administered via dual ITH and ICM administration.799. The method of any one of embodiments 774-796, wherein the AAV particle is administered via intravenous injection, optionally wherein the intravenous injection is via focused ultrasound (FUS), e.g., coupled with the intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS coupled with intravenous administration.800. The method of any one of embodiments 774-799, wherein the AAV particle is administered to a ceil, tissue, or region of tire CNS, e.g., a region of the brain or spinal cord, e.g., the parenchyma, the cortex, substantia nigra, caudate cerebellum, striatum, corpus callosum, cerebellum, brain stem caudate-putamen, thalamus, superior colliculus, the spinal cord, or a combination thereof.801. The method, of any one of embodiments 774-800, wherein the AAV particle is administered to at least two tissues, or regions of the CNS, e.g., bilateral administration.802. The method of any one of embodiments 774-799, wherein the AAV particle is administered to the cerebral spinal fluid, the serum, or a combination thereof.803. The method of any one of embodiments 774-802, further comprising performing a blood test, performing an imaging test, collecting a tissue biopsy, or collecting a blood or serum sample.804. The method of any one of embodiments 774-803, which further comprises evaluating, e.g., measuring, the level of ATXN2 expression, e.g., ATXN2 gene, ATXN2 mRNA, and / or ATXN2 protein expression, in the subject, e.g., in a cell, tissue, or fluid, of the subject, optionally wherein the level of ATXN2 protein is measured by an assay described herein, e.g., an ELISA, a Western blot, or an immunohistochemistry assay.805. The method of embodiment 804, wherein measuring the level of ATXN2 expression is performed prior to, during, or subsequent to treatment with the AAV particle.806. The method, of embodiment 804 or embodiment 805, wherein the cell or tissue is a. cell or tissue of the central nervous system (e.g., parenchyma) or peripheral cell or tissue (e.g., the liver, heart, and / or spleen).807. The method of any one of embodiments 774-806, wherein the administration results in decreased level of ATXN2 protein expression in a cell or tissue of the subject, relative to a. reference level, e.g., a subject that has not received treatment, e.g., has not been administered the AAV particle.808. The method of any one of embodiments 774-807, which further comprises evaluating, e.g., measuring, the level of ATXN2 activity m the subject, e.g., in a cell or tissue of the subject, optionally wherein the level of ATXN2 activity is measured by an assay described herein.808a. The method of any one of embodiments 774-808, wherein the administration results in an increase in the level of viral genomes (VG) per cell in a CNS cell or tissue (e.g. parenchyma).809. The method of any one of embodiments 774-808a, wherein the administration results in a decrease in at least one of:(i) the level of ATXN2 activity in a cell, tissue, and / or fluid, e.g., a CNS cell or tissue, of the subject: and / or(ii) the level of ATXN2 mRNA expression in a cell, tissue, and / or fluid, e.g., a CNS cell or tissue, of the subject.810. The method of any one of embodiments 774-809, further comprising administration of an additional therapeutic agent and / or therapy suitable for treatment or prevention of the disease associated with aberrant ATXN2 protein expression or activity or mutant ATXN2 protein, e.g., spinocerebellar ataxia type 2.811. The method of embodiment 810, wherein the additional therapeutic agent comprises riluzole.812. The pharmaceutical composition of embodiment 773 or the AAV particle of any one of embodiments 1-751 for use in the treatinent of a disease associated, with aberrant ATXN2 protein expression or activity or mutant ATXN2 protein, e.g., spinocerebellar ataxia type 2.813. Use of an effective amount of the pharmaceutical composition of embodiment 773 or the AAV particle of any one of embodiments 660-763 in the manufacture of a medicament for the treatment of a. disease associated with aberrant ATXN2 protein expression or activity or mutant ATXN2 protein, e.g., spinocerebellar ataxia type 2.
[0073] The details of various aspects or embodiments of the present disclosure are set forth below. Other features, objects, and advantages of the disclosure will be apparent from the description and the claims. In the description, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific, terms used herein have the same meaning as commonly understood by one of ordinary skill in the art in the field of this disclosure. In the case of conflict, the present description will control.BRIEF DESCRIPTION OF THE DRAWINGS
[0074] FIG. 1 depicts biodistribution (VG / cell) in the motor cortex, frontal cortex, putamen, substantia nigra, dentate nucleus, cervical spinal cord ventral hom, DRG, liver, and heart in cynomolgus monkeys at 28 days post-IV injection of TTM-002.GBA_VG17-HA, AAV9.GBA_VG17-HA, or vehicle control.
[0075] FIG. 2 depicts niRNA expression of GBA1 transgene in the motor cortex, frontal cortex, putamen, substantia nigra, dentate nucleus, cervical spinal cord ventral horn, DRG, liver, and heart in cynomolgus monkeys at 28 days post-IV injection of TTM- 002.GBA VG17-HA, AAV9.GBA VG17-HA, or vehicle control.
[0076] FIG. 3A is a. graph showing the percentage of HA positive cells (percent of cells transduced by the indicated capsid variant) in the cortex in mice on the Y axis at the indicated doses on the X-axis (from highest dose to lowest dose: le 14 vg / kg, 3.2el 3 vg / kg, l el3 vg / kg, 3.2el2 vg / kg, or lei 2 vg / kg) at 28 days post-intravenous administration of AAV particles comprising the TTM-002 or TTM-027 AAV capsid variant. FIG. 3B is a graph showing the mRNA transgene expression relative to the housekeeping gene in the brains of the mice on the Y axis at the indicated doses on the X-axis (from highest to lowest dose: le 14 vg / kg, 3.2el3 vg / kg, lel.3 vg / kg, 3.2el 2 vg / kg, or 1 e 12 vg / kg) at 28 days post-intravenous administration of AAV particles comprising the TTM-002 or TTM-027 AAV capsid variant.
[0077] FIG. 4A is a graph showing the percentage of transduced cells having HA+ nuclei as measured by co-local izati on of nuclear H2B-HA staining and hematoxylin (%HA+ cells) in the indicated brain regions (temporal cortex, caudate, thalamus, or hippocampus) of African green monkey s. Measurements are at day 28 post-intravenous injection of AAV particles comprising the TTM-002 capsid variant or the AAV9 capsid control and a self- complementary genome encoding a histone 2B protein with an HA -tag at a dose of lel 3 VG / kg. FIG. 4B is a graph showing the percentage of HA+ cells among cells positive for the indicated marker (NeuN+ neurons, SM311+ Neurons, GFAP+ astrocytes, or Sox9 + astrocytes) in the indicated brain regions (temporal cortex, caudate, thalamus, or hippocampus) of African green monkey s. Measurements are at day 28 post-intravenous injection of AAV particles comprising the TTM-002 capsid variant and a self-complementary genome encoding a histone 2.B protein with an HA-tag at a dose of le!3 VG / kg. Plotted data, in FIGs. 4A-4B represent one slice per monkey (n=2). Quantitative image analysis was performed on le3 to le5 cells according to region size. All P values are derived from an unpaired two-tailed t-test.
[0078] FIGs. 5A-5D are a series of graphs showing tropism of TTM-001 and TTM~002 relative to the AAV9 control in the brain and liver at 28 days post-intravenous administration in mice at a dose of le 13 VG / kg. FIG. 5A shows the viral genomes (VG) / diploid genomes (DG) in the brain for the AAV9 control, TTM-001 , or TTM-002; FIG. 5B shows brain RNA (fold vs AAV9) for the AAV9 control, TTM-001, or TTM-002; FIG. 5C shows the VG / DG in the liver for the .AAV 9 control, TTM-001, or TTM-002; and FIG. 5D shows the liver RNA (fold vs AAV9) for the AAV9 control, TTM-001, or TTM-002. Each data point represents an individual mouse and all plotted values represent mean ± SD (n=3). P values are derived from an unpaired two-tailed t-test.DETAILED DESCRIPTIONOverview
[0079] Described herein, inter alia, are compositions comprising an AAV capsid, variant tor delivery of modulatory polynucleotides for reducing or eliminating expression of ATXN2 to treat SCA2 or other disorders associated with aberrant ATXN2 protein expression or activity or mutant ATXN2 protein. In some embodiments, the modulatory polynucleotides reduce or eliminate expression of ATXN2 mRNA, thereby reducing or eliminating ATXN2 protein. The AAV capsid variants described herein have enhanced tropism for a cell or tissue, e.g., for the delivery of a payload to said cell or tissue, for example a CNS tissue or a CNS cell.
[0080] AAVs have proven to be usefill as a biological tool due to their relatively simple structure, their ability to infect a wide range of cells (including quiescent and dividing ceils) without integration into the host genome and without replicating, and their relatively benign immunogenic profile. Engineered adeno-associated virus (AAV) capsids with improved brain tropism represent an attractive solution to the limitations of CNS delivery. AAV-derived vectors are promising tools for clinical gene transfer because of their non -pathogenic nature, their low immunogenic profile, low rate of integration into the host genome, and long-term transgene expression in non-dividing cells. However, the transduction efficiency of naturally occurring AAVs in certain organs is too low for clinical applications, and capsid neutralization by pre-existing neutralizing antibodies may prevent treatment of a large proportion of patients. For these reasons, considerable efforts have been devoted to obtaining capsid variants with enhanced properties. Of many approaches tested so far, significant, advances have resulted from directed evolution of -AAV capsids using in vitro or in vivo selection of capsid variants created by capsid sequence randomization using either error- prone PCR, shuffling of various parent serotypes, or insertion of fully randomized short peptides at. defined positions.
[0681] The genome of tire virus may be modified to contain a minim um of components for the assembly of a functional recombinant virus, or viral particle, which is loaded with or engineered to target a particular tissue and express or deliver a desired payload . The genome of the virus may be modified to contain a minimum of components for the assembly of a functional recombinant virus, or viral particle, which is loaded with or engineered to express or deliver a modulatory polynucleotide for reducing or eliminating expression of ATXN2 mRNA (thereby reducing or eliminating ATXN2 protein), which may be delivered to a target, cell, tissue, or organism. In some embodiments, the genome encodes a modulatorypolynucleotide for reducing or eliminating expression of human ATXN2 mRNA, thereby reducing or eliminating human ATXN2 protein. In some embodiments, the target cell is a CNS cell. In some embodiments, the target tissue is a CNS tissue. The target CNS tissue maybe brain tissue. In some embodiments, the brain target comprises caudate, putamen, thalamus, superior colliculus, cortex, and corpus collosum.
[0682] Gene therapy presents an alternative approach for SCA2 and related diseases sharing single-gene etiology. AAVs are commonly- used, in gene therapy approaches as a result of a number of advantageous features. Without being bound by theory, it is believed, in some embodiments, that expression vectors, e.g., an adeno-associated viral vector (AAVs) or AAV particle, e.g., an AAV particle described herein, can be used to administer and / or deliver a modulatory poly-nucleotide, in order to achieve sustained, high concentrations, allowing for longer lasting efficacy, fewer dose treatments, broad biodistribution, and / or more consistent levels of the modulatory polynucleotide, relative to a non-AAV therapy.
[0083] Provided herein are compositions and methods with improved features compared to prior A AV-mediated approaches, including (i) increased biodistribution throughout the CNS (e.g., the cortex, striatum, thalamus, cerebellum, brainstem, and / or spinal cord), and the periphery (e.g., the liver), (ii) elevated payload expression, e.g., modulatory polynucleotide expression, in multiple brain regions (e.g., cortex, thalamus, and brain stem) and the periphery (e.g., the liver): and / or (iii) increased modulatory polynucleotide in a cell, tissue, (e.g., a cell or tissue of the CNS, e.g., the cortex, striatum, thalamus, cerebellum, and / or brainstem), and / or fluid (e.g., CSF and / or serum), of the subject. In some embodiments, an AAV particle comprising an AAV capsid variant (e.g., comprising the amino acid sequence of SEQ ID NO: 4, 36, or 982), and a viral genome comprising a nucleic acid encoding a modulatory- poly nucleotide, yields increased biodistribution and / or elevated expression of the modulatory- polynucleotide in the cerebellum, e.g., Purkinje cells.
[0084] Also provided herein, are compositions comprising an AAV capsid variant, e.g., an AAV capsid variant described herein for delivery, e.g., vectorized delivery, of a nucleic acid encoding modulatory- poly-nucleotides described herein, and methods of making and using the same. As demonstrated in the Examples below, certain AAV capsid variants described herein show multiple advantages over wild-type AAV9, including (i) increased penetrance through the blood brain barrier following intravenous administration, (ii) wider distribution throughout the multiple brain regions, e.g., frontal cortex, sensory- cortex, motor cortex, putamen, thalamus, cerebellar cortex, dentate nucleus, caudate, and / or hippocampus, and / or (iii) elevated payload expression in multiple brain regions. Without being bound by theory, itis believed that these advantages may be due, in part, to the dissemination of the AAV capsid variants through the brain vasculature. In some embodiments, the AAV capsids described herein enhance tire delivery of a payload to multiple regions of the brain including for example, the frontal cortex, sensory cortex, motor cortex, putamen, thalamus, cerebellar cortex, dentate nucleus, caudate, and / or hippocampus.
[0885] Thus, the compositions and methods described herein can be used in the treatment of disorders associated with mutant ATXN2 protein or aberrant ATXN2 protein expression or activity, such as SCA2. In some embodiments, the disclosure provides an AAV particle comprising one of the AAV capsid variants disclosed herein and an .AAV viral genome comprising a modulatory polynucleotide for use in treating disorders associated with mutant ATXN2 protein or aberrant ATXN2 protein expression or activity, such as SCA2.I. CompositionsAdeno-associated viral (AAV) Particles
[0086] AAVs have a genome of about 5,000 nucleotides in length and contain two open reading frames encoding the proteins responsible for replication (Rep) and the structural protein of the capsid (Cap). The open reading frames are flanked by two Inverted Terminal Repeat (ITR) sequences, which serve as the origin of replication of the viral genome. The wild-type AA V viral genome comprises nucleotide sequences for two open reading frames, one for the four non -structural Rep proteins (Rep78, Rep68, Rep52, Rep40, encoded by Rep genes) and one for the three capsid, or structural, proteins (VP1, VP2, VP3, encoded by capsid genes or Cap genes). The Rep proteins are important for replication and packaging, while the capsid proteins are assembled to create the protein shell of the AAV, or AAV capsid. Alternative splicing and alternate initiation codons and promoters result in the generation of four different Rep proteins from a single open reading frame and the generation of three capsid proteins from a single open reading frame. Though it varies by AAV serotype, as a. non-limiting example, for AAV9 / 11U.14 (SEQ ID NO: 123 of US 7,906, 11 1 , the contents of which are herein incorporated by reference in their entirety) VP1 refers to amino acids 1- 736, VP2 refers to amino acids 138-736, and VP3 refers to amino acids 203-736. In some embodiments, with reference to the amino acid sequence of SEQ ID NO: 982, 36, or 4, VP1 comprises amino acids 1-742, VP2 comprises amino acids 138-742, and VP3 comprises amino acids 203-742. In other words, VP I is the full-length capsid protein sequence, while VP2 and VP3 are shorter components of the whole. As a result, changes in the sequence in the VP3 region are also changes to VP1 and VP2; however, the percent difference as compared to the parent sequence will be greatest for VP3 since it is the shortest sequence ofthe three. Though described here in relation to the amino acid sequence, the nucleic acid sequence encoding these proteins can be similarly described. Together, the three capsid proteins assemble to create the AAV capsid. While not wishing to be bound by theory, the AAV capsid typically comprises a molar ratio of 1:1: 10 of VP1 :VP2:VP3.
[0087] The AAV particle typically requires a co-helper (e.g., adenovirus) to undergo productive infection in cells. In the absence of such helper functions, the AAV virions essentially enter host cells but do not integrate into the cells’ genome.
[0088] AAV particles have been investigated for delivery of gene therapeutics because of several unique features. Non-limiting examples of the features include (i) the ability to infect both dividing and non-dividing cells; (ii) a broad host range for infectivity, including human cells; (iii) wild-type AAV has not been associated with any disease and has not been shown to replicate in infected ceils; (iv) the lack of cell-mediated immune response against the particle, and ( v) the non-integrative nature in a host chromosome thereby reducing potential for long-term genetic alterations. Moreover, infection with AAV particles has minimal influence on changing the pattern of cellular gene expression (Stilwell and Samulski el al, Biotechniques, 2003, 34, 148, the contents of which are herein incorporated by reference in their entirety).
[0089] Typically, A AV particles for modulatory-' polynucleotide delivery may be recombinant viral particles which are replication defective as they lack sequences encoding functional Rep and Cap proteins within the viral genome. In some cases, the replication detective A AV particles may lack most or all coding sequences and essentially only contain one or two AAV ITR sequences and a. nucleic acid sequence encoding a modulatory polynucleotide.
[0090] In some embodiments, the AAV particles of the present disclosure may be introduced into mammalian cells.
[0091] AAV particles may be modified to enhance the efficiency of delivery. Such modified AAV particles of the present disclosure can be packaged efficie...
Claims
CLAIMSWhat is claimed is:
1. An adeno-associated virus (AAV) particle comprising: a) an AAV capsid variant comprising an amino acid sequence having the following formula:[N1]-[N2]-[N3], wherein:(i) optionally [N1] comprises XL _X2, and X3, wherein at least one of X1, X2, or X3 is G;(ii) [N2] comprises the amino acid sequence of SPH; and(iii) [N3] comprises X4, X5, and. X6, wherein at least one of X4, X5, or X6 is a basic amino acid; and b) a viral genome comprising a nucleic acid sequence encoding a modulatory polynucleotide for reducing or eliminating expression of At.axin-2 (ATXN2), optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting ATXN2 mRNA.
2. The AAV particle of claim 1, wherein the amino acid sequence [N1]-[N2]-[N3] is in hypervariable loop IV of the AAV capsid, variant.
3. The AAV particle of claim 1 or claim 2, wherein the AAV capsid variant is an AAV9 capsid variant.
4. The AAV particle of any one of claims 1-3, wherein [N1] comprises X1, X2, and X3, wherein at least one of X1, X2, or X3 is G.
5. The AAV particle of any one of claims 1 -4, wherein [N1]-[N2]-[N3] is present immediately subsequent to a position corresponding to the amino acid position 452 of SEQ ID NO: 982; and wherein the AAV capsid variant comprises an amino acid sequence at least 90% identical, e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical, to the amino acid sequence of SEQ ID NO: 982, e.g., to positions 203-742 of SEQ ID NO: 982.
6. The AAV particle of any one of claims 1-5, wherein [N1] comprises GHD.
7. The AAV particle of any one of claims 1-6, wherein [N1] comprises the amino acid G at a position corresponding to position 453, the amino acid H at position 454, and the amino acid. D at. position 455 of SEQ ID NO: 138 or SEQ ID NO: 982.
8. The AAV particle of any one of claims 1-7, wherein [M3] comprises KSG.
9. The AAV particle of any one of claims 1-8, wherein the AAV capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity to SEQ ID NO: 982;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity to positions 138-742 SEQ ID NO: 982; or(iii) a VP3 protein compri sing the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity to positions 203-742 of SEQ ID NO: 982.
10. The AAV particle of any one of claims 1 -9, wherein the AAV capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having at least 95% identity to SEQ ID NO: 982;(ii) a. VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least 95% identity to positions 138-742 SEQ ID NO: 982; or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid, sequence having at least. 95% identity to positions 203-742 of SEQ ID NO: 982.1 1 . The AAV particle of any one of claims 1-10, wherein the AAV capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having at least 99% identity to SEQ ID NO: 982;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid, sequence having at least 99% identity to positions 138-742 SEQ ID NO: 982; or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid sequence having at least 99% identity to positions 203-742 of SEQ ID NO: 982.
12. The AAV particle of any one of claims 1-11, wherein the AAV capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982;(ii) a. VP2 protein comprising the amino acid, sequence of positions 138-742 of SEQ ID NO: 982; or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982.
13. The AAV particle of any one of claims 1-4, wherein [N2]-[N3] comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941).
14. An adeno-associated virus (AAV) particle comprising (a) a viral genome comprising a nucleic acid sequence encoding a modulatory polynucleotide for reducing or eliminating expression of Ataxin-2 (ATXN2), and (b) an AAV 9 capsid variant comprising the amino acid sequence of SPHSKA (SEQ ID NO: 941).
15. The AAV particle of claim 14, wherein tire amino acid sequence of SPHSKA (SEQ ID NO: 941) is in hypervariabie loop IV of the AAV capsid variant.
16. The AAV particle of claim 14 or claim 15, wherein the amino acid sequence of SPHSKA (SEQ ID NO: 941) is present immediately subsequent to an amino acid position corresponding to position 455 of SEQ ID NO: 36 or SEQ ID NO: 4.
17. The AAV particle of claim 16, wherein tire AAV9 capsid variant further comprises one, two, or all of: an E at an amino acid position corresponding to position 451 , an R at an amino acid position corresponding to position 452, and / or a V at an amino acid position corresponding to position 453 of SEQ ID NO: 36.
18. The AAV particle of any one of claims 14-17, wherein the A AV 9 capsid variant comprises the amino acid sequence of KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589).
19. The AAV particle of any one of claims 14-1.8, wherein the AAV9 capsid variant comprises:(i) a VP1 protein comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 36;(ii) a VP2 protein comprising an amino acid sequence having at least 90% identity to positions 138-742 SEQ ID NO: 36; and / or(iii) a VP3 protein comprising an amino acid sequence having at least 90% identity to positions 203-742 of SEQ ID NO: 36.
20. The AAV particle of any one of claims 14-19, wherein the A AV9 capsid variant composes:(i) a VP1 protein comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 36;(ii) a. VP2 protein comprising an amino acid sequence having at least 95% identity to positions 138-742 SEQ ID NO: 36; and / or(iii) a VP3 protein comprising an amino acid sequence having at least 95% identity to positions 203-742 of SEQ ID NO: 36.
21. The AAV particle of any one of claims 14-20, wherein the AAV9 capsid variant comprises:(i) a VP1 protein comprising an amino acid, sequence having at least 99% identity to SEQ ID NO: 36;(ii) a VP2 protein comprising an amino acid sequence having at least 99% identity to positions 138-742 of SEQ ID NO: 36; and / or(iii) a VP3 protein comprising an amino acid sequence having at least 99% identity to positions 203-742 of SEQ ID NO: 36.
22. The AAV particle of any one of claims 14-21 , wherein the AAV9 capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 36;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQID NO: 36; and / or(iii) a. VP3 protein comprising the amino acid sequence of posi tions 203-742 of SEQID NO: 36.
23. The AAV particle of any one of claims 14-21, wherein the AAV9 capsid variant compnses:(i) the amino acid sequence SPHSKA (SEQ ID NO: 941 ), wherein the amino acid sequence is present immediately subsequent to an amino acid position corresponding to position 455 of SEQ ID NO: 36;(ii) an E at an amino acid position corresponding to position 451 , an R at an amino acid position corresponding to position 452, and a. V at an amino acid position corresponding to position 453 of SEQ ID NO: 36; and(iii) no other modifications relative to wild, type AA.V9.
24. The AAV particle of any one of claims 14-16, wherein the AAV9 capsid variant further comprises one, two, or all of: an N at an amino acid position corresponding to position 452, an E at an amino acid, position corresponding to position 451, and / or a V at an amino acid position corresponding to position 453 of SEQ ID NO: 4.
25. The AAV particle of claim 23 or claim 24, wherein the AAV9 capsid variant comprises the amino acid sequence of KTENVSGSPHSKAQNQQT (SEQ ID NO: 3272).
26. The AAV particle of any one of claims 23-25, wherein the AAV9 capsid variant compnses:(i) a VP1 protein comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 4;(ii) a VP2 protein comprising an amino acid sequence having at least 90% identity to positions 138-742 of SEQ ID NO: 4; and / or(iii) a. VP3 protein comprising an amino acid sequence having at least 90% identity to positions 203-742 of SEQ ID NO: 4.
27. The AAV particle of any one of claims 23-26, wherein the AAV9 capsid variant compnses:(1) a VP1 protein comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 4:(ii) a VP2 protein comprising an amino acid sequence having at least 95% identity to positions 138-742 SEQ ID NO: 4; and / or(iii) a VP3 protein comprising an amino acid sequence having at least 95% identity to positions 203-742 of SEQ ID NO: 4.
28. The AAV particle of any one of claims 23-27, wherein the AAV9 capsid variant comprises:(i) a VP1 protein comprising an amino acid sequence having at least 99% identity to SEQ ID NO: 4;(ii) a. VP2 protein comprising an amino acid sequence having at least 99% identity to positions 138-742 of SEQ ID NO: 4; and / or(iii) a VP3 protein comprising an amino acid sequence having at least 99% identity to positions 203-742 of SEQ ID NO: 4.
29. The AAV particle of any one of claims 23-28, wherein the AAV9 capsid variant composes:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 4;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQID NO: 4: and / or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742. of SEQ ID NO: 4.
30. The AAV particle of any one of claims 23-28, wherein the A AV 9 capsid variant comprises:(i) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to an amino acid position corresponding to position 455 of SEQ ID NO: 4;(ii) an E at an amino acid position corresponding to position 451 and a V at an amino acid position corresponding to position 453 of SEQ ID NO: 4; and(iii) no other modifications relative to wild type AAV9.
31. The AAV particle of any one of claims 1-30, wherein the modulatory polynucleotide compnses:(a) a 5’ flanking region comprising any one of SEQ ID NOs: 6413-6416 or a nucleotide sequence at least 95% identical thereto;(b) a loop region comprising any one of SEQ ID NOs: 6417-6421 or a nucleotide sequence at least 95% identical thereto: and(c) a 3’ flanking region comprising any one of SEQ ID NOs: 6422-6427 or a nucleotide sequence at least 95% identical thereto.
32. The AAV particle of claim 31, wherein:(a) the 5’ flanking region composes SEQ ID NO: 6414 or SEQ ID NO: 6415, or a nucleotide sequence at least 95% identical thereto;(b) the loop region comprises SEQ ID NO: 6417, SEQ ID NO: 6418, or SEQ ID NO: 6421, or a nucleotide sequence at least 95% identical thereto; and(c) the 3’ flanking region comprises SEQ ID NO: 6423, SEQ ID NO: 6424, or SEQ ID NO: 6425, or a nucleotide sequence at least 95% identical thereto.
33. The AAV particle of claim 31, wherein the 5’ flanking region comprises SEQ ID NO: 6414 or a nucleotide sequence at least 95% identical thereto, the loop region comprises SEQ ID NO: 6417 or a nucleotide sequence at least 95% identical thereto, and the 3’ flanking region comprises SEQ ID NO: 6423 or a nucleotide sequence at least 95% identical thereto.
34. The AAV particle of claim 31, wherein the 5’ flanking region comprises SEQ ID NO: 6415 or a nucleotide sequence at least 95% identical thereto, the loop region comprises SEQ ID NO: 6421 or a nucleotide sequence at least 95% identical thereto, and the 3’ flanking region comprises SEQ ID NO: 6425 or a. nucleotide sequence at least 95% identical thereto.
35. The AAV particle of claim 31, wherein the 5’ flanking region comprises SEQ ID NO: 6414 or a. nucleotide sequence at least 95% identical thereto, the loop region comprises SEQ ID NO: 6417 or a nucleotide sequence at least 95% identical thereto, and the 3’ flanking region comprises SEQ ID NO: 6424 or a nucleotide sequence at least 95% identical thereto.
36. The AAV particle of claim 31, wherein the 5' flanking region comprises SEQ ID NO: 6414 or a nucleotide sequence at least 95% identical thereto, the loop region comprises SEQ ID NO: 6418 or a nucleotide sequence at least 95% identical thereto, and the 3’ flanking region comprises SEQ ID NO: 6423 or a nucleotide sequence at least 95% identical thereto.
37. The AAV particle of any one of claims 1-36, wherein the modulatory polynucleotide comprises siRNA or shRNA.
38. The AAV particle of any one of claims 1 -37, wherein the modulatory polynucleotide further comprises a passenger strand and a guide strand, wherein the guide strand binds to and reduces or eliminates expression of one or more ATXN2 mRNA transcripts, where in the modulatory polynucleotide comprises from 5' to 3': the 5' flanking region, the passenger strand, the loop region, the guide strand; and the 3' flanking region.
39. The A AV particle of any one of claims 1-37, wherein the modulator}' polynucleotide further comprises a passenger strand and a guide strand, wherein the guide strand binds to and reduces or eliminates expression of one or more ATXN2 mRNA transcripts, wherein the modulatory polynucleotide comprises from 5' to 3': the 5* flanking region, the guide strand, the loop region, the passenger strand; and the 3' flanking region.
40. The AAV particle of claim 38 or claim 39, wherein the passenger strand is 15-30 nucleotides in length.
41. The AAV particle of any one of claims 38-40, wherein the guide strand is 15-30 nucleotides in length.
42. The AAV particle of claim 41, wherein the guide strand is 21-25 nucleotides in length and / or the passenger strand is 21-25 nucleotides in length.
43. The AAV particle of any one of claims 38-42, wherein the passenger strand is at least 70%, at least 80%, at least 90%, at least 95% or is 100% complementary to the guide strand.
44. The AAV particle of any one of claims 38-43, wherein the one or more ATXN2 mRNA transcripts comprises SEQ ID NO: 6428, SEQ ID NO: 6429, SEQ ID NO: 6430, and / or SEQ ID NO: 6431, or a trinucleotide repeat expansion thereof.
45. The A AV particle of any one of claims 1-44, wherein the viral genome comprises a. promoter operably linked to the nucleic acid sequence encoding the modulator}- polynucleotide.
46. The AAV particle of any one of claims 1-45, wherein the viral genome further comprises an inverted terminal repeat (ITR) sequence.
47. The AAV particle of claim 46, wherein the viral genome comprises an ITR sequence positioned 5’ relative to the nucleic acid sequence encoding the modulatory polynucleotide.
48. The AAV particle of claim 46 or claim 47, wherein the viral genome comprises an ITR sequence positioned 3’ relative to the nucleic acid sequence encoding the modulatory polynucleotide.
49. The AAV particle of any of claims 46-48, wherein the viral genome comprises an ITR sequence positioned 5 ’ relative to the nucleic acid sequence encoding the modulatory polynucleotide, and an ITR sequence positioned 3 ’ relati ve to the nucleic acid sequence encoding the modulatory polynucleotide.
50. A cell comprising the AAV particle of any one of claims 1-49, optionally wherein the cell is a mammalian cell (e.g., an HEK293 cell), an insect cell (e.g,, an Sf9 cell), or a bacterial cell.51 . A method of making the AA V particle of any one of claims 1-49, the method comprising(i) providing a. cell comprising the viral genome comprising a nucleic acid encoding a. modulatory polynucleotide for reducing or eliminating expression of ATXN2 mRNA; and(li) incubating the cell under conditions suitable to encapsulate the viral genome in the AAV capsid vanant; thereby making the AAV particle.
52. The method of claim 51, wherein the AAV capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to SEQ ID NO: 982;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity (e.g., at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 138-742 SEQ ID NO: 982; and / or(lii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 203-742 of SEQ ID NO: 982.
53. The method of claim 51, wherein the AAV capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 36 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to SEQ ID NO: 36;(ii) a VP2 protein comprising the amino acid sequence oppositions 138-742 of SEQ ID NO: 36 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 138-742 SEQ ID NO: 36; and / or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 36 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 203-742 of SEQ ID NO: 36.
54. The method of claim 51, wherein the AAV capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to SEQ ID NO: 4;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 4 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 138-742 SEQ ID NO: 4; or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 4 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 203-742 of SEQ ID NO: 4.
55. The method of any one of claims 51-54, further comprising, prior to step (i), introducing a first nucleic acid molecule comprising the viral genome into the cell .
56. The method of any one of claims 51-55, wherein the ceil comprises a second nucleic acid molecule encoding the AAV capsid variant.
57. The method of claim 56, further comprising, prior to step (i), introducing the second nucleic acid molecule into the cell.
58. The method of any one of claims 51 -57, wherein the cell comprises a mammalian cell, e.g., an HEK293 cell, an insect cell, e.g., an Sf9 cell, or a bacterial cell.
59. A pharmaceutical composition comprising the AAV particle of any one of claims 1-49, and a. pharmaceutically acceptable excipient.
60. A pharmaceutical composition comprising the AAV particle of any one of claims 13-30 and a pharmaceutically acceptable excipient.
61. A pharmaceutical composition comprising the AAV particle of any one of claims 17-23 and a pharmaceutically acceptable excipient.
62. A pharmaceutical composition comprising the AAV particle of any one of claims 24-30 and a pharmaceutically acceptable excipient.
63. A method of delivering a modulatory polynucleotide for reducing or eliminating expression of ATXN2 to a subject comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 58-61 or the AAV particle of any one of claims 1 -49, thereby delivering the modulatory polynucleotide.
64. lire method of claim 63, wherein the method reduces or eliminates ATXN2 protein in tire subject.
65. The method of claim 63 or claim 64, wherein the subject has, has been diagnosed with having, or is at risk of having an ATXN2-related disorder.
66. The method of claim 65, wherein the ATXN2-related disorder is spinocerebellar ataxia type 2 (SCA2).
67. A method of treating an ATXN2-related disorder in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 59-62 or the AAV particle of any one of claims I -49, thereby treating the ATXN2-related disorder.
68. A method of treating an ATXN2-related disorder in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 60 or the AAV particle of any one of claims 13-30, thereby treating the ATXN2-related disorder.
69. A method of treating an ATXN2-related disorder in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 61 or the AAV particle of any one of claim s 17-23, thereby treating the ATXN2 -related, disorder.
70. A method of treating an ATXN2-related disorder in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 62 or the AAV particle of any one of claims 24-30, thereby treating the ATXN2-related disorder.
71. The method of any one of claims 67-70, wherein the subject has, has been diagnosed, or is at risk of having the ATXN2-related disorder.
72. The method of any one of claims 63-71, wherein the subject has one or more mutations in the ATXN2 gene.
73. The method of claim 72, wherein the one or more mutations in the ATXN2 gene comprises a trinucleotide repeat expansion.
74. The method of claim 73, wherein the trinucleotide repeat expansion in the ATXN2 gene comprises 32 or more CAG repeats.
75. The method of any one of claims 67-74, wherein the treating results in prevention of progression of the A TXN2 -related. disorder in the subject.
76. The method of claim 67-75, wherein the treating results in amelioration of at least one symptom of the ATXN2-related disorder and / or a change in at least one biomarker of the ATXN2-related disorder in the subject.
77. The method of claim 76, wherein the at least one symptom comprises progressive cerebellar ataxia, nystagmus, slow saccadic eye movements, ophthalmoparesis, parkinsonism, or a. combination thereof.
78. The method of any one of claims 67-77, wherein the ATXN2-related disorder is spinocerebellar ataxia type 2 (SCA2).
79. A method of treating spinocerebellar ataxia type 2 (SCA2) in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of anyone of claims 59-62 or the AAV particle of any one of claims 1-49, thereby treating SCA2,80. A method of treating spinocerebellar ataxia type 2 (SCA2) in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 60 or the AAV particle of any one of claims 13-30, thereby treating SCA2.
81. A method of treating spinocerebellar ataxia type 2 (SCA2) in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 61 or the AAV particle of any one of claims 17-23, thereby treating SCA2.
82. A method of treating spinocerebellar ataxia type 2 (SCA2.) in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 62 or the AAV particle of any one of chums 24-30, thereby treating SCA2.
83. The method of any one of claims 79-82, wherein the subject has, has been diagnosed with having, or is at risk of having SCA2.
84. The method of any one of claims 63-83, wherein the subject is a human.
85. The method of any one of claims 63-84, wherein the A AV particle or the pharmaceutical composition is delivered to a cell or tissue of the CNS, optionally wherein the AAV particle or the pharmaceutical composition is delivered via intravenous administration.
86. The method of claim 85, wherein the cell or tissue of the CNS is a cell or tissue of the amygdala, brainstem, caudate, central grey, cerebellum (e.g., Purkinje cell layer and deep cerebellar nuclei), cortex (e.g., frontal cortex, motor cortex, perirhinal cortex, sensory cortex, temporal cortex), external cuneate nucleus, geniculate nucleus, globus pallidus, gracile nucleus, hippocampus, inferior colliculus, inferior olivary complex, nucleus ambiguous, oculomotor nucleus, putamen, substantia nigra, thalamus, ventral palladium, vestibular nucleus, and / or spinal cord (e.g., cervical spinal cord region, lumbar spinal cord region, or thoracic spinal cord region).
87. The method of any one of claims 63-86, further comprising evaluating, e.g., measuring, the level of modulatory polynucleotide expression, and / or the level of ATXN2 expression, e.g,, ATXN2 gene, ATXN2 mRNA, and / or ATXN2 protein expression, in the subject, e.g,, in a cell, tissue, or fluid, of the subject.
88. The method of claim 87, wherein the level of ATXN2 protein is measured by an ELISA, a Western blot, or an immunohistochemistry' assay.
89. lire method of claim 87 or claim 88, wherein the evaluating of the subject’s level of modulatory polynucleotide expression and / or level of ATXN2 expression is performed prior to and / or subsequent to administration of the pharmaceutical composition or AAV particle, optionally wherein the subject’s level of modulatory polynucleotide expression and / or the subject’s level of ATXN2 expression prior to administration is compared to the subject’s level of modulatory polynucleotide expression and / or the subject’s level of ATXN2 expression subsequent to administration.
90. The method of any one of claims 63-89, wherein the subject’s level of ATXN2 protein expression subsequent to administration is decreased relative to the subject’s level of ATXN2 protein expression prior to administration.91 . The method of any one of claims 63-90, further comprising evaluating, e.g., measuring, the level of modulatory polynucleotide activity and / or ATXN2 activity in the subject, e.g,, in a cell or tissue of the subject.
92. The method of any one of claims 63-91, wherein the administration results in:(i) a decrease in ATXN2 protein expression in a cell, tissue (e.g., amygdala, brainstem, caudate, central grey, cerebellum (e.g., Purkinje cell layer and deep cerebellar nuclei), cortex (e.g., frontal cortex, motor cortex, perirhinal cortex, sensory cortex, temporal cortex), external cuneate nucleus, geniculate nucleus, globus pallidus, gracile nucleus, hippocampus, inferior colliculus, inferior olivary complex, nucleus ambiguous, oculomotor nucleus, putamen, substantia nigra, thalamus, ventral palladium, vestibular nucleus, spinal cord (e.g., cervical spinal cord region, lumbar spinal cord region, or thoracic spinal cord region)), and / or fluid (e.g., CSF and / or serum) of the subject relative to baseline and / or relative to ATXN2 protein expression in a cell, tissue, or fluid of an individual with an ATXN2-related disorder who has not been administered the pharmaceutical composition or AAV particle;(ii) an increase in the number and / or level of viral genomes (VG) per cell i n a CNS tissue (e.g., amygdala, brainstem, caudate, central grey, cerebellum (e.g., Purkinje cell layer and deep cerebellar nuclei), cortex (e.g., frontal cortex, motor cortex, perirhinal cortex, sensory cortex, temporal cortex), external cuneate nucleus, geniculate nucleus, globus pallidus, gracile nucleus, hippocampus, inferior colliculus, inferior olivary- complex, nucleus ambiguous, oculomotor nucleus, putamen, substantia nigra, thalamus, ventral palladium, vestibular nucleus, and / or spinal cord (e.g., cervical spinal cord region, lumbar spinal cord region, or thoracic spinal cord region) of the subject relative to the number and / or level of VG per cell in a peripheral tissue of the subject; and / or(iii) a decrease in ATXN2 mRNA expression in a cell or tissue (e.g., a cell or tissue of the CNS, e.g., the amygdala, brainstem, caudate, central grey, cerebellum (e.g., Purkinje cell layer and deep cerebellar nuclei), cortex (e.g., frontal cortex, motor cortex, perirhinal cortex, sensory cortex, temporal cortex), external cuneate nucleus, geniculate nucleus, globus pallidus, gracile nucleus, hippocampus, inferior colliculus, inferior olivary complex, nucleus ambiguous, oculomotor nucleus, putamen, substantia nigra, thalamus, ventral palladium, vestibular nucleus, and / or spinal cord (e.g., cervical spinal cord region, lumbar spinal cord region, or thoracic spinal cord region) of the subject relative to baseline and / or relative toATXN2 mRNA expression in a cell or tissue of an individual with an ATXN2-related disorder who has not been administered the pharmaceutical composition or AAV particle.
93. The method of any one of claims 63-92, further comprising administering to the subject at least one additional therapeutic agent and / or therapy.
94. The method of claim 93, wherein the at least one additional therapeutic agent and / or therapy comprises an agent and / or therapy tor treating the ATXN2-related disorder.
95. The method of claim 93 or claim 94, wherein the at least one additional therapeutic agent and / or therapy comprises one or more of; growth and trophic factors, cytokines, hormones, neurotransmitters, enzymes, anti-apoptotic factors, angiogenic factors, modulatory polynucleotides, and any protein known to be mutated in pathological disorders such as ATXN2 -related disorders .
96. The method of claim 94 or claim 93, wherein the ATXN2 -related disorder is SCA2, amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), or frontotemporal lobar d egene rati on (FTLD) .
97. The method of any one of claims 94-96, wherein the ATXN2 -related disorder is SCA2.
98. The method of any one of claims 63-97, further comprising administering an immunosuppressant to the subject.
99. The method of claim 98, wherein the immunosuppressant comprises a corticosteroid (e.g., prednisone, prednisolone, methylprednisolone, and / or dexamethasone), rapamycin, mycophenolate mofetil, tacrolimus, rituximab, and / or eculizumab hydroxychloroquine.
100. A method of treating a. subject having or diagnosed with having amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), or frontotemporal lobar degeneration (FTLD), comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 59-62 or the AAV particle of any one of claims 1-49.
101. The method of claim 100, further comprising administering to the subject at least one additional therapeutic agent and / or therapy.
102. The method of claim 101 , wherein the at least one additional therapeutic agent and / or therapy comprises one or more of; growth and trophic factors, cytokines, hormones, neurotransmitters, enzymes, anti-apoptotic factors, angiogenic factors, modulatory polynucleotides, and any protein known to be mutated in pathological disorders such as ATXN2-related disorders.
103. The method, of any one of claims 100-102, further comprising administering an immunosuppressant to the subject.
104. The method of claim 103, wherein the immunosuppressant comprises a corticosteroid (e.g., prednisone, prednisolone, methylprednisolone, and / or dexamethasone), rapamycin, mycophenolatemofet.il, tacrolimus, rituximab, and / or eculizumab hydroxychloroquine.
105. The pharmaceutical composition of any one of claims 59-62 or the AAV particle of any one of claims 1-49 for use in a. method of treating a disorder according to any one of claim s 67-104.
106. The pharmaceutical composition of any one of claims 59-62 or the AAV particle of any one of claims 1-49 for use in treating an ATXN2-related disorder in a. subject, optionallywherein the ATXN2-related disorder is SCA2.
107. The pharmaceutical composition or the AA V particle for use of claim 106, wherein the subject has, has been diagnosed with having, or is at risk of having the ATXN2-related disorder, optionally wherein the ATXN2-related disorder is SCA2.
108. Use of the pharmaceutical composition of any one of claims 59-62 or the AAV particle of any one of claims 1-49 in the manufacture of a medicament for the treatment of an ATXN2-related disorder in a subject, optionally wherein the ATXN2-related disorder is SCA2.
109. The use of claim 108, wherein the subject has, has been diagnosed with having, or is at risk of having the ATXN2 -related disorder, optionally wherein the ATXN2-related disorder is SCA2.
Citation Information
Patent Citations
Mineral hollow fiber bioreactor for the cultivation of animal cells
US5064764A
Method for improved transduction by recombinant adeno-associated viruses
US5756283A
An improved method for the production and purification of adenoviral vectors
US6194191B1
AAV capsid vehicles for molecular transfer
US6204059B1
Recombinant adenovirus and adeno-associated virus, cell lines, and methods of production and use thereof
US6261551B1
Cited By
AAV capsid variants and uses thereof
US12296025B2
AAV capsid variants and uses thereof
US12419969B2
Redirection of tropism of AAV capsids
US12467046B2
AAV capsids with increased tropism to brain tissue
US12577588B2
Redirection of tropism of AAV capsids
US12630842B2
